Investigation into the synthesis of biodegradable polymers for use as drug targeting agents by Lowndes, Gareth J.
        
University of Bath
PHD









Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 23. May. 2019
INVESTIGATION TNTO THE SYNTHESIS OF
BIODEGRADABLE POLYMERS FOR USE AS 
DRUG TARGETING AGENTS.
The research contained within this thesis has been carried out in the School of Pharmacy 
and Pharmacology under the supervision of Dr. Michael D Threadgill and Dr. Colin W
Pouton.
Attention is drawn to the fact that copyright of this thesis rests with it's author. This copy 
of the thesis has been supplied on condition that anyone who consults it is understood to 
recognise that it's copyright rests with it's author and that no quotation from the thesis and 
no information derived from it may be published without prior written consent of the
author.
This thesis may be made available for consultation within the University Library and may 
be photocopied or lent to other libraries f "
Thesis
submitted by Mr Gareth J Lowndes, HND, BSc (Hons), 







INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U601921
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
S o V ^ z .
INVESTIGATION INTO THE SYNTHESIS OF BIODEGRADABLE POLYMERS 
FOR USE AS DRUG TARGETING AGENTS.
ABSTRACT.
Macromolecular drug carriers offer the potential to deliver inherently toxic drugs in a site-specific, 
controlled manner. However, once the function of the carrier is over it should be expelled from the 
cell. Soluble polymers are captured by pinocytic uptake, rendering them lysosomotropic. It is 
proposed that co-polymerisation of PEG with alternating oligopeptide sequences would afford a 
biodegradable polymer. Hie peptide sequences are selected for sensitivity to hydrolysis by 
lysosomal enzymes. Poly(ethyleneglycol) (PEG) is biocompatable and may infer beneficial 
properties onto the PEG / peptide conjugate such as , a reduction in immunogenidty, and increase 
in solubility and plasma half-life. The soluble macromolecule would be stable in body fluids but 
could undergo complete degradation into small chains within the lysosomes of the target cell.
The oligopeptide sequences GlyGly, PheLeuGly and GlyPheLeuGly were synthesised by solution 
methods between (benzyloxy)aiyl structures. For example, 2-(4-benzyloxyphenyl)ethylamine was 
coupled to BOCglycine using DCC. Treatment with HC1 afforded the de-protected amine salt 
Coupling of this amine with BOC protected amino acid and dipeptide active esters, served to 
extend the peptide chain in an iterative process. Final deprotection (HO) was followed by coupling 
with N-(4-BnOC6H4CO)GlyOPFP to give the a,o>-bis(OBn) peptides. Hydrogenation effected 
debenzylatioa The phenolic hydroxy groups were subsequently converted to the glycidyl ethers by 
treating with cpichlorohydrin. The copolymerisation of cx,o>-bis(methylaniino) PEGs with a,co- 
bis(glycidyl) peptides was chosen as the polymerisation strategy towards the alternating PEG- 
peptide linear polymers. To provide the appropriately derivatised monomer the PEGs were 
converted to the oc,co-bis(chlorofonnate) with phosgene. Treatment with BOCSarNHCH2CH2NH2 
gave the corresponding bis(urethane). Deprotection with HQ gave the required a,o> 
bis(methylamino)-derivatised PEG. By introducing a secondary amine onto the PEG the risk of 
polymeric cross linking was reduced. The PEG containing polymers were functionalised further by 
the inclusion of glutamic add within the oligopeptide sequence. The glutamate side chain may be 
used to attach cytotoxic drugs or targeting moieties in the future.
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Chapter 1. Introduction
1.1. Introduction.
1.2. Drug-Polymer Conjugates:- potential for improved chemotherapy?
The work presented in this thesis concerns the design and synthesis of novel, 
biodegradable, polymer carriers for drugs or diagnostic reagents. It is an attempt, primarily 
to improve on the existing methods of drug delivery and targeting. The introduction begins 
by asking if any improvement is required in present day chemotherapy. Further sections 
discuss key concepts including the use of controlled drug delivery to achieve better 
biodistribution and activity. The general principles of a drug carrier are reviewed with 
pertinent examples of polymer and drug targeting moieties. A final comprehensive section 
critically assesses the use of polyethylene glycol as a therapeutic agent and discusses it's use 
as a soluble, polymeric drug carrier.
Over the past 40 years cancer chemotherapy has evolved significantly. Opinions on 
the overall success of chemotherapy are often conflicting. They range from the pessimistic 
view that because cancer mortality has remained essentially unchanged since 1954 (1), 
chemotherapy has been an unqualified failure, to the optimistic view that most cancers can 
now be treated in some way offering the chance of remission and an overall improvement in 
the quality of life. The reality lies somewhere between the two. In all malignant conditions 
therapy may involve surgery, radiation, immunotherapy, chemotherapy or a synergistic 
combination of treatments. Of the above, chemotherapy has played an important and 
effective role in treating both solid and haematological malignancies.
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Despite efforts to develop novel cytotoxic drugs and treatments, progress is being 
made in small steps with no effective chemotherapy available to date for certain solid tumour 
types and advanced tumours. In addition, the therapeutic indices of most anticancer drugs in 
systemic chemotherapy still remains marginal with no site specificity, and inhibition of 
tumour growth is invariably accompanied by serious damage to proliferating normal host 
cells. Of particularly relevance to this is the destructive effect on the rapidly dividing cells of 
the haematopoietic system, gastrointestinal tract as well as the hair follicles which can lead 
to alopecia and a reduction in patient self-esteem.
Growing interest in the drug-polymer field has in part been due to this limited 
progress in the successful development of effective new drug entities, but also due to the 
realisation that new approaches must be adopted if we are to see an improvement in 
therapeutic activity. The efficiency of drugs would increase enormously if we were able to 
direct them selectively to their cellular targets. This dream was echoed by Paul Ehrlich (2) 
who in 1906 predicted the application of antibodies as "bodies which possess a particular 
affinity for a certain organ.... as carriers by which to bring therapeutically active groups to 
the organ in question". The concept of Ehrlich's "magic bullet" is deceptively simple:- get 
the right amount of the active agent at the right time to the right place. These ideas were 
not tested experimentally until the mid 1950's when Math6 (3) attempted to target 
methotrexate (MTX) to L1210 leukaemia cells in the mouse. It is, however, work on the 
use of polylactic acid by Yolles et al (4) that is regarded as initiating the avalanche of 
practical advancements seen over the last twenty years. Since then many different 
approaches to drug delivery have been explored, within a diversity of scientific fields. This 
reflects the inter-disciplinary nature of macromolecular research.
Although polymer chemistry now occupies a central role, with the use of polymer- 
based technologies for improved delivery of cancer chemotherapy, it has not been as widely
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explored as the liposomal and antibody-based strategies. This is disappointing as polymers 
have been extensively studied and are already in daily use in many biomedical applications 
including, contact lenses, plasma expanders, wound dressings and pharmaceutical excipients. 
In addition, research into new polymers for implantable, or insertable controlled release 
devices, targeted drug carriers and transdermal systems shows great pharmaceutical 
potential. To this end powerful commercial interests have tended to fuel this area of 
research and this is a situation which is reflected by the number of collaborative programmes 
between scientists in academia and industry.
There have already been a number of commercial successes. Zoladex ®, the 
polylactide-co-glycolide subcutaneous implant delivering a luteinising hormone releasing 
hormone (LHRH) over a 28 day period is used for treating prostate cancer (5), and a poly 
anhydride matrix containing carmustine is currently in phase m  evaluation for treatment of 
glioma multiforme (6). Soluble polymer conjugates comprising of monomethoxy 
polyethyleneglycol (M-PEG) have been bound to various proteins including asparaginase (7) 
and interleukin Q (TL-2) (8) and await approval for their use in cancer chemotherapy. Initial 
results with another polymer-protein conjugate, styrene maleic acid (SMA)-neocarzinostatin 
(NCS) or SMANCS, evaluated in more than 500 patients presenting with primary 
hepatomas or secondary tumours of the liver (9) are very encouraging.
13. The Concept of Controlled Release v The Concept of Drug Targeting.
The objective in designing a controlled release system is to liberate a 
pharmacologically active agent in a predetermined, predictable and reproducible fashion. 
Such formulations are generally very useful and exhibit few side effects as the drug circulates 
systemically at an optimum level for a prolonged period of time (Figure 1.1). Bolus 
administration of an antitumour agent typically leads to high peak concentrations in the
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plasma, tumour and unfortunately also in sites of toxicity. With the use of controlled release 
formulations the peaks and valleys of plasma concentration are eliminated. This extends the 
time the effective therapeutic dose is present at the target site which is important as many 
antitumour agents express differential activity throughout the cell cycle. The premise of 
targeted drug delivery is the assumption that the therapeutic index of a drug can be 
improved when the drug accumulates selectively in specific tissues, organs or cell types. 
Drugs can be targeted by a wide range of mechanisms. However, both the targeted and the 
controlled concepts of drug release share the potential to decrease the dosage of drug 
required by improving the pharmacokinetics and localisation of the drug respectively. This 
is important when expensive recombinant enzymes or active ingredients are involved.
Figure 1.1. Theoretical plasma concentration after administration of various dosage forms.
(a) Standard oral dose.
(b) Oral overdose
(c) IV injection




There are two fundamental approaches to the targeting of drugs. On a very basic 
level one can differentiate between insoluble, particulate drug carriers and the soluble 
macromolecular drug conjugates. Furthermore one has to distinguish between actively and 
passively targeted systems. Briefly, passive targeting takes advantage of an existing body
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process, e.g., the rapid accumulation of particles < 1 micron in the liver or spleen after i.v. 
injection. In contrast, during active targeting the natural tendency of the body to distribute 
the active substance is altered due to targeting moieties on the drug or carrier.
Polymeric controlled release systems can be placed into virtually any of the available body 
cavities. In addition they can be implanted or attached externally to the skin, allowing a 
considerable choice as to the route of drug administration. Crude targeting can be achieved 
by introducing a polymeric matrix or reservoir system adjacent to a tumour, where the 
tumour can be exposed to a localised, continual drug exposure. Both passive and active 
targeting have been used to deliver chemotherapeutic agents. This will be reviewed in 
Section 1.11.
1.4. Characteristics of the Drug Carrier System.
Trouet (10) defined a carrier system as "a molecule or an assembly of molecules, the 
major characteristic of which is that it is unable to cross (native or bound to a drug) the 
plasma membrane of eucaryotic cells by permeation or active transport". The carrier 
requirements of different therapeutic agents will vary widely, but most drugs are restricted 
by their lack of selectivity towards their respective targets. Macromolecular drug carrier 
systems are being developed in an attempt to alter the tissue localisation of drugs (11). This 
would enhance the effects of a drug at a desired site of action relative to the unwanted side 
effects. The application of such carriers to chemotherapy where extremely toxic agents are 
used, is clearly an advantage although other disease states, e.g. viral, protozoal infections, 
emphysema and arthritis could also benefit from selective drug delivery. The in vivo 
distribution of a carrier linked drug will largely depend upon the properties of the carrier and 
will therefore differ from the distribution of the free drug given by the same route (11).
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There are certain criteria that must be considered for a macromolecular carrien-
(a) the carrier should be easily prepared in a homogenous, cost effective manner;
(b) the carrier should be biocompatible and it's metabolic products should lack any 
intrinsic toxicity;
(c) the chemical reactivity of the carrier should be suitable for attachment of the 
drug, and should have a high drug carrying ability;
(d) the carrier should be biodegradable, and not show substantial accumulation in the
body;
(e) the carrier molecule may be a natural substrate for a physiological receptor;
(f) the carrier may have influential physical properties. One needs to consider 
whether it is a compact or extended molecule?. Is the molecular weight smaller or larger 
than the renal threshold?, What are it's solubility and electrical charge?.
The following is a list of objectives which may be achieved using a drug or enzyme carrier 
system:-
(a) stabilisation of a drug or enzyme in it’s active form, thereby retarding normal 
biodegradation;
(b) improved localisation via passive or active targeting;
(c) release of the active drug, either chemically or enzymatically, at a controlled and 
predictable rate;
(d) increased circulation half-time;
(e) minimisation of non-specific cytotoxicity;
(f) enhancement of solubility.
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1.5. Drug Carriers.
A comprehensive review of the literature relating to controlled delivery and 
targeting, revealed several hundred publications. Many different systems have been explored 
including soluble low molecular weight prodrugs (12), polymeric implants (13), and not least 
the use of devices such as infusion pumps (14). Macromolecular and cellular (or particulate) 
drug carriers have been extensively investigated, with macromolecules forming the basis of 
the majority of systems. Examples of insoluble particulate carriers include microspheres 
(15), nanoparticles (16), liposomes (17,18,19), emulsions, and cellular drug carriers, for 
example, the erythrocytes (20) and leucocytes (21). Such delivery systems may incorporate 
magnetic control to localise the drug carrier complex in a certain area of the body (22). 
However, the micro-particulate carriers will not be discussed here as they are neither 
soluble, degradable or readily targeted. Instead, the reader is directed to the excellent 
reviews cited.
Considering the effort expended in the area of macromolecular conjugates, the 
number of reports of improved efficacy has been quite low. This section will review the 
benefits and shortcomings of some of the key macromolecular drug delivery systems 
available today. Detailed accounts concerning the methods used for the coupling of drugs to 
their carriers will be omitted as it is beyond the scope of this thesis. An exhaustive review 
on the coupling procedures of PEG is included in Section 1.13.
1.6. Macromolecular Drug Delivery Conjugates.
Macromolecular carriers can be divided into a number of categories. The first class, 
the natural polymers, include protein carriers (antibodies, albumin, glycoprotein, lectin, 
hormones), dextran and deoxyribonucleic acid (DNA). The second class is comprised of the
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synthetic polymers such as N-(2-hydroxy-propyl)methacrylamide (HPMA) and may include 
some pseudo-synthetic polymers such as the polyamino acids, e.g., poly (lysine).
1.7. The Natural Carriers.
Natural carriers, by their nature are derived from sources which have existed long 
enough for mechanisms to evolve that utilise them as substrates. For this reason many of 
them are susceptible to degradation, thus facilitating metabolic removal from the organism 
after administration. This is an advantage as it prevents the accumulation of the carrier 
material within the cells once the drug has been delivered. This process is known as 
thesaurosis, and can lead to an immune reaction and toxicological problems. Natural 
polymers were pioneer degradable drug carriers but one disadvantage was that they were 
frequently recognised as foreign in vivo and induced immunogenic problems (23). In 
addition, as products of biosynthesis their structure and properties could hardly be shaped 
according to clinical needs.
1.7.1. Proteins.
1.7.1.1. Monoclonal Antibodies.
The coupling of a drug to a monoclonal antibody (mAb) that can bind to specific cell 
surface antigens has great promise for directing cytotoxic agents to appropriate sites. In 
1958, Math6 and co-workers (3) were successful in treating a mouse leukaemia (L1210) 
with diazo linked conjugates of the antitumour drug methotrexate and hamster antibodies 
prepared against the L 1210 cells. Despite this, thirty five years later, the use of antibodies in 
routine clinical practice still remains as elusive as Ehrlich's magic bullet The problems are 
many fold. From Mathd's results it is not possible to determine whether the antibody was
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actually delivering the drug to the tumour site or whether it was simple altering either the 
pharmacokinetics of the drug delivery or enhancing the toxicity of the drug molecule by 
altering the properties of the tumour cell.
The possibility of antibody drug synergism was re-investigated in the 70’s by 
conjugating the alkylating agent, chlorambucil with an anti-tumour antibody. It was 
reported (24) that the growth of transplanted tumours was prevented in conditions under 
which equivalent amounts of either free drug or free antibody were ineffective. However, 
further study (25) showed that protection against tumour growth was as effective as when 
the drug and antibody were injected separately. Rubens and Dulbecco (26) postulated that 
the antibody was not therefore directing the drug to the target but that each acted 
synergistically to increase the susceptibility of the tumour. This synergism has also been 
demonstrated with the anti-tumour agent cytosine arabinoside (27).
The discovery of tumour specific antigens (TS A) (28) allowed the large scale 
production of selective tumour antibodies. Gilliland et al (29) coupled the diphtheria toxin 
via a disulphide linkage to a mAb directed against a colorectal carcinoma tumour associated 
antigen. The conjugate showed nearly 100% cytotoxicity to the colorectal cells in vitro and 
did not affect the cells which lacked the antigen. The danger with the use of a mAb 
preparations against a single antigenic determinant is that some cells within primary or 
metastatic cancers may not possess, or may have lost that specific antigen, thereby escaping 
the antibody-drug conjugate (30). This typical pattern is termed "patchwork" and may be 
due to the cell cycle-dependent expression of some cell surface tumour antigens. In 
addition, circulating tumour specific antigen may bind antibody or antibody-drug complexes 
in the serum before they have a chance to attack the target tumour cells. Similarly, Mach et 
al (31) found the use of antibodies against carcino-embryonic antigen (CEA) difficult to use 
in diagnostic situations due to the presence of high levels of circulating CEA in the serum.
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The use of highly selective mAb-directed treatment may be further compromised by cross- 
reactivity due to shared antigens on normal tissues or by non-specific tissue uptake (32). 
Heterogeneity is a characteristic shared by all human carcinoma-associated antigens. This is 
manifested in a variety of ways. Often the tumour antigens may be integral components of 
the cell membrane and do not undergo internalisation after antibody binding. In addition, 
there may be a significant quantitative difference with respect to the antigen density per cell.
Recently the above problems were addressed by utilising mAb’s that carry light- 
activated molecules (photosensitizers, e.g., chlorin e6), (see Section 1.12). These conjugates 
are innocuous without illumination but produce reactive species, such as a singlet oxygen 
OOj), upon absorbing light By confining illumination to areas containing specifically bound 
photosensitiser, toxicity can be limited to target cells only (33,34). This dual selectivity 
(mAb binding and illumination) means the mAb need not be completely tumour selective.
As long as the cross-reactive or non-specifically bound mAb-photosensitiser (mAb-PS) is 
not illuminated there will be no adverse effects to normal tissue. In contrast to most 
conventional cytotoxic drugs and toxins the mAb-PS need not be internalised to have their 
effect Diffusion of the potent singlet oxygen can produce a cytotoxic effect in cells to 
which it is only loosely associated. In addition neighbouring antigen-negative tumour cells 
which are not bound to the mAb-PS conjugate may also be killed. Oseroff et al (35) found 
that haematoporphyrin molecules could be directly coupled to the carbohydrate moieties on 
the Fc portion of mAbs with no effect on the antigen binding site and permitting the mAb to 
exert highly selective phototoxicity. However, with direct attachment, less than 5 
chromophores could be linked to the mAb. To increase this ratio, with a concomitant 
increase in toxicity, dextran-dye conjugates were prepared and linked to the mAb 
carbohydrate. The authors found that unconjugated chlorin e6 under the same conditions 
was not phototoxic (33,36).
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Vitetta and colleagues (37) have questioned the accessibility of solid tumours to 
immunotoxin therapy due to their dense connective tissue component. One of the problems 
associated with the use of mAb is their relative large molecular weight (IgG =150 KDa). 
Conjugating a drug to the mAb will increase the molecular weight still further. This presents 
an important obstacle to diffusion of the conjugate through the vasculature and subsequent 
loss of material to the reticulo-endothelial system (RES). The vasculature does not normally 
have receptors capable of recognising this large conjugate (38) and despite the inherent 
leakiness of tumour vasculature there is often a poor localisation of the mAb-conjugate.
This is reflected in human tumours where only 0.005% of the mAb administered can be 
found at the target (39) and much of this is shown to be confined to the periphery of the 
tumour mass (40,41). This led Poznansky and Juliano (42) to propose that bound 
vasodilators such as histamine could be administered to facilitate the penetration of the 
blood tissue barrier. Another approach is through the administration of a biological 
response modifier, such as recombinant human interferon (rH-IFN) , which can result in 
amplifying the cell surface tumour antigen expression. By increasing the level of mAb 
binding to the tumour cell population more effective therapy may result
There are reports in the literature of antibodies that have been bound to a number of 
highly toxic substances. With a concomitant rise in toxicity the amount of effective mAb- 
conjugate at the target site need not be so high and problems of localisation are reduced. 
Unfortunately, experiments with the toxin, ricin (A chain), have shown that the therapeutic 
index of the immunotoxin must be improved if any significant tumour burden is to be 
challenged. Masuho et al (43) demonstrated in vitro that the mAb-CALLA (common acute 
lymphoblastic leukaemia antigen) conjugate appeared much less toxic than free ricin. Other 
workers report similar findings, (44) and suggest this may be due to the inability of certain 
antibodies to induce endocytosis either because of low binding affinities, or because the 
target antigen may be one which is either shed or not readily internalised. The reduction in
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binding affinity may be due to an alteration in the tertiary structure of the antibody during 
drug binding (45). This loss of binding activity and consequently toxicity can be reduced if 
the antigen-binding site is blocked reversibly before drug conjugation takes place (46).
The difficulty in coupling adequate amounts of drug to an antibody without denaturation is a 
problem. The use of low molecular weight toxins as opposed to large conventional 
cytotoxic drugs solves this problem to a certain degree. However, this may not be totally 
acceptable since uptake of even tiny amounts of the toxin by healthy cells, through non­
specific pinocytosis, could be lethal
1.7.1J2. Albumin.
The biocompatibility of albumin is established. Albumin lacks toxicity and any 
intrinsic site selectivity (47) and therefore specificity must be provided in some other way. 
Chu and Howell (48) used this lack of site selectivity to their advantage when they bound 
MTX to bovine serum albumin (BS A) and injected this into the peritoneal cavities of BDF 
mice with the L1210 tumour. The attachment of the drug to the high molecular weight 
carrier led to the prolonged localisation of MTX in the ascitic fluid together with elevated 
intracellular MTX levels after 24 hours. By decreasing the clearance of the drug from the 
compartment, the total drug exposure in the tumour was increased and exposure to normal 
cells was decreased. In contrast, it was reported (49) that MTX-BSA was 50 -100 fold less 
toxic to L1210 cells in culture than was free MTX. The reasons behind this discrepancy lie 
in the large molecular size of the conjugate. Rapidly proliferating cells, such as those found 
in tumours, often have increased pinocytic uptake rates. The in vitro study essentially 
compared the uptake of free MTX to that of the bound MTX. The former is normally taken 
up via facilitated transport mechanisms (48), whereas the latter, being much larger, is 
incorporated into the cell by fluid phase pinocytosis, which is a much slower uptake 
mechanism. Hence the free MTX appeared to have a more rapid, toxic effect compared to
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the conjugate. During in vivo experiments, the bulky conjugate is confined by physiological 
barriers, i.e. membranes, to the compartment into which it is injected, where it has a 
localised effect as described above. Free MTX, on the other hand, is able to penetrate the 
vasculature and is removed from the site of injection rapidly. In addition the short half-life 
of the MTX in vivo reduces the apparent toxicity of the drug. Intraperitoneal injections of 
BSA-MTX were also found to be superior to free MTX against Lewis lung carcinoma and 
subcutaneous implanted solid tumour in rats and mice, where an increased life span was 
observed, and the number and size of metastatic nodules was reduced (50).
Albumin has been used as a drug carrier in other instances, e.g. Amantin, 5 fluoro- 
deoxyuridine and cytosine arabinoside have been coupled to rabbit serum albumin (RS A)
(51,52). More topically, daunorubicin (DNR) was linked to succinylated albumin using 
peptide spacers (53). Following incubation of the drug conjugate with lysosomal enzymes in 
vitro it was shown that the tetrapeptide spacer (Ala-Leu-Ala-Leu) was cleaved most readily, 
with 74% of DNR being released after 10 hours. The possible use of these conjugates for 
the delivery of cytotoxic drugs to the lysosome encouraged the authors to test the 
chemotherapeutic activity of the various SA-DNR conjugates on LI210 leukaemia in vivo. 
Both in vitro and in vivo experiments revealed that the conjugates showed less toxicity than 
the free DNR.
Lactosaminated serum albumin (L-S A) is reported (52) to bind to galactosyl 
terminated glycoprotein specific receptors, on hepatocytes. This conjugate was devoid of 
immunogenicity, even when coupled to arabinofuranoside (a simple sugar) and shows 
potential as a hepatocyte-specific drug delivery system.
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1.7.1.3. Other Proteins. Glycoproteins, Lectins and Hormones.
The use of glycoproteins (54), lipoproteins (55), lectins (56) and hormones, particularly 
melanotropin-drug conjugates (57) as drug carriers has not been extensive. This is in 
general due to the highly selective and ubiquitous nature of their respective receptors, 
making organ or tissue specificity difficult In the case of melanocyte stimulating hormone 
(MSH) which could be used to target melanoma, this has been considered tolerable as the 
only side effect should be non-fatal de-pigmentation. Daunomycin (DNM) was linked to 
MSH and found to be three times more toxic to melanoma cells in vitro than free DNM 
(57).
However, in vivo experiments were not successful and the conjugate showed toxicity 
to the liver and kidneys. These findings reflect the possibility that melanocytes were not the 
only non-target cells possessing MSH receptors. Also a possible problem in all receptor- 
mediated site-specific drug delivery systems is that endogenous ligands can compete for a 
finite number of receptors on the target cell. Anderson et al (58) demonstrated the uptake 
of cholesterol-labelled or protein-labelled HDL by rat adrenal cells, only after administration 
of ACIH had caused depletion of the circulatory pool of cholesterol.
Exposure of the terminal sugar residues on glycoproteins reveals asialoglycoproteins 
(59) which are recognised and rapidly cleared from the circulation by hepatocytes 
(galactosyl groups) and macrophages (mannosylated ligands) (60). Hepatocytes are targets 
for various infective agents particularly those producing hepatitis and malaria. To this end 
galactosyl-terminating glycoproteins have been used as hepatocyte-specific drug carriers, 
namely asialofeutin (AF) (59). Coupling of trifluorothymidine (F3T) and adenine-9- 
arabinofuranoside (ara-A) to AF did not interfere with the binding of AF to surface 
receptors on the hepatocytes and the results in mice injected with Ectromelia virus (infection
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of the Kupfer cells) were optimistic. However, ara-A conjugates of AF have shown 
immunogenicity which could lead to inactivation of the conjugates, rapid clearance from the 
circulation and allergic reactions. Trouet et al (53), in some pioneering work, succeeded in 
coupling primaquine (PQ) (an anti-malarial agent) to AF via a tetrapeptide spacer, Ala-Leu- 
Ala-Leu-PQ. Selective hepatocyte endocytic uptake of the conjugate together with 
intracellular degradation within the lysosomal compartment resulted in an increased 
hepatocyte concentration of PQ over the free drug. The theoretical applications of this 
initial research will be discussed in later chapters.
It is generally accepted that neoplastic cells have an increased endocytic rate 
compared to normal cells. In conjunction with this there will be an increased turnover of cell 
surface receptors that are continually being internalised. In 1981 Gal et al (61) suggested 
this process could be used to achieve preferential site selectivity of LDL-drug conjugates 
enabling more drug to be internalised. Other workers (62) demonstrated the internalisation 
of fluorescent lipoprotein preparations in cultivated human fibroblasts via receptor-mediated 
endocytosis of LDL and recently this receptor has been used extensively by Geze et al (63) 
to deliver porphyrin loaded LDLs to the lysosomal compartment in order to investigate 
photochemical reactions within the lysosomes. In contrast, the compound benzo(a)pyrene 
incorporated into LDL was shown to enter these cells by a mechanism independent of the 
LDL receptor complex (64). This questions the usefulness of LDL as a selective drug 
carrier in certain situations. Another example of receptor-protein interaction was cited by 
Chang et al (65). The toxic sub-units of the diphtheria toxin were coupled to a human 
placental lactogen and epidermal growth factor (66). The conjugate was able to bind 
effectively to lactogenic receptors. However, upon binding, the receptor was unable to 
mediate entry of the toxin into the cells. This point is an important concept in drug 
targeting, since often the drug must be internalised to exert it's biological effect. More 
positive results were obtained with ricin conjugates. When linked to human chorionic
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gonadotrophin (hCG) (67) the conjugate showed selectivity for rat Leydig cells possessing 
receptors for the p subunit of hCG. However, cell kill was not as efficient as with free ricin.
The use of lectins as drug carriers has largely been ignored due to their lack of ligand 
selectivity and adverse interactions with body tissues (56). At doses as low as 10 |ig intense 
inflammatory response with oedema and erythema occurs at the site of injection. Lectins are 
proteins that agglutinate cells by binding to specific carbohydrate residues. Due to the 
ubiquitous distribution of sugar residues in vivo, lectin usually remains at the injection site as 
a result of interactions between the sugar-binding receptors on the lectins and sugar residues 
present at the injection site. In terms of localised therapy this regimen may be advantageous, 
and some authors (68) have suggested using the non-toxic lectin from the tomato to act as a 
bioadhesive in anchoring drug-bearing microparticles at a certain site (69). Preliminary 
studies have shown that it’s use improves the bio-availabilty of oral drug delivery by 
adhering to the gastrointestinal tract of the rat
1.7.2. The Polysaccharides. Dextran.
The polysaccharides dextran, inulin, cellulose and starch are frequently used as drug 
carriers. Dextran is a collective name for a class of bacterial (Leuconostoc mesenterrides) 
polysaccharides composed of (1 - 6)-linked-a-D-glucopyranosyl residues [see Figure 
12(a)]. Native dextran has a molecular weight reaching several hundred million and a high 
polydispersity. Commercial dextran fractions with a well defined range of molecular weight 
are prepared by controlled hydrolysis and repeated fractionation with fractions of average 
molecular weight 40,70 and 110 KDa being used for blood plasma substitutes.
The reader is directed to the many reviews on the activation and biodegradation studies of 
dextran (70,71). The advantages of dextran as a drug carrier are:- (1) high water solubility; 
(2) well characterised and repetitive chemical structure; (3) availability of different molecular 
weight fractions ranging from 2 x 103 to 106; (4) low toxicity and low pharmacological
16
activity; (5) protection of conjugated drugs or enzymes from biodegradation. The clinical 
use of dextran as a plasma expander makes it very popular as a drug carrier (72,73) or as a 
polymeric spacer between drag and carrier macromolecules. In this latter use dextran is 
usually employed as the linking polymer between a drag and a tumour-specific antibody (74) 
[see Figure 12b(b)\ to direct antitumour drags or boron compounds (used in neutron 
capture therapy) (75). Drags or enzymes can be coupled to the hydroxyl groups of dextran 
in a variety of ways, promoting the versatility of dextran as a drag carrier. Linking drags or 
enzymes to dextran generally confers greater chemical and biological stability to the 
conjugated compound, as in the case of methotrexate (76), insulin (77), haemoglobin (78) 
and procainamide (79).
In 1978, the potency of daunomycin-dextran conjugates using periodate-activated 
dextrans was investigated (80). Experiments in vitro on YAC cells were disappointing as 
they showed that at low dosages the conjugate was less active than the free drag. On the 
contrary, evaluations in vivo of these conjugates in mice bearing YAC lymphoma cells 
revealed that at high doses (20-25 mg /  kg), the conjugates could completely prevent tumour 
growth. In this dosage range, the free drag was very toxic, highlighting the advantage of the 
repeated use of a drag-carrier over the parent drag.
A general mistake made when developing drag carriers is the assumption that all the 
properties which were tested with free carrier polymer will be retained after the 
modifications necessary for drag binding, and after attachment of various ligands to the 
macromolecule. Firstly, the degradability of dextran depends on natural branching (81), 
with the bonds in the vicinity of branch linkages and at the ends of the chain being more 
resistant to enzymatic attack by dextranase. Any modification of these branches might 
further increase the stability of the bonds and may decrease the susceptibility to degradation 
(82). This was demonstrated neatly when Hurwitz et al (83) covalently coupled
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daunorubicin via the keto group to dextran hydrazide yielding products with a potentiated 
antitumour activity in mice which had received 105 YAC cells. This group demonstrated 
that binding of the drug to dextran via a non-hydrolysable sulphide bond resulted in a loss of 
antitumour activity in vitro and in vivo. This suggests, therefore, that in order for dextran- 
daunombicin derivatives to have retained antitumour activity, the drug-carrier linkage must 
be cleavable. This is in contrast to the work with aminoethylated dextran and methotrexate 
by Chu and Whiteley (84, 85). Here, it was found that the carrier bound drug retained the 
ability to interact with dihydrofolate reductase. The dextran derivative also persisted for 
longer time periods after intra-peritoneal administration in BDF2 mice when compared to a 
similar group of mice treated with free methotrexate.
Fig 1.2(a). Pearan. Fig 1.2(b) Drug is linked tn an immunoglobulin
Many authors consider that the immunological properties of the polysaccharides 
have not yet been fully clarified. Although immunological responses to dextran are rare, 
adverse reactions to repeated injections have been reported, including haematological
via a dextran spacer group.




changes and inflammatory reactions (86). Further research has suggested that the 
immunogenicity of dextrans may be affected by a high degree of modification with different 
functional groups or residues. The introduction of a chain of six to eight residues into the 
dextran polymer substantially increased the immunogenicity of dextrans, and Rihova and 
Riha (88) included dextran in a review of the immunological problems associated with 
polymer-bound drugs. They indicated that the immunogenicity of polysaccharides is 
dependent upon the molecular size of the polymer, the resistance of the polymer to 
enzymatic cleavage and the injected dose.
1.72.1. Dextran and Charge.
Positively-charged macromolecules such as protamine and poly-L-lysine (PLL) have 
been reported to show high cellular interactions. The poly-cationic mitomycin-polylysine 
conjugate, for instance, is more strongly adsorbed to tumour cells than many conjugates 
which have a negative (anionic) charge (89). To this end, the cytotoxic agent, mitomycin C 
(MM-C) has been coupled to dextrans of various molecular weights (90), using hexanoic 
acid as a spacer. The physicochemical properties of the dextran conjugate, e.g. the net 
electrical charge and the rate of release of the drug from the conjugate, were controlled by 
changing the structure and /  or the method of introducing the spacer linkage to the dextran 
backbone. A cationic conjugate, MMC-D^ was found to rapidly accumulate in the liver, 
spleen and lymph nodes after intravenous administration of the drug (91), while the 
interaction between anionic MMC-Dm and hepatocytes was negligible. The amount of 
MMC-D^ associated with hepatocytes increased as the molecular weight of the dextran 
chain increased. Interestingly, after i.v. administration, MMC-D^ disappeared from the 
circulating blood faster than MMC-Dm as it rapidly accumulated in the liver through 
adsorption onto the hepatocytes. MMC-Dm on the contrary circulates in the body without 
any significant interaction in the tissues and slowly accumulates in the liver. By using this
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long circulatory half-life, MMC-D^ conjugates may find a future use in systemic targeting 
to tumour tissue which has capillaries of enhanced permeability to macromolecules (92).
The rapid removal of MMC-D^ to the liver, on the other hand, may be a possible targeting 
device to the liver. However this effect certainly negates it's systemic use. On the other 
hand, previous studies (93) have shown that local injections of MMC-D^ are suitable for 
intratumour injection as the conjugate acts as a depot which gradually supplies active drug. 
This interaction is mediated through electrostatic forces and results in a larger antitumour 
effect than free MMC-D (94). In this circumstance, any MMC-D^ leaking from the 
injection site to the circulating system might be rapidly cleared by the liver, thereby reducing 
systemic side effects.
The long term probability is that polysaccharides will continue to be used in site- 
specific drug delivery as carriers, and as components to alter distribution in vivo. To date, 
however, only a few derivatives have reached the clinical stage of testing.
1.7.3. Deoxyribonucleic Acid (DNA).
Trouet (53) and Atassi (95) have made extensive use of deoxyribonucleic acid 
(DNA) as a carrier for several anti-tumour drugs, most often the anthracycline derivatives, 
daunorubicin and adriamycin. These drugs show a high affinity for DNA without resorting 
to chemical modifications, and in addition they are resistant to hydrolysis by the lysosomal 
enzymes. Trouet (53) and other workers (96) demonstrated a number of important 
advantages when compared to the free drug. Perhaps the most significant is the greatly 
reduced cardiotoxicity of the complex when compared to the free drug. This was attributed 
to a lack of endocytic activity shown by the myocardium, and the confinement of the 
conjugate to specific compartments by capillary barriers. While this is an important 
advantage there is no indication that DNA enhances the anti-tumour activity of the drugs
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themselves. However, both daunombicin and adriamycin conjugates are more effective 
antitumour agents in the murine leukaemia, L1210, than the free drug (97). One theory 
suggests that DNA can augment the pinocytic uptake of a cell (87) and thereby introduce an 
increased amount of drug to the cell interior. One disadvantage of this could be the rapid 
clearance of the conjugate by the potent endocytic cells of the RES, resulting in damage to 
non-target tissue. In a later paper (98), Trouet demonstrated a rapid dissociation of 
daunorubicin and high molecular weight DNA, indicating the instability of the DNA-DNR 
bond in vivo. The susceptibility of the DNR-DNA linkage may be related to the non- 
covalent nature of the bond.
1.8. Synthetic Polymers.
The potential for biocompatible water soluble synthetic polymers is well established 
(99,100,101). Synthetic polymers have been used for a wide variety of biomedical uses 
including heart valves, polyester arteries, hip-joints and carriers or depots for bioactive 
agents. Many recent polymeric innovations in the field of drug delivery have followed in the 
wake of the developments within these specialised fields. The discussion in this section is 
limited to the water soluble polymeric drug carriers, their fate in vivo and their potential use 
as site-selective, biodegradable drug carriers.
Polymeric-based drug delivery has benefited from a renaissance within the polymer 
chemistry field which suggests synthetic drug-carriers have a very real potential. Of course, 
the general characteristics which govern tumour localisation of natural macromolecular 
carriers also relate directly to the design of synthetic polymeric carriers but the latter group 
have the enormous advantage that their structure can be tailor made. Manipulation in the 
laboratory offers an unlimited spectrum of novel polymeric systems where the molecular 
weight can be optimised and pendant drugs or targeting agents easily added. A corollary of
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this is that man-made synthetic polymers are frequently non-degradable and the polymer 
must therefore incorporate degradable linkages, or be restricted to conjugates of molecular 
weight lower than the renal threshold, allowing excretion.
A discussion of soluble polymers as drug carriers would not be complete without 
mentioning the work of Ringsdorf in the mid 1970's. His schematic model for polymeric 
drugs [see Figure 1.3] depicts the design of an optimal polymeric system (102). He 
suggested that an ideal polymeric carrier would be hydrophilic to ensure water solubility 
(indeed many effective carriers have been shown to solubilise poorly water soluble anti- 
tumour agents) and also contain the functional groups necessary to permit covalent linkage 
to a drug.
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The main advantage of biocompatible, water soluble synthetic polymers compared to 
other drug delivery systems is their targetability. Soluble macromolecules are handled by the 
body quite differently than particulate carriers (103). Attaching drugs to water soluble 
macromolecules limits their cellular capture to the pinocytic route and renders them 
lysosomotropic (see Section 1.9).
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Of the synthetic polymeric carriers described in the literature, N-(2-hydroxypropyl)- 
methacrylamide (HPMA) copolymers, monomethoxypolyethylene glycol (M-PEG), styrene- 
co-maleic acid /  anhydride (SMA), poly-L-lysine (PLL), poly-vinyl alcohol (PVA) and 
divinylether maleic anhydride (DIVEMA) have been most extensively explored. The 
majority of polymers are not chemically inert and can exhibit properties which can be toxic, 
therapeutic or anti-neoplastic (104). One polymer that is inert and has been systematically 
developed for the controlled release and targeting of anti-tumour agents (105,106,107) is 
N-(2-hydroxypropyl)methacrylamide (HPMA). HPMA is a biocompatible polymer 
originally developed as a plasma expander. Copolymers of approximately 20 000 Da size 
possess characteristics that would optimise it's use as a drug carrier. Conjugates of this 
molecular weight are relatively small, (e.g. polymer-ADR has a diameter of about 8 nm), 
allowing maximum tumour penetration and effective excretion from the body. Conjugate 
synthesis is described elsewhere (108), but the method of preparation usually involves initial 
synthesis of a reactive polymeric precursor by radical co-polymerisation of HPMA with p- 
nitrophenyl esters of N-methacryloylated oligopeptides. These copolymers react readily 
with compounds which contain an aliphatic amino group in their molecule with the 
formation of the amide bond, [see Figure 1.4].
This versatile concept has generated a number of tailor made conjugates that contain 
therapeutic agents, e.g. adriamycin (109), puromycin (107), daunomycin (107,110) and 
melphalan and more recently targetable carriers for photoactivatible drugs (110,111,112). 
The polymer-drug conjugates avoid many of the harmful side effects associated with the use 
of these drugs. Pharmacokinetic studies show that administration of daunomycin (113) or 
adriamycin (114) decreases up to 100 fold the level of anthracycline measured in the heart 
tissue when compared to an equivalent dose of free drug.
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Drugs and targeting groups can be bound to HPMA via biodegradable oligopeptide 
side chains which are designed to limit drug release in plasma and serum but be susceptible 
to degradation by lysosomal proteases (115). Considerable research has been carried out to 
optimise the side chain length and composition to facilitate degradation by lysosomal 
enzymes. Pioneering work by Kopecek and his co-workers with HPMA (108) found that 
Gly-Phe-Leu-Gly showed the greatest susceptibility to lysosomal enzymes. The 
immunogenicity of the polymers was investigated by determining their ability to induce 
antibody formation in mice (116). The polymer itself was non-immunogenic, but following 
repeated administrations of the oligopeptide-drug conjugate a weak, non-significant 
immunogenic reaction was observed.
Styrene-co-maleic acid neocarzinostatin (SMANCS) consists of two molecules of 
the synthetic polymer styrene-co-maleic acid /  anhydride (SMA) (each of Mw = 1500) [see
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Figure 15(a)] covalently bound to the anti-tumour protein neocarzinostatin (NCS) to give a 
final molecular weight of approximately 15 000 (9) [see Figure 15(b)], The conjugate is 
soluble in organic solvents and the contrast agent lipiodol used for lymphography. 
Administration of SMANCS in lipiodol enables both the dose and the tumour image to be 
quantitated by CT (computer tomography) scanning. In addition it has been shown that 
extremely efficient tumour targeting can be achieved using this formulation. Polymer 
conjugation was originally undertaken to increase the plasma half life of NCS (a 10 fold 
increase was seen) (119) and to improve tumour and lymph node localisation, but 
additionally the conjugate has been shown to be immunostimulatory (117). In 1983, a 
clinical study demonstrated that this conjugate has remarkable anti-tumour activity against 
hepatomas (118). These findings were corroborated by Maeda with rigorous evaluations in 
1991.
Figure 1.5(b) describes the chemistry of SMA conjugation with NCS although the reader is 
directed to a more extensive account by Maeda (119). The SMA contains styrene and 
maleic acid in which 30 - 50% of the maleic acid is in reactive anhydride form and half of the 
free carboxyl groups are butylated. This gives substantial hydrophobicity making the 
conjugate more lipophilic and allowing it to be directed more efficiendy to the lymphatics. 
SMA can react with the free amino groups of NCS, one at Ala-1 and the other at Lys-20.
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Figure 1.5(a). Structure ofSMANCS (stvrere - co-maleic acid / anhvdrideY





Figure 1.5(b). Diagramatic representation of the reaction with NCS to produce 
foe conjugate SMANCS.
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The synthetic polymer divinylether-maleic anhydride copolymer (DIVEMA) [see 
Figure 1.6 and 1.7] shows impressive activity against a wide range of animal tumour 
models. This activity appears to be mediated by a mixture of cell activation and interferon 
induction although DIVEMA also gives rise to a range of toxic side effects including 
anaemia, leucocytosis and hepatosplenomegaly.
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DIVEMA (divinvl efter-maleic anhydride copolymer)





The chemical structure of DIVEMA;- (Fig. 1.6.) unhydrolysed form; (Fig. 1.7.) hydrolysed form.
Manipulation of the molecular weight to less than 18 000 D with a narrow 
polydispersity permitted a reduction in many of the toxic effects without serious impairment 
of the anti-tumour activity. This modified DIVEMA was termed MVE-2 and has shown 
promise in the augmentation of the immune system following the immune suppressed period 
following surgical trauma. This is thought to be a vulnerable period for tumour metastasis 
which may be alleviated by the administration of MVE-2 (104).
1.9. Drug-carrier conjugates as lysosomotropic agents.
The principle consequence of drug conjugation to a macromolecular carrier is the 
limitation of the cellular uptake of drug by the mechanism of pinocytosis (120,53,102).
This is followed by the immediate transfer of the macromolecular drug conjugate to the 
lysosome, where the majority are thought to exert their activity. Hence they are described as 
lysosomotropic agents, a term adopted by de Duve, who proposed the phenomenon could 
also find application in the area of drug delivery (121). At the cellular level, this contrasts
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with the ability of most low molecular weight antitumour agents to enter the cell by 
transversing (either actively or passively) the cell membrane before exerting their 
pharmacological effect. This is the single most important factor in determining altered 
pharmacological activity of all macromolecular drug conjugates, irrespective of their 
composition.
Pinocytosis is a ubiquitous process which can be divided into three categories, fluid 
phase (non-specific), adsorptive and receptor-mediated [see Figure 1.8], Fluid phase 
pinocytosis is a constitutive phenomenon common to all cell types, and is characterised by 
ongoing membrane invagination to form a vacuole, called a pinosome. This enables the 
capture of macromolecules, such as PVP, dextran and HPMA, (122) present in the extra 
cellular fluid. Uptake is poorly efficient and the rate is directly proportional to the extra 
cellular concentration of the macromolecule.
In the case of adsorptive pinocytosis, the substrate binds to the plasma membrane 
and is internalised with the pinosome (123). This results in an increased rate of uptake over 
fluid-phase mediated processes (124). Non-specific adsorptive pinocytosis of 
macromolecules usually occurs due to hydrophobic or charge-dependent interactions, and is 
frequently independent of cell type (125,126). It can be influenced by a number of factors, 
such as; chemical composition of the macromolecule; molecular size (a large molecule 
having an increased number of interaction sites per molecule); or by having a positive 
charge, resulting in ionic interactions with the negatively-charged cell surface. Interactions 
between macromolecules and soluble serum components may result in large complexes, and 
an increased uptake (127) which is occasionally referred to as "piggy-back" endocytosis.
In contrast, receptor-mediated pinocytosis can be a highly efficient, highly specific 
uptake process. The ligand of, for example, low density lipoprotein (LDL), hormone (EGF), 
or plasma proteins, can occupy a receptor, resulting in internalisation of receptor-ligand
28
complex. Most endocytic vesicles fuse with and deliver their contents to primary lysosomes, 
thereby forming secondary lysosomes. In some cells, a part of the endosome escapes 
degradation and is transferred to another part of the plasma membrane. Here the vesicle 
fuses and releases it's contents to the exterior, a process called exocytosis. If the cells are 
polarised, e.g. endothelial cells, macromolecules can be transferred from the apical to the 
basolateral cell membrane, a process called transcytosis.
Figure 1.8. Endocytosis: the internalisation of extracellular 
material by invagination of the plasma membrane.
Endocytosis.
Phagocytosis. 


















In the case of receptor-mediated endocytosis, the receptor-ligand complexes tend to 
cluster into special membrane areas that are invaginated forming coated pits. The number of 
available receptors on the cell surface is therefore temporarily reduced (down regulated) for 
some time after the uptake (128). This down regulation is a way in which the cell can 
control the uptake of specific macromolecules and has limited the use of monoclonal
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antibodies to act as drug carriers (129). The coated pit pinches off from the cell surface and 
rapidly loses it's clathrin coat before fusing with other vesicles to form large endosomes.
The endosome (or C.U.R.L. - Compartment of Uncoupling of Receptor and Ligand) has a 
dual purpose. An active proton pump maintains a low pH and enables the receptor to 
dissociate from the ligand (130). Often the receptors are recycled to the plasma membrane, 
e.g. LDL and asialoglycoprotein (ASGP) receptors (131), or in contrast, the receptor can be 
transferred to the lysosome with the ligand, e.g. epidermal growth factor. Most 
macromolecules are then directed via a series of vesicle fusion events, which may involve the 
Golgi apparatus, into a secondary lysosomal compartment where they are exposed to 
lysosomal enzymes. A proportion of the endosomes may fuse with the Golgi apparatus 
which can rapidly transfer ligands into primary lysosomes and recycle receptors to the 
plasma membrane (132). The acid milieu of the lysosomes comprises approximately sixty 
enzymes including proteases, nucleases, phosphatases, glycosidases, sulphatases, lipases and 
phospholipases, and is capable of degrading every class of natural macromolecule entering 
the cell (133). Within the lysosome, the macromolecules are degraded to small metabolites 
which can be transported across the plasma membrane to be used in metabolism in other 
parts of the cell [see Figure 1.9].
Macromolecules that are non-biodegradable are retained within the lysosome for 
long periods of time, for example, hydroxyethyl starch and PVP have a half-lives of 132 and 
64 days respectively in the liver and spleen of the rat (134) while the lysosomal half-life of 
the endocytosed protein is, in general, only a few hours (135). This means that a drug 
carrier that is metabolically inert or only slowly biodegradable may reside within secondary 
lysosomes long after the drug has been released and eliminated. Lysosomal accumulation 
(thesaurosis) of the carrier may be acceptable, or even positively advantageous, if the target 
cell is a cancer cell, but less so if the target is a normal cell (136).
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Figure 1.9.
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Reports suggest that thesaurosis may cause an increase in osmolarity within the 
compartment which may result in the swelling and rupturing of the lysosomal membrane 
whereas other studies suggest the storage of non-degradable or slowly degradable material 
within the lysosome may impair the normal phagocytic capacity of the target cell (137).
In general, the lysosomal membrane is impermeable to hydrophilic compounds that 
are larger than the natural monomers used in the various metabolic pathways, e.g. amino 
acids, monosaccharides (136). In order to avoid "storage disorders" and effect the complete 
removal of a carrier from the body, the carrier must therefore be totally biodegradable within 
the lysosome. The rate of degradation within the lysosome will be dependent on the 
hydrophilicity of the carrier, the type of linkage between the carrier and drug, and the degree 
of drug substitution. Lysosomal storage disorders will also depend on the dose given, the 
frequency of administration and the kinetics of lysosomal accumulation.
1.10. The incorporation of biodegradable spacer molecules in drug-carrier 
conjugates.
Ringsdorf (102) conceived the concept that covalent conjugation of a drug to a 
polymeric carrier via a biodegradable spacer amenable to specific enzymatic or hydrolytic 
cleavage would be advantageous. Careful choice of the drug-polymer linkage can ensure 
that the drug is released only following internalisation and subsequent cleavage by lysosomal 
enzymes. The conjugate should be completely stable and inactive in the bloodstream. If the 
spacer is cleaved before arrival at the target site, the carrier becomes totally redundant, and 
the drug is released, which may cause harmful side effects. In early studies, mixtures of 
isolated rat lysosomal enzymes (tritosomes) were used as the most convenient in vitro test 
system to study spacer degradation. Later, purified bovine spleen enzymes, cathepsins B, H 
and L were also used, which have activity analogous to human cathepsin (138).
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The acidic pH of some solid tumours, albeit an extracellular phenomenon, suggests 
that an acid-sensitive linker may provide both rate control of drug delivery and some tumour 
selectivity. Shen and Ryser (139) were the first to demonstrate the use of pH-sensitive 
spacers to conjugate daunorubicin to poly(lysine), using the pH-sensidve cis-aconityl spacer. 
The spacer had a half-life of less than 3 hours at pH 4, but was much more stable at pH 6, 
having a half-life of more than 96 hours.
Peptidyl spacers have been developed for attachment of drugs to polymers as their 
amino acid sequence can be specifically chosen to facilitate intracellular degradation by the 
lysosomal proteases (138,140). Addition of the thiol-proteinase inhibitor leupeptin to the 
incubation medium caused a pronounced decrease in the rate of intracellular hydrolysis of 
peptidyl side chains indicating the involvement of thiol proteinases in degradation (141). 
These include the lysosomal thiol-dependent proteases, cathepsins B, H, L (142) and 
lysosomal aspartic protease cathepsin D (143). Cathepsin D has a pH optimum in the acidic 
range (pH 2.8 - 5.0), whereas the thiol-dependent enzymes have much broader optima and 
retain considerable activity at neutral pH. Drug conjugates that contain non-biodegradable 
spacers do not show anti-tumour activity in vivo confirming the need for extensive research 
to find a degradable peptide link that will ensure efficient drug release once the carrier is 
within the lysosomal environment The first drug bound to a non-degradable polymer by 
enzymatically-degradable side chain was prepared by Jatzkewitz (145). He used poly(vinyl- 
pyrrolidone)(PVP) as a carrier for 3,4,5-trimethoxyphenethylamine (mescaline) which was 
attached to the carboxylic acid of the dipeptide spacer, glycyl-L-leucine, as an amide.
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Figure 1.10. Time course of enzymatic hydrolysis of HPMA polymeric prodrugs containing 
adriamycin (ADR) by tritosomes.
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(O) Gly-Leu-Gly; (A) Gly-Phe-Gly; (O) Gly-Phe-Leu-Gly; (■) Gly-Phe-Leu-Gly (polymer also containing 
galactosamine); ( • )  Gly-Leu-Phe-Gly. [from Subr et al (144)].
Kopecek (146) later studied a series of co-polymers of HPMA bearing oligopeptide 
side chains terminating in 4-nitroaniline (drug model). The study convincingly showed that 
by changing the length and composition of the oligopeptide sequence it was possible to 
change the rate of drug model release. The highest drug release was obtained with cathepsin 
B-catalysed hydrolysis of the oligopeptide sequences, Gly-Phe-Tyr-Ala and Gly-Phe-Leu- 
Gly. Similar results were reported by Subr et al (144) who found that the rate of release of 
melphalan and adriamycin from HPMA copolymers varied from 10% (Gly-Gly) released per 
day to more than 80% (Gly-Phe-Leu-Gly) per day [see Figure 1.10]. Trouet (98) in 1984 
used a variety of spacer arms based on leucine and alanine to link albumin to the 
anthracycline, daunorubicin.
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The most successful of those conjugates were based on the tripeptide, Leu-Ala- 
Leu-daunorubicin or the tetrapeptide, Ala-Leu-Ala-Leu-daunorubicin, which showed 
gready improved chemotherapeutic activity against LI210 leukaemia both in vitro and in 
vivo. Several amino acid and dipeptide derivatives of daunorubicin were also synthesised 
with Leu-daunorubicin, Leu-Leu-daunorubicin, and Ala-Leu-daunorubicin, showing 
striking activity against sub-cutaneously implanted L1210. The hydrophobic nature of 
these conjugates suggests that they may easily gain access to the sub-cutaneous tissues 
and that they are extensively hydrolysed into daunorubicin by lysosomal enzymes present 
in the tumour cells.
1.11. Targeting.
Many drugs show little, if any, inherent specificity for their site of action. 
Selective targeting of drugs to a specific site will not only reduce the side effects to the 
host, but will also increase the therapeutic efficacy. Many first order delivery systems 
[see Figure 1.11] have been identified that achieve very effective organ (compartmental) 
drug targeting.
Figure 1.11.: Theoretical aspects of first- and second-order targeting.
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Liposomes, particulate systems and macromolecular carriers have been developed 
which can deposit a large percentage of an intravenous dose into the liver, lung or
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kidneys. This approach is advantageous for regional delivery of antitumour agents for 
treatment of primary or secondary disease, but clinical success is awaited. To achieve 
tumour-specific (second order) targeting, it is necessary to identify unique features of 
tumour cell biology that will concentrate drug within the tumour. Researchers have 
investigated both passive and active targeting strategies to achieve this goal.
1.11.1. Passive targeting.
Passive targeting is often associated with liposomal and particulate fields of drug 
delivery with their embolisation or capture by phagocytic cells of the reticulo-endothelial 
system. However, there is unequivocal evidence that many macromolecules do passively 
accumulate within solid tumours and it is unlikely that this is solely as a result of 
enhanced pinocytic capture. The phenomenon has been studied in depth by Maeda and 
co-workers (148) who termed tumour accumulation of macromolecules the "enhanced 
permeability and retention effect (EPR)", attributing it to two factors; leaking tumour 
vasculature and lack of effective lymphatic drainage.
The capillary endothelium is of profound significance in the biodistribution of 
macromolecules and drug conjugates. The three main types of capillary endothelium are; 
continuous, with the lowest permeability characteristics, found in the skeletal muscle, 
skin, lung, heart, brain; fenestrated, present in the kidney, gastro-intestinal tract mucosa 
and endocrine glands; and sinusoidal found in the liver, spleen and bone marrow. 
Fenestrated and sinusoidal epithelium are virtually freely permeable to molecules < 20 
KDa although most tumour capillaries are of a continuous type (149). It has been 
demonstrated that some tumours, particularly those found in the liver, kidneys or 
exocrine glands, can induce the angiogenesis of fenestrated or sinusoidal vessels (150).
A substantial number of solid tumours have been reported to possess blood vessels that 
are relatively permeable to macromolecules, compared with blood vessels serving normal 
tissue (151,152). This leakiness was shown to be confined to the venules running along
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the periphery of tumours and at the tumour - host interface (153). This phenomenon has 
been attributed to tumour angiogenesis, i.e. the process by which tumours attract in 
growths of new capillaries to provide a blood supply to neoplastic tissues. Such in 
growths are almost entirely composed of endothelial cells, whereas normal capillaries 
contain pericytes. The function of pericytes is to induce maturity and differentiation to 
the capillary, thereby reducing non-specific permeability.
The EPR effect can also be augmented by a tumour vascular permeability factor 
(154) and other factors such as bradykinin and it’s derivative (3-hydroxypropyl)- 
bradykinin. Kinin is a potent permeability and pain-inducing factor, with highly elevated 
levels shown to be present in rodent and human ascitic fluid of many cancers (155). In 
addition, it has been demonstrated that a vascular permeability factor is secreted by a 
broad spectrum of animal and human tumour cells (154). The physiological purpose 
underlying hyperpermeability of tumour epithelia is concerned with the import of 
sufficient fibrin to permit the formation of a functional tumour interstitium, essential to 
successful tumour development This clinically-observed phenomenon (156,157) allows 
the passive targeting of soluble macromolecules through enhanced tumour extravasation. 
The process is generally size exclusive (< 30 nm diameter) and therefore amenable to 
soluble macromolecules, whose functional size is often less than 30 nm (typically 5-8 nm) 
(158). There is little morphological evidence to date suggesting the increased rates of 
extravasation observed are due to enlarged interendothelial spaces. Instead, authors 
suggest that the process is mediated by enhanced vesicular transport or by 
transendothelial channels (159).
Lipophilic molecules and macromolecules ordinarily show little bulk diffusion 
into the blood circulation following extravasation from normal tissue. Instead they are 
preferentially returned to the general circulation via the lymphatics (160). In solid 
tumours, this situation is fundamentally different since they lack any organised system of 
lymphatic drainage [see Figure 1.12]. Consequently, components of the interstitial fluid
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that are not drained by entry into the post-capillary venules, have no effective mode of 
drainage and accumulate. This was demonstrated by using the lipid lymphographic 
agent, lipiodol (161). This may give rise to elevated interstitial pressures which 
encourages the movement of macromolecules through the tumour interstitium by a 
process called convection. After seeping through the tumour, conjugates will collect on 
the periphery of the tumour, from here they are drained by the lymphatics of normal 
tissue. This simple concept forms the basis of the EPR effect, and is the basic 
mechanism being applied in cancer-targeting chemotherapy.
Angiotensin Il-induced hypertension has been proved to result in the selective 
increase in the blood flow in tumour tissue only, and not in normal tissue (162). 
Therefore, following angiotensin Il-induced hypertensive state, anticancer agents bound 
to macromolecules leak out less effectively into normal tissues. Conversely, the lack of 
vascular contraction within the tumour bed facilitates leakage of plasma and 
macromolecules which may enhance the selective deposition of drugs. This has recently 
been effectively demonstrated in vivo with SMANCS and (51 Cr)BSA administration to 
rats (163). In addition, anticancer drags would be more readily confined to the normal 
circulation following angiotensin II administration, reducing the side effects seen using 
an equal amount of anticancer agent. It was noted that small molecules, i.e. (3H) methyl 
glucose were able to diffuse freely in and out of the blood vessels and showed no 
preferential accumulation Thus, both the anatomical differences and the molecular size 
and property of the drag appear to be critical for selective tumour targeting.
Although drag carriers can display effective first order targeting to the organs, 
e.g. liver, and advantageous pharmacokinetics with ability to concentrate passively in 
solid tumours, the feasibility of tumour-specific second order (active) targeting is 
continually being pursued. The use of carriers that recognise an antigen receptor or 
some other marker at the target site may enhance this delivery of drags. In recent years, 
much progress has been made in efforts to target cytotoxic agents to tumour cells using
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monoclonal antibodies recognising tumour cell-associated antigenic markers (129, 164) 
[see Section 1.7.1./.].
Figure 1.12. Schematic representation o f extravasation and fluid drainage 
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Ref; Maeda et al (148).
1.11.2. Active targeting.
A number of ligands of importance to metabolism are brought into the cell by receptor- 
mediated endocytosis and include nutrients such as vitamin B12 (as a B12-transcobalamin
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II complex), and growth factors such as insulin. This highly efficient uptake process 
does have the potential for tumour targeting when cells display a high density of ligand- 
specific membrane receptors. Unfortunately, many of these receptors have a broad 
cellular distribution, e.g. transferrin, LDL, epidermal growth factor, making them less 
than ideal targets. Recognition systems for terminal sugars on carbohydrate chains of 
glycoproteins include; galactose receptors of mammalian hepatocytes (165), Kupffer 
cells (166), liver endothelial cells (166) and bone marrow (167), the N-acetyl 
glucosamine receptor of avian hepatocytes (168), the mannose-6-phosphate receptor on 
a variety of mammalian tissues (169), the receptor for a high affinity for fucose on mouse 
L1210 leukaemia cells (170) and the mannose/N-acetyl glucosamine receptor on alveolar 
macrophages (60) and other cells, including the reticulo-endothelial system [see Figure 
1.13]. The asialoglycoprotein receptor is exclusive to hepatocytes and responsible for 
the clearance of galactose-terminated glycoproteins from the circulation (171). This 
receptor has been used to good effect In 1986, it was shown that HPMA co-polymers 
modified with galactosamine were internalised by rat liver hepatocytes, in vivo, and a 
drug was liberated intralysosomally (112). When administered iv . at low dose, the 
polymer ADR-Gal is captured very effectively by the liver (more than 80% of the dose 
administered). However, receptor saturation does occur at higher doses and thus 
significantly decreases the desired specificity (105). Therefore, to facilitate first order 
targeting to the liver for treatment of primary or secondary liver disease, a continuous 
infusion or repeated low bolus dose regimen would be ideal.
The hepatic galactose receptors occupy a dominant role in the clearance of 
galactose-bearing conjugates. This is advantageous to site-selective drug delivery but it 
is possible that other potentially useful or harmful galactose mediated interactions may be 
obscured by the hepatic recognition systems. Seymour et al (172) demonstrated that 
both intraperitoneal and sub-cutaneous injection of HPMA co-polymers, bearing a high 
concentration of galactose residues, resulted in pronounced accumulation in local fatty 
tissue.
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Optimistically, this interaction may afford the possibility of drug targeting to fat cells, 
although it underlines the dangers of targeting drug carriers to supposedly discrete 
second order receptors.
Seymour et al reported, in 1987, enhanced deposition of HPMA copolymers 
bearing mannosamine or glucosamine in liver macrophages of rats. These in vivo 
experiments demonstrated that polymers bearing the targeting moiety were internalised 
rapidly by a common receptor. This interaction could be inhibited by free D-mannose or 
L-fucose, giving further evidence for a receptor-mediated system (173). Bard et al (174) 
proposed a different approach to the targeting problem. A superactive analogue of a- 
melanocyte stimulating hormone (MSH) was conjugated to diethylenetriamine penta- 
acetic acid (DTPA) (MSH(4-10)-DTPA), and was successfully used for the targeting of 
imaging agents for mice melanomas in vivo. Recently, Sunassee et al (175) produced 
125I-labelled MSH-HPMA polymer conjugates which showed a broad body distribution 
in normal mice. Unfortunately, preliminary experiments using mice bearing a MeWo 
(melanoma cell line) xenograph, suggested that less than 1% of an intravenous dose 
localised in the tumour.
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Photodynamic therapy (PDT) has been developed in order to achieve double 
targeting; site specificity of the drug by virtue of a targeting moiety (176,177) and light 
specificity. Photosensitizers, e.g. chlorin e6 bound to targeted HPMA co-polymers will 
become associated with target tissues in discrete areas of the body. However, by 
illumination of the target area only two-fold selectivity may be achieved and side effects 
reduced. Preliminary results are satisfactory although one major side effect is 
phototoxicity which requires patients to remain out of direct sunlight for six to eight 
weeks following treatment
It is perhaps obvious to state that targeted polymer drugs enter the cell via 
different receptor mechanisms, depending on the targeting moiety. In the case of the 
HPMA-chlorin e6 targeting groups, galactosamine and anti-Thy 1.2 antibody, this gave 
rise to differences in the observed phototoxicity (176). The asialoglycoprotein receptor 
participates in the regulation of serum glycoprotein homeostasis (178), while Thy 2.1 
antigen may function as a signal transducing molecule (179). Such differences in 
phototoxicity may be explained by; (a) the different number of membrane receptors; (b) 
the difference in the affinity of the receptors; (c) different rates of endocytic uptake; (d) 
different endosomal fates.
1.12. Macromolecular Drugs and Enzymes.
Most pharmacologically active agents are low molecular weight compounds 
which readily penetrate into all cell types, but are also rapidly excreted. Consequently 
large and repeated doses must be applied in order to maintain a therapeutic effect 
However, due to a limited specificity of the majority of drugs a range of serious side 
effects are often observed. By conjugating a drug to a soluble polymeric macromolecule 
such side effects are often reduced as the conjugate uptake is restricted to certain target
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cells. At the same time the efficiency of drug action can be dramatically increased by 
directing them selectively to their cellular targets.
One of the most important limiting factors when designing a polymeric drug 
delivery system is the drug carrying capacity of the conjugate. The drug must possess 
adequate functional groups for conjugation but these should be separate from the active 
site of the drug. The pharmokinetics, formulation and clinical issues should also be 
addressed, together with the influence of high drug substitution on the pattern of 
biodistribution and biodegradation. McCormick (180) demonstrated that metribuzin 
when linked to PVA via a number of different linkages exhibited an increased drug 
release when the degree of substitution was decreased. It was proposed that at high 
drug substitution the access of water due to the hydrophobicity of the drug was 
restricted and this was responsible for the rate limiting step of degradation.
Although many anti-tumour agents have been conjugated to soluble 
macromolecular drug carriers, three classes of drug have received most attention:
(a) Anti-metabolites:- drugs in this category are analogues of essential endogenous 
compounds, (for example replacing -OH and -H in folic acid with -NH2 and -CH3 
respectively produces methotrexate (MTX)). MTX [see Figure 1.14(a)] inhibits the 
enzyme dihydrofolate reductase in both tumour cells and normal tissues. Although 
potent effects on tumour cell growth can be obtained toxicity against other rapidly 
dividing cells makes it's effective use difficult;
(b) Drugs affecting DNA:- the anthracycline antibiotics, e.g. daunomycin, adriamycin a 
similar problem is encountered with intercalating agents which are effective antitumour 
agents against a variety of human malignancies. Daunomycin is principally active against 
acute lymphocytic leukaemia (ALL), but adriamycin has a much broader spectrum of 
activity against a variety of tumours including certain solid tumours [see Figure 1.14(b)]. 
This class of drugs is believed to inhibit the activity of DNA and RNA polymerases. 
However, in addition to causing bone marrow depression these drugs demonstrate
43
serious and irreversible cardiac toxicity which frequently necessitates withdrawal of 
therapy (181). Analogues of the anthracyclines such as epirubicin and idarubicin have 
improved properties but their clinical success has been slight and adriamycin is still 
frequently used;
(c) Alkylating agents:- e.g. melphalan. All effective anti-neoplastic drugs in this class 
possess two alkylating groups [see cis-platin, Figure 1.14(c)]. The highly reactive cyclic 
cations formed spontaneously in an aqueous solution bind to side chains of large 
molecules, especially the guanine codon of DNA. This causes functional damage to the 
DNA. Any unbound cyclic cation is spontaneously hydrolysed to an inactive alcohol. 
Cis-platin has a wide spectrum of clinical activity but is often associated with 
nephrotoxicity and emesis. Chlorambucil is another derivative of Nitrogen mustard 
which has been cross-linked to a number of carrier molecules, e.g. TS-mAb (3,182).
Neoplastic drugs which are routinely administered to patients in high doses such 
as 5-fluoruracil and MTX are poor candidates for use with polymeric carriers considering 
the paucity of conjugates finally reaching the tumour (183). For this reason many 
investigators have chosen to combine more potent drugs, e.g. anthracyclines, mitomycin 
C and cis-platin analogues to the polymer.
The natural toxins are ideal in this respect since they are powerful therapeutic agents, 
examples include ricin, diphtheria toxin and abrin. Unlike drugs which usually react 
stoichiometrically, plant toxins react catalytically and are thereby capable of extreme 
cytotoxicity in very low doses; one molecule of toxin per cell may cause cell death (184). 
These toxins comprise of two polypeptide chains (A and B, disulphide bridged, each 
about 30 KD) neither of which is separately toxic to cells (185). The B-chain is 
concerned with binding to the cell surface and internalisation of the A-chain into the 
cytosol where it terminates protein synthesis (186). The toxins have been conjugated to 
a number of macromolecular carriers in an attempt to restrict their action to specific 
locations, these include antibodies (187), lectins (188), hormones (189) and epidermal
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growth factor (190). It is usual to use the A-chain alone since the complete molecule 
may still retain some non-specific action leading to toxic effects on normal cells. Certain 
polymeric biological carriers (tumour specific mAb) or biological response modifiers 
{e.g. recombinant inter-leukin-2 ) are capable of exerting a direct cytotoxic or an immune- 
system mediated effect respectively. Conjugation of rIL- 2  to PEG markedly increased 
the anti-tumour potency of rEL-2 in the Meth A sarcoma model (191). Synthetic 
polymers with antineoplastic activity have also been reported (104).
Eigigg_L 14(a), Methotrexate.
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Photosensitisers arc molecules that are activated by visible light and are currently 
being assessed as cytotoxic agents both for cancer therapy and for autoagressive immune 
disorders (176,177). Two photosensitisers that have been extensively studied are the 
porphyrins and chlorins [see Figure 7.75], with the latter achieving greater tissue 
penetration and photoactivation. To this end, contemporary interest now centres on 
photosensitisers activatable by red light which is of a higher wavelength and enables a 
better tissue penetration. Photodynamic therapy (PDT) is based on the dye-sensitised 
photo-oxidation of intracellular components with damage at multiple sites. The 
photolytic activity of galactosamine targeted or anti-Thy 1.2 targeted polymeric (HPMA) 
chlorin e6 has been documented, with promising results. However, more work is needed 
to evaluate their full therapeutic potential.
Conjugating a drug to a soluble polymeric macromolecule will render the drug 
lysosomotropic. The drug must therefore not be acid labile or undergo lysosomal 
degradation. Equally if a drug requires access to an intracellular receptor to initiate 
activity then it is useless to bind that drug to a carrier via a non-biodegradable linker, this 
will prohibit drug release and therefore cytoplasmic penetration. Similarly compounds 
with limited plasma stability are often not good candidates for polymer conjugation since 
they would be theoretically inactivated whilst in transit before reaching their cellular 
target. The use of macromolecules has to some extent resolved this problem as the 
carrier often acts to sterically protect the drug from hydrolytic degradation increasing the 
stability of the drug.
There are some drugs which are active even when permanently bound to a 
carrier. Trypsin-kallikrein inhibitor retains most of it's activity against trypsin when 
bound to the polyaspartamide carrier (192) provided the lysine residues are not blocked. 
Another example is novocaine which retained 95% of it's activity when bound to dextran 
(72). On the contrary, the mitomycin C-dextran [see Figure 1.16] conjugates exert their
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toxicity following chemical hydrolysis, thus providing a sustained release of the active 
drug.
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One of the most important factors in designing a biodegradable carrier is the 
choice of the polymer. Existing as the major component within the final product the 
polymer will influence the pharmacokinetics of the system. With extensive study PEG 
has found applications as a plasma expander and is approved by the Federal Drug 
Administration (FDA) for use in drugs (parenterals, topicals, suppositories, nasal sprays), 
foods and cosmetics. In addition, the linear polymers have been employed as soluble 
matrices for liquid - phase peptide synthesis, metal complexing and phase partitioning of 
immiscible aqueous solutions. PEG has as an uncharged, hydrophilic, inert, non- 
immunogenic nature (193) and exists in a variety of molecular weights. Other useful 
properties include their low cost, ease of chemical modification and solubility in both 
aqueous and organic solvents. It is therefore clearly suitable as a drug carrier in the 
body. Removal of PEG from the body takes place passively through renal clearance, 
with a higher molecular weight polymer having a greater half-life. The above qualities 
alone do not constitute a biodegradable carrier compound. However, by activating the 
two functional groups present on PEG the polymer can be modified to carry groups 
which are susceptible to degradation.
1.13.1. The Advantages of PEG-Modifled Proteins.
The potential value of proteins as therapeutics has been recognised for years. To 
use as a drug a compound which is found in vivo would seem to have no equal. Such a 
drug would have activity at specific sites only and should not illicit any side effects. 
However, the therapeutic applications of a number of proteins, peptides, hormones, 
enzymes and drugs are often compromised. Proteins tended to have low stability as 
pharmaceuticals and short blood circulating lives. This problem arises whether the 
source of protein is human, exogenous or recombinant and is often mediated through 
immunological processes and circulating proteases. In addition to this, repeated
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administration of proteins is often associated with the development of hypersensitivity 
(194,195,196) which could lead to anaphylactic reactions and even death. 
Hypersensitivity is a problem irritated by the need to maintain regular administration, or 
increase high dosages to combat efficient blood clearance. The clearance of therapeutic 
drugs in vivo results in the characteristic rise and fall of the circulating drug. Often this 
results in sufficient beneficial levels that are maintained only for a brief period with much 
of the drug circulating at sub-clinical dosage for the majority of time.
The development of cloning techniques and the establishment of large scale 
manufacturing processes allowed the production of huge quantities of human 
recombinant protein (HrP). It was believed that proteins derived from human sources 
would eliminate many of the problems found with non-human protein. In general the 
immunogenic problems of protein therapeutics were resolved, although poor stability and 
short circulating half life still existed. This again made it necessary to administer large 
doses of what was now a high cost drug due to the recombinant technology required to 
produce HrP. Non-human protein costs were generally low, and resulted in low cost 
pharmaceuticals.
To overcome the problems associated with the use of proteins (from both human 
and non-human sources) for therapeutics, a number of drug delivery technologies are 
being evaluated. The discussion in the preceding chapter hinted at the plethora of drug 
delivery molecules under investigation. In some cases proteins can be manipulated with 
polymers to eliminate some of the drawbacks of native proteins and it is an area of 
research which is crucial to the development of a general application for enzyme therapy.
Several enzymes have been favourably modified with PEG (196,197,198,199). 
As a general rule, PEG-modified proteins exhibit increased stability, increased resistance 
to proteolytic inactivation, decreased /  non-existent immunogenicity, increased
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circulating lives and low toxicity. In addition PEG-modified proteins have been shown 
to be soluble in organic solvents yet retain activity (2 0 0 ).
The modification of proteins with PEG can confer a number of advantages and 
unique characteristics to the conjugate. From a clinical viewpoint the increase in 
circulatory life and a reduction in immunogenicity have had greatest impact. Smaller 
doses of PEG-enzyme should be needed, and the frequency of injections could be 
decreased facilitating patient management In chemical terms, the enhanced solubility 
and stability of proteins conjugated to PEG has opened up attractive avenues of research.
The sharp rise in circulatory half life seen when proteins are modified with PEG is 
due to a change in a number of factors. However, it has been postulated that all these 
effects are due to the formation of a shell of PEG molecules around the protein. This is 
believed to sterically hinder recognition of the foreign protein by the immune system 
(201). In some cases modified proteins circulate similarly in virgin and immunised (to 
the protein) mice, indicating that the PEG adduct is non-immunogenic (194,196,202, 
203), and therefore not cleared from the circulation by the immune system. The extent 
of immunogenicity, however, varies with each protein and the percentage of PEG 
attached to the protein surface (204). Steric hindrance may play an important role in 
preventing the uptake of protein conjugates by RME (receptor mediated endocytosis)
(205), and the recognition by various circulating enzymes (195). It has also been shown
(206) that proteins conjugated to PEG are more resistant to proteolysis and clearance 
through glomerular filtration by the kidney (205) than their unmodified counterparts, 
thus increasing their circulatory half life still further. Davis et al (207) reported little 
change in the immunogenicity or blood circulating lives of rIL-2 after repetitive 
injections. This important work revealed that maintaining systemic exposure caused no 
detrimental reaction by the immune system. This will be clinically important for patients 
under a long term medical regime.
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As PEG is extremely hydrophilic, the formation of a water shell around the 
protein can explain the retention of biological activity of the protein in organic solvents 
and the increase in solubility (208). Solubility is increased to an extent whereby proteins 
which are normally insoluble under physiological conditions can be solubilised by PEG 
attachment (209). Solubility in organic solvents such as benzene, toluene, acetone, 
ethanol and dimethylformamide has also been demonstrated (2 1 0 ).
The activity of most proteins following modification by PEG is usually decreased
(211), often as a result of conformational changes in the protein structure. However, this 
loss of activity is more than offset by the concomitant increase in vivo in circulating life 
in the blood stream [see table 1.1]. Several cases of enhanced activity obtained as a 
result of PEG attachment to proteins have been described in the literature. Beauchamp
(212) and Zalipsky et al (213) both observed enhanced activity of PEG-modified trypsins 
toward substrates. Naoi et al reported an enhanced activity of PEG- p-galactosidase 
toward hydrophobic substrates and substantial activity toward GMr ganglioside (214).
To summarise, a clinically useful enzyme appropriately modified with PEG would have:-
(1) an increased circulatory life.
(2 ) a reduction in immunogenicity and antigenicity.
(3) minimal loss of biological activity.
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Table 1.1. A comparison of the half life of various PEG modified proteins.







30 min 28 min 326



















5 min 4.20 h 330
Uricase Candida
utilis
IV human < 3 h 8 h 331
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1.14. The Project
It is clear from the work cited in this preliminary introduction that both PEG monomers 
and biodegradable oligopeptide sequences offer interesting opportunities for further 
development With the exception of Ulbrich's paper on PEG containing enzymatically 
degradable bonds (341), research into biodegradable copolymers with oligopeptide 
chains has largely been over-shadowed by HPMA work, (Section 1.8).
Ulbrich successfully demonstrated the degradation of an oligopeptide sequence attached 
pendantly to a PEG polymer backbone, with the release of a fluorescent dye. It is 
proposed that by incorporating an oligopeptide in series with a suitably derivatised PEG 
monomer the degradation rate of the peptide chain will remain unchanged. It is expected 
therefore that a copolymer comprised of alternating PEG and oligopeptide will be 
susceptible to enzymatic degradation. Such a copolymer could be suitable for in vivo 
applications since complete degradation of the polymer would produce discrete PEG 
monomers capable of traversing the cell membrane and ultimately being excreted. In 
addition by carefully selecting the size of PEG monomer the solubility of the peptide / 
PEG conjugate could be enhanced providing a biodegradable, soluble copolymer.
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Chapter 2. The Epoxides
2.1. Strategy.
The reaction of a,o>-bis(methylamino)PEGs with a,co-bis(glycidyl)peptides was 
chosen as the copolymerisation strategy. The ability to generate the a,oo-bis(glycidyl)- 
peptides was studied using three approaches. In the first a bis-allyl was treated with the 
peroxy acid, MCPB A to affect the conversion of the olefin to an epoxide. In an 
alternative strategy, the peptides were synthesised between (methoxy)aryl or 
(benzyloxy)aryl groups. Hydrogenation of the less robust a,co-bis(benzyloxy)peptides 
affected debenzylation and the phenolic hydroxy groups were subsequently converted to 
the a,G>-bis(glycidylethers) by treating with epichlorohydrin.
2.2. Introduction. The Epoxides.
Heterocyclic compounds are cyclic structures in which one or more ring atoms are 
hetero atoms, a hetero atom being an element other than carbon. The three membered 
rings, containing oxygen, are readily prepared from alkenes and because of this they are 
sometimes referred to as olefin oxides. The simplest heterocycle is ethylene oxide which 
can be called an epoxide, but is formally recognised by IUPAC as an oxirane. Ethylene 
oxide is a significant commercial item and is prepared industrially by the catalysed air 
oxidation of ethylene, (,Scheme 2.1).
H2C=CH 2 ^ »  A Scheme 2.1 
Ag Z \
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Due to the ring strain associated with the three membered ring, epoxides are much 
more reactive than other ethers. However, the epoxides are cleaved quite easily and 
protonated epoxides more readily still. The oxetanes are four-membered ring ethers which 
are more stable than the epoxides to ring opening reactions, but are still cleaved more 
readily than open chain ethers, (Figure 2.1).
Oxirane Oxetane Tetrahydrofuran 1,4-Dioxane
One of the most important of the cyclic ethers is tetrahydrofuran (THF), which is 
frequently used as a solvent. The five-membered ring is generally stable to ring opening, 
but this can be accomplished under conditions that cause the ether cleavage reactions of 
open chain ethers. A final group of large ring polyethers that have attracted a good deal 
of attention is the crown ethers. These compounds are cyclic polymers of ethylene glycol, 
(-OCH2CH2)n and are important for their ability to solvate cations strongly, (Figure 2.2).
18-Crown-6 Fig. 22.
O
2.3. Methods of Epoxidation (addition of oxygen).
23.1. Hydrogen Peroxide.
It has been reported by Payne that H20 2 has been successfully used for the 
epoxidation of acrolein and acrylonitrile under conditions of controlled pH (215), {Scheme 
2 2 ).
/ C=C-CN + H*°* - ^ 1  ^ C O N H , S c h e m e 2 2 '
H20 2 is, by itself a relatively poor oxidising agent and to achieve epoxidation it must be 
'activated' by conversion to another species. In the above reaction the intermediate is 
probably a peroxycarboximidic acid (216). Another remarkably powerful intermediate is 
trifluoroperoxyacetic acid which is prepared by the reaction of trifluoroacetic anhydride 
with 85 - 92% hydrogen peroxide (so called high test H20 2). The use of this reagent is 
however severely limited by the lack of stability.
232. The peroxidic reagents.
Olefins can be epoxidised with any of a number of peracids of which perbenzoic 
acid is the most commonly used, {Scheme 23). The reaction, which is called the 
Prilezhaev reaction has wide utility. Alkyl, aryl, hydroxyl, ester and other groups may be 
present, though not amino groups, since these are not affected by the reagent. Electron- 
donating groups increase the rate, and the reaction is particularly rapid with tetraalkyl 
olefins. Conditions are mild and oxiranyl yields are high.
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PhCOOH V V
+ I! --------► Vf Scheme 23.
O °
The peroxycarboxylic acids are generally unstable and must be stored in the cold, 
or preferably be prepared as needed. An important exception to this is 3-chloroperoxy 
benzoic acid (MCPB A) which is a stable crystalline solid. Other peracids, especially 
peracetic acid and trifluoroperacetic acid (217) are also reported. Conjugated dienes can 
be epoxidised although the reaction is slower than for the corresponding olefins.
a,P-Unsaturated ketones do not generally give epoxides when treated with 
peracids, for exceptions refer to Hart (218). However, MacPeek reported that a,p 
unsaturated esters react normally to give glycidic esters (219). When a carbonyl is in the 
molecule but not conjugated with the double bond, the Baeyer-Villiger reaction may 
compete.
Allenes are converted by peracids to allene oxides [1] or spiro dioxides [2] which 
are often unstable and react further to give other products, (Scheme 2.4).
C=C=C Peracid /  \  I Pferacid ^ -----r O r —JI | -------- —<j:-c=c—  ► —y \J-
(1). (2).
Scheme 2.4.
Peracids react with C=N to give oxaziridines.
233. Cyclisation of halohydrins.
Many epoxides can be prepared through a displacement reaction involving the 
dehydration of a p-halo alcohol, (Scheme 23).
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Scheme 2 5
The base removes the proton from the OH group and the epoxide then attacks in an 
internal SN2 aliphatic nucleophilic substitution reaction. The method can also be used to 
prepare larger cyclic ethers; five and six-membered rings.
Cainelli et al suggested that the gem dihalides treated with a carbonyl compound 
and lithium or butyl lithium gave epoxides (2 2 0 ), (Scheme 2.6).
R-2 R2
I Li or I R3—C—R4
" ■ T " '  E ,_ ? _ I J  * J
Br Br
li^) Ri O
R3—c —c —R2  ► R3— 1^ | — R 1
R4 Br R4 R2
Scheme 2.6.
An alternative effective oxidation of the double bond may be achieved by the two-step 
addition of aqueous halogen followed by base-catalysed cyclisation, {Scheme 2.7).
r i r ^  ,CH3 ^  .CH3




23.4. Dehydration of alcohols.
Alcohols which have a hydrogen in the 5 position can be cyclised with lead 
tetraacetate (221), (Scheme 2.8). The reaction has also been carried out with a mixture of 
halogen (Br2 or I2) and a salt or oxide of silver or mercury (especially HgO or AgOAc) 
(323).
I n  ?H r-v
Scheme 2.8.
Glycols can be converted to cyclic ethers by dehydration, although the reaction is most 
successful for five-membered rings, thus tetrahydrofurans can be formed in high yields.
233. Carbon adding to carbon.
Aldehydes and ketones can be converted to epoxides in good yields with sulphur 
ylides (222) such as dimethyloxosulphonium methylide [1], {Scheme 2.9);
* * 2 ^ = 0 *  ^ „  M e ^ - C H f  Scheme 2.9.
o o
and the dimethylsulphonium methylide [2 ], {Scheme 2.10);
Me2 S=CH 2 ^ ----- ► Me S—CH2 Scheme 2.10.
When diastereomeric epoxides can be formed, these two reagents attack at 
different sites. Thus 4-f-butylcyclohexanone treated with [1] and [2] will give the 
products shown below, {Scheme 2.11). With reagent [1] the new bond is axial whereas 






Another difference in behaviour between [1] and [2] is that with a,p unsaturated ketones, 
[1] gives only cyclopropanes, while [2 ] leads to formation of the oxirane.
Other sulphur ylides have been used in an analogous manner to transfer CHR or CHR2, 
e.g. Me2S=CHCOO", Me2S=CHPh, Me2S=CH-vinyl. The generally accepted mechanism 
is described, (Scheme 2.11(a)).
Scheme 2.11(a)..
Aromatic aldehydes can be dimerised to epoxides by treatment with hexamethyl 
phosphorous triamide, (223) (Scheme 2.12).
e
f a
+ (Me2N)3PO2ArCHO + (M ^N )^
O
Scheme 2.12.
The reagent is converted to hexamethylphosphoric triamide (HMPT). The reaction can be 
used for the preparation of mixed epoxides by the use of a mixture of two aldehydes in 
which the less reactive aldehyde predominates.
23.6. Damns glycidic ether condensation.
Aldehydes and ketones condense with a  halo esters in the prescence of bases to 
give a , P epoxy esters called glycidic esters in good yields, (Scheme 2.13). For a more 
complete review the reader is directed to Ballester (224).
The reaction consists of an initial condensation followed by an internal SN2 reaction. The 
Darzen reaction has also been carried out on a-halonitriles, a-halo sulphones, a-halo 
N,N-disubstituted amides and even on benzylic halides.
2.4. Discussion
To provide the appropriately derivatised peptides for polymerisation, it has been 
necessary to investigate a number of experimental strategies. The target polymers are 
formed by the copolymerisation of nucleophilic PEG monomers, and short peptide 
sequences derivatised with complimentary electrophilic groups. The glycidylether- 
(peptide) derivatives were chosen as a suitable electrophile for this purpose as they show 







As a model for the peptide chain, L-phenylalanine was chosen for investigation 
into the feasibility of forming a glycidyl ether directly onto the peptide chain. 
Phenylalanine is a convenient, commercially available model to use, as it possesses a 
chromophore which can be visualised easily on T.L.C. using U. V. light. This allows the 
experimental progress of a reaction to be monitored. This amino acid is also an integral 
part of the final tetrapepdde sequence and as such will reflect the chemical strategy 
eventually adopted.
Peroxybenzoic acid was discussed at length in Section 2.3.2. to generate oxiranes 
and has been found to be an efficient reagent for epoxidation of alkenes. By generating an 
unconjugated terminal alkene on both N and C terminals of phenylalanine and treating 
with peroxybenzoic acid, the bis(oxiranyl) amino acid can be generated.
To this end, the N-protected amino acid, BOCphenylalanine (iCompound 7) was 
treated with isobutyl chloroformate and triethylamine. The resulting electrophilic mixed 
anhydride coupled with allylamine to give the N-allylamide, (Scheme 2.14).
BOC—N C—OH
Compound 1.






The first of the attempts to make Compound 2 involved adding one equivalent of 
allylamine quickly to the anhydride, at 0°C. Analysis by NMR revealed a mixture of 
products comprising predominantly of the isobutyl esters. In order to push the reaction 
towards the desired product, an excess of allylamine was used in later preparations, and 
was added dropwise at - 40°C. Conventional work-up afforded a crude product which
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was recrystallised from light petroleum to give the amide in good yield. This material was 
identified as the allylamide by proton NMR spectroscopy. Peaks in the aliphatic region, 5 
3.69 - 5.74, of the spectra were indicative of the alkene and were corroborated by mass 
spectroscopy, (mJz 305 (M + H)) and elemental analysis.
The BOC protecting group was removed by treating the BOCPhe-N-allylamide 
directly with an excess of trifluoroacedc acid (TFA) (225). The mixture was neutralised 
with aqueous potassium carbonate to give the free base phenylalanine-N-allylamide in 
good yield {Compound 3) {Scheme 2.15). Similar deprotection was also achieved using 
hydrogen chloride in dichloromethane. Deprotection of Compound 2 was successful in 
both cases according to JH NMR which showed the disappeareance of the f-butyl peak at 
8  1.3. A method involving cationic Dowex ion-exchange resin refluxed with the protected 
amino acid was attempted with no success.
To attach the second alkene an excess (2 eq.) of allyl isocyanate was added to 
phenylalanine-N-allylamide, {Scheme 2.16) with the formation of the urea. Compound 4 
was obtained in good yield, and was characterised fully by !H NMR. Mass spectroscopy 
revealed a parent ion peak at mlz 288.
The terminal double bonds that were present in Compound 4 should be, according 
to the literature (226), susceptible to epoxidation using the peroxybenzoic acids. MCPB A 
was chosen as a suitable reagent as it provides a simple one step route to epoxide 
formation. However, a mixture of Compound 4 and MCPB A (3 eq.) which was boiled in 






compound. Further analysis of the isolated product by !H NMR revealed a confusing 
spectrum, containing multiple peaks within the alip hatic region. This region of the 
spectrum corresponds to the approximate shift values of the oxiranyl groups. Although 
full structural assignment was not possible it appeared that this material contained one 
oxiranylmethyl group and one allyl group. A series of model experiments were therfore 
undertaken to predict which of the allyl groups had been epoxidised and which was 
resistant to MCPB A.
2.4.1. Modes fo r the epoxidation reaction
To investigate which olefin was susceptible to epoxidation with MCPB A, 
analogues bearing terminal allyl groups were synthesised. The first analogue was 
synthesised by treating benzoyl chloride with an excess of allylamine to form N- 
(allyl)benzamide, Compound 5, (Scheme 2.17). The amide was formed in good yield after 
a conventional work up. The broad singlet in the NMR at 5 6.97 could only be 








For the second analogue, Compound 6, reaction of aniline with allyl isocyanate 
gave the urea in moderate yield after careful trituration with heptane, (Scheme 2.18).
Characterisation with NMR revealed the loss of the aniline primary amine peak circa 5 
9.5 ppm and the formation of the two amides NHs at 8  7.62. Further data from mass 
spectroscopy showed a parent ion at mlz 176. The formation of the urea in low yield was 
uncharacteristic of this type of reaction, where the reaction of the isocyanate involves 
nucleophilic attack on the multiply-bonded carbon, followed by the addition of a proton to 
nitrogen to form the urea. It was noted that the aniline used for the experiment showed 
signs of deterioration which may have introduced impurities into the reaction.
It was hypothesised that the third analogue N-phenylpent-4-enamide {Compound 
7) {Scheme 2.19) may be more susceptible to epoxidation. By introducing pent-4-enoic 






The acid chloride of pent-4-enoic acid was isolated by distillation and added to an excess 
of aniline to give the known amide Compound 7 in good yield, (227).
Reflux
co2h  + socfe
Compound 7.
Scheme 2.19.
The primary route to the formation of an oxirane with N-(allyl)benzamide was to boil the 
olefin in dichloromethane with an excess of MCPBA (3 eq.). Chromatography gave the 
expected oxirane (iCompound 5) and the corresponding diol (Scheme 220), as revealed by 
mass spectroscopy (M + H at m!z Y ll and M at m!z 195, respectively).
Consequently the experimental protocol was modified to reduce the amount of MCPBA (1 
eq.) and avoid washing the product with weak acid. Following column chromatography, a 
small amount of the product was isolated as an oil but the majority of the material was 
recovered as the N-(allyl)benzamide starting material, suggesting that the MCPBA was 
not the cause of the ring opening. The mechanism can be represented as a displacement 










The mechanism of epoxidation by MCPBA.
:C=C:
© e
h : 0 - H  O—C—R
*  ^ A
o
N. HO—<L ^  JC\O  +
Scheme 221
Treatment of the urea of Compound 6 and the amide of Compound 7 with MCPBA in 
refluxing dichloromethane gave no material which could be identified as products of 
oxidation, (Scheme 2.22).
The results with model compounds suggest that the bis-allyl phenylalanine derivative 
(Compound 4) had been epoxidised solely at the N-allyl amide and not at the N-allyl urea. 









2.42 Using phenols as points of attachment of epoxides.
The unforeseen problems thrown up by attempting to generate an oxirane on a 
peptide group encouraged new approaches to be investigated. One attractive strategy was 
to completely avoid synthesising the oxirane and instead incorporate a compound already 
containing the group epichlorohydrin, (Figure 2.3).
A linker was therefore required that was capable of carrying an epoxide but was also 
sympathetic to coupling at both N- and C- peptide terminals, (Figure 2.4).
To provide an appropriately derivatised linker, it was necessary to synthesise various 
protected phenols. Various groups were investigated for their ability to : (a) couple to the 
peptides; (b) carry a suitable epoxide-containing compound.
Fig. 2.3.
or> _C LINKER |— | H2N--PEPTIDE~C=0 |— [ LINKER
Fig. 2.4.
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Figure 15 lists a series of orthogonal structures with various side protecting groups for the 
left (A) and right (B) side of the target compound. All the compounds listed in series (A) 
offer the opportunity to attach amino acids via the peptidic nucleophilic primary amine and 
a suitable coupling reagent On the contrary, series (B) includes aryl amines, with 
functional groups susceptible only to electrophilic substitution at the peptidic carbonyl 
group. All the compounds listed within the table possess para phenols or protected 
phenols for reaction with epichlorohydrin. It is not within the scope of this chapter to 
discuss the incorporation of peptide sequences between the phenyl groups, and the reader 
is directed to Section 3.5.
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Experimental Strategy. Fig. 2.5.


























Preliminary work was initiated using 4-acetoxybenzoic acid, A[l] in which the 
phenol is protected as an ester. Repeated attempts were made to couple the acid to
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compounds containing primary amines in an attempt to show that the attachment of 
peptides was possible. However, neither aniline, allylamine, N-2-(4-hydroxyphenyl) 
glycinamide or glycine methyl ester hydrochloride were successfully coupled despite 
attempts using a variety of coupling reagents, {Scheme 2.23).
Scheme 223.
The reason for the lack of reactivity of A[l] was unclear. In a reaction designed to 
increase the reactivity of 4-acetoxybenzoic acid to nucleophiles the acid was converted to 
the acid chloride {Compound 9), {Scheme 2.24), in a reaction catalysed by 










In order to test the utility of a more robust protecting group for the phenol, 4- 
methoxybenzoyl chloride was investigated. Compound A[2] reacted successfully 
(iCompound 10) with a primary amine (glycine methyl ester hydrochloride) (Scheme 225) 
in the presence of triethylamine.
Compound 10.
Scheme 225.
The ability to initiate a peptidic sequence on one of the methoxybenzoyl compounds 
encouraged the epoxidation process to be studied in more detail.
2.42.1. The 4-methoxybenzoyl peptide work.
To generate a series of models for further investigation 4-methoxybenzoyl chloride 
was coupled to a number of compounds from the Series (B). The overall strategy was to 
attempt to convert the para-side group protecting derivatives into functionalities bearing 
an epoxide, before any amino acids were introduced into the compound.
2.42.1.(a). 4-Methoxyaniline.
4-Methoxyaniline, (Anisole B[2]) showed no reactivity at all with 4-methoxy- 







Tyramine (2-(4-hydroxyphenyl)ethylamine) B[3] was chosen as a candidate for further 
work because of the extended alkyl chain bearing an amino group. By increasing the 
distance of the amino group from the ring system, the nucleophilic nature of the amine is 
increased and problems due to steric hindrance and delocalisation from the phenyl are 
decreased. 2-(4-Hydroxyphenyl)ethylamine was successfully allowed to react with 4- 
methoxybenzoyl chloride in good yield according to Scheme 227  to form Compound 11.
A solution of triethylamine and tyramine were prepared in dimethylformamide prior to 
carefully adding 4-methoxybenzoyl chloride. If the 4-methoxybenzoyl chloride is first 
dissolved in DMF there is a danger that the dimethylformamide will initiate a reaction with 








The oxygen which is present on dimethylformamide has a greater electronegativity than 
the amino group present on 2-(4-hydroxyphenyl)ethylamine. If dimethylformamide and 
anisoyl chloride are mixed then the oxygen will be allowed to react in preference to the 
amine and no product will be formed. Compound 11 was extracted from the reaction 
medium by the addition of water and collected by filtration in good yield. The material 
was identified as the monomethoxy, monohydroxy product by JH NMR with the singlet 
peaks of the methoxy group at 5 3.78 and hydroxy group at 5 9.15 giving equivalent 
interaction with the amide NH multiplet at at 6 8.42. This characterisation was also 
strengthened by the observation of the M + H ion at mlz 271 in the mass spectrum.
2.42.1.(c). 2~(4-Methoxyphenyl)ethylamine.
At the same time, additional work was successfully progressing with a compound 
analogous to tyramine. 2-(4-Methoxyphenyl) ethylamine, B[4], also contains an alkyl 
amino group at a distance from the aromatic ring, but has the phenyl protected as the 
methyl ether (Scheme 229). The additional methoxy protecting group introduced by this 
reaction was thought to be advantageous in a number of ways:-1. the overall solubility of 
the compound in organic solvents was increased when compared to compound B[3] 
containing a hydroxyl; 2. the phenolic OH group is comparitively reactive compared to the 
methoxy. By incorporating a methyl ether group to protect the phenolic side group any 
further reaction at this site, during peptide synthesis for example, is denied.
The acid chloride A[2] was treated with an amine B[4] in the presence of triethylamine (a 
tertiary amine) and DMAP (a nucleophilic catalyst). The synthesis of the bis(methoxy) 
compound was completed after a conventional work up afforded a crude product which 
was recrystallised to give Compound 12 in good yield. The characterisation was 
substantiated by mass spectroscopy, M + H ion at mlz 286 and ]H NMR characterisation 











Compound 12. Scheme 2.29.
2.4.3. The cleavage of the ethers
A great deal of research time was spent optimising a suitable experimental protocol 
to remove the methyl ether protecting groups from the aryl compounds prior to the 
inclusion of any peptides.
Ethers, particularly alkyl aryl ethers can be cleaved by heating with concentrated hydrogen 
bromide or hydrogen iodide (228). Hydrogen chloride is seldom successful. Hydrogen 
bromide reacts more slowly than the iodide, but it is often a superior reagent since it 
causes fewer side reactions. Ethers have also been cleaved with Lewis acids such as BF3, 
BQ3, BBr3 (229,230) or A1C13. In such situations, the departure of the alkyl group is 
assisted by complex formation with the Lewis acid, (Figure 2.6).
Alkyl aryl ethers can also be cleaved with lithium iodide to give alkyl iodides and salts of 
phenols (231). Dialkyl or aryl ethers may be cleaved with anhydrous sulphonic acids for
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the aryl alkyl ethers, cleavage always takes place to give the phenol. Elkobaisi (232) 
reported that when a benzyl phenyl ether heated to 250°C for some days it undergoes 
thermal rearrangement to give o- and p-benzylphenols!. When R is a tertiary alkyl group,
the ether cleavage is especially facile; cleavage occurs by the SN1 mechanism (Scheme 
230).
An attempt was made to adapt BurwelTs synthesis of phenols by the nucleophilic 
substitution of the methoxy aryl protecting groups with hydrogen bromide, (<Scheme 231). 
The bis(methoxy) and mono(methoxy) compounds (iCompounds [11] and [12]) were 
boiled in an excess (10 eq.) of hydrogen bromide / acetic acid (30%). The reaction 
mechanism involves protonation of the ether which undergoes SN1 or SN2 cleavage. 
Because the phenyl group is not susceptible to either SN1 or SN2 reaction, cleavage of the 
aliphatic C-O bonds should always occur. The alkyl oxygen bond is broken and the 
phenolic compound is the leaving group (Scheme 232).
OC(CH3)3




Compound 12. Scheme 2.31.
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The results of the attempted ether cleavage using hydrogen bromide were not as 
successful as the literature reviews indicated. Typically the bis(methoxy) compound [72] 
was refluxed for 12 hours with an excess of hydrogen bromide (30%) in acetic acid. A 
crude product was isolated in poor yield that on further characterisation OH NMR) 
revealed a mixture of starting material and product Subsequently, the reflux times were 
extended in addition to increasing the molar ration of hydrogen bromide to starting 
material. These changes appeared to have little effect on the cleavage of the aryl ethers, 
although a small amount of 4-hydroxy-N-(2-(4-hydroxyphenyl)ethyl)benzamide 
(1Compound 13) was separated from the starting material by column chromotography. 
Compound 13 was verified by NMR, which revealed that the two singlets 
corresponding to the methoxy groups had been replaced with two broad singlets at 8 9.0 
and 5 10.0 corresponding to the formation of the diol compound.
Despite the poor yield of Compound 13 the cleavage of aryl ethers was shown to be 
feasible. However, the conditions in which the alkyl groups were cleaved must be made 
more aggressive if there was to be an increased yield in the conversion of Compound 12 to 
Compound 13. Boron tribromide has been used for effecting the complete demethylation 
of aryl methyl esters. McOmie et al (230) reported that aromatic ethers similar to
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compound [12] were cleaved at or below room temperature by means of boron 
tribromide. Over twenty aryl ethers were reported to have been successfully cleaved, 
many of which were resistant to demethylation with hydrogen bromide or aluminium 
bromide. When the bis(methyl) compound [12] was allowed to react direcdy with boron 
tribromide in dichloromethane [1.0 M] and no other solvent, successful demethylation was 
achieved, {Compound 14). The reaction probably proceeded via a complex formed 
between the reagent and the ethereal oxygen atom, {Scheme 233). It was advisable 
therefore to use one mole of boron tribromide per ether group.
After the reaction was complete, the dibromide complex and excess reagent were 
hydrolysed by adding water to the reaction. The phenolic product quickly precipitated as 
a solid and was collected by filtration whilst the boric acid and hydrogen bromide 









Preliminary experiments with boron tribromide were largely disappointing as 
complete demethylation was not achieved. Simple characterisation (T.L.C., NMR) 
often revealed a mixture of starting material and product This was alleviated in a number 
of ways. The molar ratio of boron tribromide was increased from 2 equivalents to 3.5 
equivalents to take account of other potentially nucleophilic groups, e.g. the nucleophilic 
oxygen, which may have been allowed to react with the reagent thereby decreasing it's 
molarity, (Figure 2.6). In addition, the volume of solvent was increased and the reaction 
boiled in dichloromethane.
Compound 14 (Scheme 2.34) was obtained in a good yield following recrystallisation from 
alcohol and ether. A narrow melting point was auspicious of a pure product which was 
verified through !H NMR. Elemental analysis was accurate and the parent ion peak at mlz 
258 in the mass spectrum was further evidence of the correct product.
2.43.1. Peptide compounds and ether cleavage.
The synthesis of a number of di-, tri- and tetra- peptide sequences between 
orthogonal groups, protected by methyl ethers had been accomplished, (Figure 2.7). As a 
test substrate and target compound, the tetra peptide, GlyPheLeuGly {Compound 15) was 
proposed as a good candidate for further modification.
BBr3








R = Gly, (Compound27).
Gly Gly, (Compound 38).
Gly Phe Gly, (Compound 50).
Gly Phe Leu Gly, (Compound 15). Fig. 2.7.
Using fresh boron tribromide / dichloromethane (1.0 M) (3.5 equivalents) the tetrapeptide 
was refluxed in dichloromethane for 12 hours. The reaction was frequently monitored by 
T.L.C. which indicated that the reaction was proceeding slowly, if at all. It was 
propounded that the incorporation of the tetrapeptide between the alkylaryl ethers was 
interfering in some way with the reaction of boron tribromide. The most likely scenario 
was that the nucleophilic oxygen on the peptidic carbonyl groups were complexing the 
electrophilic boron tribromide, (Figure 2.8). As a consequence, the molar ratio of boron 
tribromide was increased to 10 molar equivalents and the reaction was refluxed for a 
further 3 hours under nitrogen.
Diagramatic representation of the possible Lewis basic sites for BBr3 interaction.
MeO
*
•C-N ■C-N •C-N XT'
A
A OMe*
----------► = Site of boron complexes. 2 g
Provisional T.L.C. using methanolic iron in  chloride solution (to visualise phenolic OH 
groups) provided no evidence for the presence of the target phenolic compound. This was
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corroborated with a more detailed characterisation. Using TX..C. revealed a multi­
component plate that could not be separated despite using an arsenal of solvent systems. 
The *H NMR spectrum was tremendously complicated but more importantly there was no 
evidence of any phenolic groups.
Despite the previous limited success with hydrogen bromide a further attempt was 
made using this reagent to demethylate the tetra-peptide compound. A huge excess of 
HBr /  acetic acid (70 eq.), was boiled with the bis(methoxy) compound however, no 
material which could be identified as the required a,o>-bis(phenol) derivative was isolated 
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2.5. The use of aryl phenyl ethers.
Owing to the unforeseen problems associated with demethylation of products 
possessing bis (methyl) groups and a peptide sequence an alternative strategy was 
adopted. The revised putative precursors to epoxide derivatisation were synthesised 
according to the reaction schemes below. The phenolic functions were protected during
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the syntheses as benzyl ethers. These could be easily removed, under milder conditions, by 
hydrogenolysis in a penultimate step before epoxide addition.
Unlike the methoxyaryl compounds which were commercially available the analogues 
shown in Figure 2.9 were prepared from empirical compounds.
The Proposed Target Compounds.
2.5.1. The Left Side. [4-(Phenylmethoxy)benzoyl chloride].
In a three step procedure, adapted from the method of Herbert et al (233), 4- 
hydroxy benzoic acid was initially refluxed in acetonitrile which contained benzyl chloride, 




2- (4- (Phenyknethoxy)phenyI) 
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The product, phenylmethyl-4-(phenylmethoxy)benzoate had properties identical to those 
reported (233). Compound 16 was converted to 4-(phenylmethoxy)benzoic acid 
(iCompound 17) by hydrolysis which involved refluxing the benzoate with sodium 
hydroxide (2.0 M) and ethanol, (,Scheme 237). The product was initially afforded as the 
sodium salt which would neither dissolve in water or organic solvent, at room 
temperature. However, once this intermediate was acidified with sulphuric acid (2.0 M), it 
could be extracted into warm ethyl acetate. Evaporation of the solvent afforded the 
product in good yield and characterisation with !H NMR established the loss of five 
protons in the integrated benzyloxy peak. The formation of a new broad peak at 5 12.6 
was recognised as the hydroxyl functionality of the carboxylic acid
In order to provide a suitably derivatised compound capable of reacting further 
with a peptide chain, the acid was converted into an acyl halide using thionyl chloride.
This type of reaction is the best and most common method for the preparation of acyl 
chlorides. The use of thionyl chloride is attractive as the by products of the reaction are 
gases and the acyl halide is therefore easily isolated. 4-(Phenylmethoxy)benzoic acid 
0Compound 17) was boiled under reflux with thionyl chloride for 4.5 hours whereupon the 
thionyl chloride was removed by distillation, (Scheme 2.38). A black residue was 
produced which could not be dissolved or recrystallised in any of a number of solvents 




Oxalyl chloride and bromide are other, frequently used acyl halide reagents which 
on reaction form the acid chloride and decompose to carbon monoxide and carbon 
dioxide. A further attempt was made to make 4-(phenylmethoxy)benzoyl chloride 
(iCompound 18) by using oxalyl chloride. The acid and oxalyl chloride (2 eq.) were 
dissolved in dioxane and one drop of DMF was added to catalyse the reaction. The 
reaction was complete when the evolution of gas had ceased whereupon the solvent was 
evaporated and the crude product was recrystallised from light petroleum.
The acid chloride was characterised with I.R. which showed a migration of the carbonyl 
peak from 1600 cm"1 in the acid to 1775 cm"1 for the acid chloride carbonyl group. In 
addition the identity of the acid chloride was substantiated by NMR which detected the 
increased electron withdrawing effect of the acid chloride on the aryl protons ortho to the 
substituted group. The shift values for the doublet peak at position 2’ - 6' in Compound 17 
were 7.89 with respect to 8.07 in Compound 18 for the two protons.
2.5.2. The Right Side. [2-(4-(Phenylmethoxy)phenyl)ethylamine].
This method was adapted from Agorta (234) and involves condensation of 
nitromethane with 4~(phenylmethoxy) benzaldehyde in ethanol at 5°C catalysed by sodium 
hydroxide. The crude product l-(2-nitroethenyl)-4-(phenylmethoxy)benzene (iCompound 







corroborated the structure of the product with two doublets corresponding to the alkene 
protons at 5 7.43 and 5 7.85 ppm. The latter peak at 8 7.85 is more deshielded than the 
former and as a result it is likely that this peak can be assigned to the olefin proton nearest 
the aryl group.
Reduction of Compound 19 may be accomplished by catalytic hydrogenation or by the use 
of chemical reducing agents in acidic solution. The nitro compounds readily undergo 
reduction to yield the primary amines and this method constitutes the most general 
synthesis of aromatic amines.
2-(4-(Phenyl-methoxy)-phenyl)-ethyl-amine was prepared in a Soxhlet apparatus using an 
excess of lithium aluminium hydride (LiAlH4) which was boiled under reflux in dry ether 
as the nitro compound was added dropwise from a side funnel. The reflux was continued 
for 16 hours before the LiAlH4 was quenched with water and the product (Compound 20) 
was extracted in a conventional work-up, {Scheme 2.40).
Compound 20.
Scheme 2.40.








comprising of the carbon chain terminating in the amine were assigned as triplets at 5 2.56 
and 5 2.71 in the spectrum.
The successful synthesis of three bis(benzyloxy)phenyl protected model 
compounds containing di-, tri-, and tetra- peptide sequences (GlyGly {Compound 2i), 
PheLeuGly {Compound 22) and GlyPheLeuGly {Compound 23) respectively) is described 
fully in Chapter 3. In an attempt to cleave the phenolic protecting groups to allow further 
derivatisation of the diol compounds the bis(benzyloxy)phenyl groups were hydrogenated 












Conventional work-up of the tripeptide, PheLeuGly, {Compound 22) furnished a material 
that was isolated in good yield and identified as the diol, {Compound 24). A spectrum 
generated by !H NMR was assigned accurately to the proposed structure of the compound 
with two characteristic singlets at 8 9.22 and 8 10.06 providing further evidence of the 
newly formed phenolic groups. Further characterisation was provided by mass
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spectroscopy with the observation of the M + H ion at mlz 575 and mlz 573 in the FAB 
[+] and FAB [-] mass spectrum.
Hydrogenation of the bis(benzyloxy)phenyl tetrapeptide {Compound 23) in a similar 
experimental technique to the above afforded a product in good yield. Unfortunately, 
characterisation of this material by NMR and subsequently by COSY provided no
evidence that could confirm the identity of this material. A further attempt to characterise 
this material with FAB [-] mass spectoscopy confirmed the prescence of the required 
product {Compound 25) with a M - H ion at mlz 630.
2.6. Epichlorohydrin experiments
In Section 2.4.3., the successful demethylation of test Compound 12,4-methoxy 
N-(2-(4-methoxyphenyl)ethylbenzamide) resulted in a bis(hydroxy) compound 
{Compound 14) that was suitable for further reaction with epichlorohydrin. Compound 14 
was an extremely important analogue to the latter compounds {Compound 24 and 
Compound 25), which were derived from an alternative strategy, but possessed identical 
functional groups. As a model, the diol {Compound 14) was dissolved in aqueous base 
with an excess of epichlorohydrin and benzyltrimethylammonium hydroxide (a phase 
transfer catalyst). Conventional work-up gave a multicomponent gum but direct 
application to a chromatography column and subsequent elution permitted the isolation of 
a single product in moderate yield. This material was identified as the bis(glycidylether), 
{Compound 80) by accurate analysis of the elemental composition and mass spectroscopy. 
Further corroboration, by proton spectroscopy revealed no evidence of the phenolic 
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Scheme 2.42.
The success of this experiment was tremendously exciting as it opened up a synthetic 
pathway via the activated PEGs to the target polymerisation reactions.
The conversion of the oligopeptide diols to oxiranyl compounds involved a similar 
experimental strategy to the one described above. In the case of the tripeptide, 
PheLeuGly, {Compound 24) removal of the organic solvent by evaporation afforded a 
multicomponent material that was separated by column chromatography. Elution of a 
single product in good yield led to characterisation studies which confirmed the identity of 
the bis(glycidylether)tripeptide, {Compound 79) {Scheme 2.43). Proton spectroscopy 
revealed a "crowded" spectrum but comparison of the integrals of the leucyl methyls at 8
0.84 and 0.88, of the oxiranyl cluster circa 8 2.69 - 3.30 and of the aromatic cluster 8 7.00 
- 7.79 showed a 1: 1 ratio of bis(glycidylether) to tripeptide. Further elucidation of the 
spectrum using COSY enabled each signal to be assigned more accurately, {see Spectrum
1, Appendix 1). Mass spectroscopy provided additional evidence as to the identity of the
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Compound 79.
Epoxidation of the tetrapeptide GlyPheLeuGly (Compound 25) was attempted in order to 
synthesise the target bis(glycidylether) compound. However, treatment of the diol with an 
excess of epichlorohydrin and phase transfer catalyst gave no material which could be 
identified as the required bis(epoxide) derivative, {Scheme 2.44).
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It is proposed that polymerisation of PEG with alternating oligopeptide 
sequences would afford a biodegradable copolymer. The peptide sequences are to be 
selected for their sensitivity to hydrolysis by lysosomal enzymes. The synthesis of a 
library of oligopeptide analogues, i.e. GlyPheLeuGly, GlyGly, GlyPheGly, 
PheLeuGly, and Gly is to be pursued in order to compare the rates of polymer 
degradation with lysosomal enzymes. In addition amino acids containing side chains, 
e.g. glutamic acid could be incorporated into the copolymer to provide pendant 
linkages which may be further activated in order to attach drugs or targeting groups.
The oligopeptides were prepared using standard solution coupling methods. 
For example, 2-(4-(benzyloxyphenyl)ethylamine was coupled to BOCglycine using 
DCC. Treatment with HC1 afforded the deprotected amine salt Coupling of this 
amine with BOC protected amino acid and dipeptide active esters served to extend 
the peptide chain in an iterative process.
3.2. Introduction.
The L-amino acids constitute a particularly important class of natural di­
functional compounds because they are the building blocks from which proteins are 
constructed. They all have the general structure given in Figure 3.1(A), or in the 
case of the atypical amino acid, L-proline, Figure 3.1(B).
91
(A). (B).
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Fig. 3.1.
The amino acids, in part, owe their importance to the fact that they may form 
amide or peptide bonds which link these building blocks together forming natural 
polymers or proteins. Their fascination is extended further by the fact that each of 
the twenty members of the amino acid series have a unique chemical identity. This is 
reflected in proteins which may be acidic, basic or neutral; globular, soluble or 
insoluble, depending on their amino acid composition. It follows that there has been 
an enormous level of research into clinical applications for these biomaterials, both as 
mimics of endogenous ligands for biochemical pathways, or as peptide drugs.
Peptides (which are classed as molecules containing fewer than fifty amino 
acids) are often 'tailor made' to conform to specific criteria, e.g. size or solubility 
constraints. Oligopeptides containing amino acids such as lysine or glutamine, which 
possess side chains terminating in functional groups, are able to undergo further 
chemical modification.
In the early 1980s, a plethora of papers were published on the design of short 
oligopeptide chains that would match known specificities of lysosomal enzymes. By 
varying the peptide length and composition, the susceptibility to lysosomal hydrolysis 
under different conditions of pH or enzyme sub-type could be controlled.
Rejmanovci et al (138) optimised an amino acid sequence which facilitated the 
intracellular degradation by lysosomal thiol proteases. The oligopeptide consisted of
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four amino acids, Gly-Phe-Leu-Gly, which has been extensively studied over the last 
ten years for use as a labile drug-polymer linkage.
Oligopeptides can be synthesised in a stepwise assembly controlled through a 
series of sequential protection, coupling and deprotection reactions. Protecting 
groups have been developed for both the amino and carboxy groups as well as for 
other groups that occur in the side chains of the various amino acids. A suitable 
protecting group must fulfil several criteria:
1. The protecting group should be easy to introduce into the molecule;
2. The protecting group should not adversely affect the molecule;
3. The protecting group should protect the functional group under conditions of 
amide formation;
4. The protecting group must be removable, under conditions that have no 
adverse effect on the structure being assembled;
5. The protecting group should be susceptible to specific cleavage which does 
not affect other protecting groups on the molecule;
6. The protecting group should not, at any stage, jeopardise the chiral integrity 
of nearby chiral centres.
3.3. a-Amino protection.
The groups that are available for a-amino group protection can be divided 
into five categories; the alkoxycarbonyl groups, triphenylmethyl (trityl) protection, 2- 




The alkoxycarbonyl family of amino protecting groups has dominated the 
field of amino-protection for many years, mainly due to their stability, selective ease 
of removal, and chiral integrity.
3.3.1.1. Benzyloxycarbonyl (CBZ) protection.
Fig. 32.
The CBZ group is normally introduced via the chloroformate reagent,
CFigure 32) (330), but minor side reactions such as dipeptide formation under 
Schotten-Baumann conditions with amino acids are occasionally a nuisance. A less 
reactive acylating agent is often preferred, (Figure 3.5).
The cleavage conditions of the CBZ group include hydrogen bromide (HBr) /  protic 
acid (AcOH), Lewis acid (trimethylsilyl iodide), or catalytic hydrogenolysis. 
However, it should be noted that the prescence of a good nucleophile is important 
for the former two cleavages. This protecting group is stable under moderately basic
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or non-nucleophilic acidic conditions (TFA), enabling it to be carried through a range 
of structural intermediates. Electron-releasing substituents in the aromatic ring 
accelerate the cleavage, whereas electron-withdrawing groups have the opposite 
effect For instance, the 4-methoxybenzyloxycarbonyl group which is cleaved by 
TFA, is the most useful ring-substituted analogue (235), (Figure 3.4).
MeO
Fig. 3.4.
33,12. t-Butoxycarbonyl (BOC) protection.
The BOC anhydride is a convenient solid which gives good yields and can be 
stored under refrigeration for long periods (236).
° °  ? 
Me3C—o - S ) - S j—CMe3 Me3C - 0 - C- N
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The BOC group {Figure 33) is completely stable to catalytic hydrogenolysis 
conditions, but it is much more labile to acids than the CBZ group, to which it is 
therefore completely orthogonal. BOC removal is conveniently carried out by 
dissolution in TFA, however mineral acids will attack BOC groups rapidly and must 
be avoided in wash procedures. Basic and nucleophilic reagents have no effect on 
the BOC group, even on prolonged exposure. In this respect the stability of BOC is 
better than that of the CBZ groups.
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33.13. 2 -{4-Biphenyl)-isopropoxycarbonyl (Bpoc) protection.
The Bpoc group (Figure 3.6) (237) is even more acid labile than BOC, and 
can be removed by brief treatment with, for example, chloroacetic acid / 
dichloromethane mixtures at ambient temperature. These are conditions which 
would leave BOC and CBZ groups intact. Bpoc is very stable to bases and 
nucleophiles, but like the CBZ group, it is cleaved by catalytic hydrogenolysis.
The Ddz (a,a<limethyl-3,5-dimethoxybenzyloxycarbonyl) (Figure 3.7) group is 





33.1.4. 9-fluorenylmethoxycarbonyl (Fmoc) protection.
The Fmoc group, according to Carpino (238) is normally introduced in the 
Schotten-Baumann manner, using the rather stable chloroformate, (Figure 3.8) 
although several less reactive reagents have been investigated, e.g. the succinimido 
carbonate.
The Fmoc group is very stable to acidic reagents, but it is cleaved swiftly under 
certain basic conditions. Piperidine is the routine reagent but other systems, e.g. 
fluoride ion in DMF are also effective.
33.1.5. 2 2 2-Trichloroethoxycarbonyl (Troc) protection.
The Troc group (Figure 3.9) is stable to both acid and base, but Woodward 







33.2. Triphenylmethyl (trityl, Trt) protection.
The principal effectiveness of the trityl protecting group is largely dependent 
on steric hindrance, {Figure 3.10).
The trityl group is very stable to base and very labile to acid. It does not survive 
even mildly acidic conditions which is advantageous since it enables the use of gentle 
deprotection reagents such as acetic acid, and rarely catalytic hydrogenation (240).
33.3. 2-nitrophenylsuIphenyl (Nps) protection.
Zervas prepared Nps amino acids by the reaction of NpsCl with amino acids 
in basic conditions (241). They are not very stable, and are generally isolated, 
purified and stored as dicyclohexylammonium salts from which they can be liberated 
when required by acidification with sulphuric acid, {Figure 3.11).
o Fig. 3.11.
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The Nps group is stable to mild base, but not to acidic conditions (HQ) or to 
catalytic hydrogenolysis.
33.4. Dithiasuccinoyl (Dts) protection.
The Dts protected amino acids, {Figure 3.12) are not widely employed 
perhaps as a result of their complicated synthesis via esters (242). However, this 
group is completely orthogonal to BOC and other acid-labile groups, as cleavage is 
induced by base-catalysed disulphide exchange with thiols.
3.3.5. Diphenylphosphinyl (Dpp) protection.
Kenner reported that Dpp amino acids, (Figure 3.13) are prepared indirectly 
via esters using diphenylphosphinyl chloride (243). The Dpp group survives both 







The usual means of carboxy protection is esterification, and seven types are 
discussed more fully.
3.4.1. Methyl and ethyl esters.
Methyl and ethyl esters provide good carboxy protection throughout most 
peptide bond forming procedures and deprotective operations. Their removal, 
however, often calls for rather vigorous treatment involving hydrolysis, which may 
cause racemisation.
Amino acids react easily with hot methanolic hydrogen chloride to give the 
corresponding methyl ester hydrochlorides. Treatment with thionyl chloride and 
methanol is however, a convenient alternative procedure (244), (Scheme 3.1).
?  + SOCfe MeQHr  1  Scheme 3.1.
K - C - O H  R ^O —Me • HC1
3.4.2. Benzyl esters.
Amino acid benzyl esters (245) are best prepared by 4-toluenesulphonic acid 
catalysed esterification with benzyl alcohol, driven by azeotropic removal of water 
(iScheme 3.2). Benzyl ester groups are cleaved by hydrolysis and by hydrazinolysis. 
More importandy, they are cleaved by HBr/AcOH, HF and catalytic hydrogenolysis.
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R—C—OH
(Cat*)O HO'\\ + K )l Scheme 32.
3.43 . /-Butyl esters.
Unlike methyl and benzyl esters, amino acid /-butyl esters are stable in the 
free base form and diketopiperazines (DKPs) are not easily formed from the 
dipeptides. They can be prepared directly from the amino acids, but the standard 
procedure is indirect, (.Scheme 33).
(1). MezOCHz
H2SO4 (cat) OCMe*
z - ” ' r ° H a w - .  Seht^ , 3 J
°  (2).H j/W (Q  O
BOH
Alternatively:- BOCFButOH 
B 3N DMAP 
CH2 a 2
The stability and lability of /-butyl esters generally parallel the properties of the BOC 
group.
3.4.4. 2-TrimethylsilylethyI esters (Tmse).
The Tmse group (Scheme 3.4), is orthogonal to acid-sensitive groups (245). 
Tmse survives catalytic hydrogenation conditions and very mild acid, but is cleaved 
rapidly with TFA. However, the preferred method of cleavage is with quartemary 




















Allyl esters, {Figure 3.14) can be cleaved undo: the influence of palladium 
complexes without disturbing BOC, CBZ, Fmoc or related groups.
O
II
R O -CH2CH=CH2 Fig. 3.14.
(1)Pd(PPh3 ) 4
(2)H®/H20
3.4.6. Phenacyl esters (Pac).
PhCOCHzBr 9
'C OH v  n  c
II Zn/AcOH R C ^  ^  Scheme 3.5.
Base ^
Phenacyl ester (Pac) protection, {Scheme 35) is very stable towards 
acidolydc conditions. It is not stable to catalytic hydrogenolysis, but complete 
orthogonality with a-BOC protection makes it a useful reagent
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3.5. The Synthesis of the Enzyme Labile Peptide Sequence, Gly Phe Leu Gly.
The work discussed in this section concerns the strategy adopted for the 
complete synthesis of the tetrapepdde Gly-Pne-Leu-Gly, within the chosen aryl side 
groups. In addition to the enzyme labile peptide sequence other oligopeptide 
derivatives were synthesised which, hypothetically, do not undergo lysosomal 
degradation.
The strategy adopted for peptide chain synthesis was often divergent in that 
the amino acids were first joined into dipeptide fragments of aryl conjugates and 
these were then allowed to react The advantages of ’’fragment condensation" over 
the "stepwise" approach include an increase in overall yield, better isolation of 
products and reduction in synthesis time. On the other hand, the choice of protective 
group was often made more complicated and racemisation can be a problem.
The remainder of this chapter can be divided into three sections. Section 
3.5.1. is an account of the oligopeptide chains synthesised in connection with the 4- 
methoxy(phenyl) derivatives. An alternative strategy, in Section 3.5.2., focuses on 
the 4-phenylmethoxy(phenyl) peptidic compounds which were precursors to the 
attachment of epoxides. Finally, in Section 3.5.3, there is a brief discussion on the 
synthesis of oligopeptide chains bearing side chains for further modification.
3.5.1. 4-Methoxy (phenyl) derivatives.
The target compound was N-(N-(N-(N-(4-methoxybenzoyl)glycyl)- 
phenylalanyl)leucyl)glycine N-(2-(4-methoxyphenyl)ethyl)amide, (Figure 3.15).
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Preliminary experiments therefore addressed the feasibility of introducing a single 





^Gly—Phe— Leu—Giy^ Fig. 3.15.
MeO OMe
3.5.I.I. The Mono Amino Acid Compounds. (Gly).
Gledhill et al (246) prepared many N-benzoylglycines by conventional Schotten- 
Baumann techniques by addition of the aroyl chloride to the amino acid in aqueous sodium 
hydroxide solution, followed by acidification and collection of the N-aryl amino acid by 
filtration. Despite previous reports with related compounds (247) numerous attempts to 
repeat the Schotten-Baumann technique using 4-methoxybenzoyl chloride and glycine 
proved difficult and multi-component materials were afforded which could not be identified 
as the required N-aryl glycine, {Scheme 3.6).
The carboxy-protected glycine methyl ester is more soluble in organic solvents than glycine 
and an alternative strategy was undertaken. 4-Methoxybenzoyl chloride was carefully added 
to glycine methyl ester hydrochloride in dichloromethane containing triethylamine (a tertiary 
amine base). Conventional work-up afforded a product in good yield which was 






confirmed N-(4-methoxybenzoyl)glycine methyl ester, Compound 10 with a peak at mlz 223 
M + H. Data from elemental analysis and !H NMR is consistent with the identity of 
Compound 10.
Deprotection of the methyl ester in boiling methanolic sodium hydroxide was 
straightforward and following acidification, Compound 26 was produced in good yield. The 
identity of the product was shown by NMR which revealed the disappearance of the 
methyl ester at 8 3.81, which is consistent with Compound 26.
Reaction of Compound 26 and N-(2-(4-methoxyphenyl)ethyl)aimne using DCC as a 



















It was therefore appropriate to use an activating agent which would facilitate the 
attack of the amino group on the acyl carbon on the carboxy component Active esters are 
suitable activating agents and include 4-nitrophenyl ester (ONp) [Fig. 3.16(a)], penta and 
trichlorophenyl ester (OPCP, OTCP) [Fig. 3.16(b)], pentafluorophenyl ester (OPfp) [Fig. 











Attempts were made to prepare three active ester derivatives of N-(4-(methoxy- 
benzoyl)glycine (iCompound 26), namely the 4-nitrophenyl ester (ONp), succinimido ester 
(OSu) and pentafluorophenyl ester (Pfp). These derivatives were prepared by a common 
route described by Atherton (248) which involved DCC mediated coupling in dioxan at 0°C.
Treatment of the carboxy component with 4-nitrophenol or hydroxysuccinimide resulted in 
intractable mixtures of products and starting material which were not purified any further,
(Scheme 3.9).
On the contrary, esterification with pentafluorophenol at 0°C in dry THF was successful,
(.Scheme 3.10). The by-product dicyclohexylurea (DCU) was removed and a conventional 
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Scheme 3.9.
Compound 26. Compound 28.
Scheme 3.10.
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The disadvantage of using an active ester such as Pfjp over Np, OSu or TCP is that it is 
essentially invisible to NMR detection. However, the influence of this electron- 
withdrawing group was reflected in the shift change of the glycyl CH2, which was more 
deshielded in Compound 28 (8 4.57) than Compound 26 (8 3.92). Fluorine spectroscopy, 
19F NMR, confirmed the integrity of the pentafluorophenyl group and additional evidence to 
the identity of the product was provided by mass spectroscopy {mlz 376) (M + H) and 
elemental analysis.
Since N-(4-methoxybenzoyl)glycine pentafluorophenyl ester {Compound 28) should 
be a good electrophile, synthesis of N-(4-methoxybenzoyl)glycine-N-(2-(4-methoxyphenyl)- 
ethyl) amide was reinvestigated. The active ester was treated with the primary amine in the 
presence of triethylamine (a tertiary amine base), {Scheme 3.11). The product was isolated 
in good yield and identified as Compound 27. Comparison of the integrals of the aromatic 
methoxy singlets at 8 3.70 and 8 3.81 and the amide multiplet at 8 7.85, verified the 
structure. Further characterisation by mass spectroscopy confirmed the identity of the 






Compound 27. Scheme 3.11.
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3.5.I.2. The Dipeptide Compounds. (GlyGIy)
The task of synthesising the dipeptide GlyGIy within the model aryl side groups 
appears deceptively simple. A number of strategies were explored. A useful route to the 
dipeptide would come from the reaction of 4-methoxybenzoyl chloride with a 
dipeptidemethyl ester hydrochloride. An attempt was made to treat 4-methoxybenzoyl 
chloride with N-glycylglycine methyl (Scheme 3.12) and ethyl esters in the presence of 
triethylamine in a similar experimental protocol to Compound 10.
A /  c r  o
CHjOj
B3N
H ? ? + H ?
JSL X —OH 4%N.OH/ N . .C—OMe
jo r  n  — jot n
Compound 31. Compound 29.
Scheme 3.12.
4-Methoxybenzoyl GlyGIy methyl ester (iCompound 29) was isolated in good yield 
and identified by analytical techniques. The newly-formed amide peak at 8 8.69 was 
identified in the NMR spectrum along with the aryl methoxy group at 5 3.83 and the 
ester methyl group at 8 3.65. This characterisation was substantiated by mass 
spectroscopy and elemental composition data. Synthesis of the 4-methoxybenzoyl GlyGIy 
ethyl ester (iCompound 30) was straightforward with the glycyl ethyl ester group identified 
at 8 1.18 (3H) and 8 4.08 (2H) in the NMR spectrum. The facile removal of the ester 
groups in a hydrolysis step gave products which were shown, by NMR 
characterisation, to be the deprotected dipeptide, (iCompound 31).
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Several experiments were conducted to investigate the feasibility of coupling 
Compound 31 directly with N-(2-(4-methoxyphenyl)ethyl)amine in a DCC reaction to give 
the desired target compound, {Scheme 3.13).
I H ?  Ife N . DCC
 c - N^ c_O H  + - X ^
DMF,  ,  ,  - OMeMeO
Compound31.
_X)Me
O I ?  O
# H  "
MeO Scheme 3.13.
Unfortunately, this method gave no material which could be identified as the required 
compound and a more indirect approach was sought Attempted esterification of 
Compound 31 with pentafluorophenol or 2,4,5-trichlorophenol was unsuccessful and 














A related reaction with N-hydroxysuccinimide and DCC was investigated in DMF 
at 0°C, (Scheme 3.15). The removal of the DCU and DMF afforded a crude material 
which was recrystallised and a single product was isolated. The identity of the active ester 
of the dipeptide was confirmed by !H NMR spectroscopy as Compound 32. The logical 
succession to this experiment was the reaction of Compound 32 with N-(2-(4-methoxy- 
phenyl)ethyl)amine, however this work was not completed.
Several experiments were conducted to investigate whether a a-amino protected 
dipeptide (BOCGlyGly) could be encouraged to undergo a coupling reaction with N-(2- 
(4-methoxyphenyl)ethyl)amine. Preliminary experiments using DCC for a direct coupling 
were only partially successful. A crude product was afforded after a conventional work­
up, which was identified as a mixture of two components by lH NMR. The ratio of the 
two components was calculated by comparison of the integrals, and found to be 
approximately 2:1 in favour of the desired product. Isolation of the two compounds by 








In contrast, an alternative strategy was attempted whereby the dipeptide, N- 
glycylglycine was a-amino protected by BOC, in the conventional manner, (249) and the 
acyl peptide ester was prepared, in good yield, by the reaction of N-hydroxysuccinimide 
with equivalent amounts of DCC and Compound 33, (Scheme 3.16).
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Nucleophilic substitution of the active ester by N-(2-(4-methoxyphenyl)ethyl)amine 
was carried out in a catalysed reaction at elevated temperature. Following a conventional 
work-up, a product was isolated in a moderate yield. Evidence as to the identity of the 
product was provided by NMR. Comparison of the large singlet at 8 1.44, of the three 
amide NH signals at 8 5.49,6.70 and 7.19 and of the aromatic cluster at 8 6.82 - 7.09, 
showed a 1:1  ratio of BOCGlyGly to the aryl side group, (iCompound 34). One may 
speculate that the deprotection of Compound 34 to the hydrochloride salt would provide a 
suitable intermediate with which 4-methoxybenzoyl chloride could be treated, and the 
target compound formed. However, this experiment was not performed as the
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disadvantage with this hypothesis lies in the fact that previous attempts to treat the acid 
chloride with a primary amine have met with disappointing results.
A simpler option was to generate the dipeptide in the final coupling reaction, as 
opposed to carrying the dipeptide through a synthetic pathway.
Glycine was successfully amino-protected under basic conditions with di-f-butyl 
dicarbonate [(BOC)20] according to the method of Anderson and McGregor (249). The 
crystalline product, {Compound 35) was obtained in good yield and the literature melting 
point was confirmed.
Further reaction of BOC-glycine with 2-(4-methoxyphenyl)ethylamine was completed by 
mixing the amino and carboxy components with dicyclohexylcaibodiimide (DCC) in 
equimolar amounts in tetrahydrofuran. After 16 hours at 5°C, the DCU was filtered off 
and the product was afforded in good yield following recrystallisation, {Scheme 3.17). 
Compound 36 was often obtained in better yield if a slight excess of BOC-Gly was used. 












Compound 37. Compound 36.
Scheme 3.17.
113
The 1:1 ratio of the singlet peaks of the r-butyl group at 8 1.37 and of the 4-methoxy 
group at 8 3.72 suggested the coupling reaction had been successful. This was 
corroborated by the broad triplet at 8 6.91 which corresponds to the newly formed amide. 
This verdict was confirmed by observation of the M + H ion at m/z 309 in the mass 
spectrum and through elemental analysis.
Treatment of Compound 36 in an acid milieu enabled the protecting group to be 
cleaved. An attempt to remove BOC with a large excess of TFA failed to give any 
material which could be identified as the deprotected compound. Further investigation 
using hydrogen chloride was successful and the free base, {Compound 37) was given up by 
treatment with aqueous sodium hydroxide. Verification by NMR clearly showed that 
the large singlet at 8 1.37 corresponding to the BOC group had been removed and a 
primary amine, 8 8.30, had been formed.
The flexibility of the divergent strategy adopted for the synthesis of the target compound 
enabled further model compounds to be developed for attachment of epoxides.
Previous experiments had established the synthesis of N-(4-methoxybenzoyl)- 
glycine pentafluorophenyl ester {Compound 28) and glycine N-(2-(4-methoxyphenyl)- 
ethyl)amide {Compound 37). An attempt to extend the scope of these intermediates 
involved reaction of the active ester of Compound 28 with the primary amine of 
Compound 37 in ethyl acetate in the presence of a catalytic amount of HOBt 
Recrystallisation permitted the isolation of a single product in modest yield, {Scheme 
3.18). This material was identified as the dipeptide target compound by standard 
analytical techniques, {Compound 38). The M + H ion at mlz 400 and M - H ion at m/z 
398 were observed in the mass spectrum for FAB [+] and FAB [-] respectively. Further
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verification of the identity by *H NMR spectroscopy revealed singlet peaks at 5 3.70 and 5 
3.81 for the aromatic methoxy group which were in agreement with the integrated glycyl 
doublet protons at 8 3.23,3.67 and glycyl amides; 8 8.18 and 8.73.
33.1.3. The Tetra peptide Compounds. (GlyPheLeuGIy).
The iterative addition of leucine to glycine N-(2-(4-methoxyphenyl)ethyl)amide 
(iCompound 37) would provide a useful intermediate to the tetrapeptide formation. The 
direct coupling of BOC leucine to the primary amine using a DCC coupling regimen was 
dismissed following the disappointing yields previously obtained with this method. 
However, a-amino protection of leucine with BOC (249) in good yield enabled the amino 
acid to be activated, (Scheme 3.19). Pentafluorophenol was the reagent of choice as it is 
especially reactive and does not interfere with the chiral integrity of susceptible 
compounds. The methodology was the same as for Compound 28  and the ester was 
afforded in good yield. The melting point of Compound 40 was in agreement with the
Compound 28.
Compound 37.
Compound 38. Scheme 3.18.
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literature value (332) and a mass spectral peak for the M + H ion at mlz 398 substantiated 
the identity of the product.
An attempt was made to treat glycine N-(2-(4-methoxyphenyl)ethyl)amide 
(<Compound 37) with BOCLeuOPfp in the presence of diisopropylethylamine (hindered 
non-nucleophilic base) and HOBt, (Scheme 3.19). A crude product which contained some 
active ester starting material was washed with aqueous base, with no effect Direct 
application of the crude reaction mixture to a chromatography column and subsequent 
elution permitted the isolation of a single product in moderate yield. This material was 
identified as Compound 41 by NMR, mass spectroscopy and elemental analysis.
(BOQzO +
(1). Dio ran 
NaOH
H2 N Y ~ °H (2)> H2SQ4 BOC—N £—OH







H A0  H
Compound 41. Compound 40.
Scheme 3.19.
If the free amine of BOCLeuGly N-(2-(4-methoxyphenyl)ethyl)amide (iCompound 
41), is to undergo iterative amino acid elongation to form a tripeptide compound, then the 
BOC protecting group must be removed. In addition, the amino acid to be introduced into
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the chain, i.e. phenylalanine must be amino protected and activated in order to react with 
the leucyl amino group. Finally, the tripeptide must be deprotected in readiness to accept 
the next amino acid. A more convergent strategy to lengthen the peptide chain involved 
the reaction of Compound 37 with the activated dipeptide, BOCPheLeuOPfp.
BOC phenylalanine, (Compound 1) was synthesised in good yield following a 















The BOCPhe was converted to the active ester by treatment with N- 
hydroxysuccinimide (HONSu) using dicyclohexylcarbodiimide. Following the removal of 
the DCU from the dioxan, the evaporation residue from the filtrate was triturated from 
ether to give the known compound BOCPheOSu (Compound 42) (250). This material 
was identified by spectroscopic, melting point and elemental analysis.
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The dipeptide was conveniently prepared by the reaction of the N-hydroxy- 
succinimide derivative and leucine in a mixture of organic solvent and aqueous base 
according to the method of Bower et al (251). The product was afforded in good yield. 
The disappearance of the four proton singlets at 8 2.79 in the NMR spectrum implied 
that the active ester had been removed, and further peaks integrated accurately to 
corroborate the identity of Compound 43.
The acyl dipeptide ester {Compound 44) was obtained in good yield from a DCC 




Scheme 3 21 .
The identity of Compound 44 was confirmed by elemental analysis mass 
spectroscopy by the observation of the M + H ion at m/z 545. The electron-withdrawing 
effect of the Pfp group on the leucyl a-proton could not be compared accurately with 
BOCPheLeu since the spectra were generated using different deuterated solvents. 
However, the presence of the aromatic phenyl cluster at 8 7.30, f-butyl at 8 1.41, and 
quartet of the a-Leu proton at 8 4.40 corroborated the identity of the product.
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The choice of active ester was partly dictated by the reactive nature of the 
pentafluorophenyl esters and partly by issues of racemisation. There is a risk of 
racemisation when amino acids with chiral centres, i.e. Phe and Leu, are coupled together, 
directly (DCC) or indirectly (active ester). This risk is increased when active esters are 
coupled, in the prescence of base, from susceptible carboxy components. However, the 
Pfp esters are regarded as being less susceptible to racemisation and the formation of 
stereoisomeric compounds is therefore avoided.
An important step in the synthesis of the final tetrapeptide compound was the coupling of 
glycine N-(2-(4-methoxyphenyl)ethyl)amide (iCompound 37) to BOCPheLeuOPfp 
{Compound 44) to form the tripeptide conjugate BOCPheLeuGly N-(2-(4-methoxy- 
phenyl)ethyl)amide, {Compound 45). By slightly modifying a standard procedure to 
include a small amount of DMAP (a nucleophilic catalyst), Compound 45 was afforded in 
moderate yield, {Scheme 322). The NMR spectrum contained no duplicate signals for 
the product, indicating the presence of only one diastereoisomer and it was concluded that 
racemisation had been avoided. All the signals were assigned, and the product melted 















The hydrochloride salt of deprotected Compound 46 (PheLeuGly N-(2-(4- 
(methoxyphenyl)ethyl)amide hydrochloride) was isolated in moderate yield by removing 
the BOC protecting group with hydrogen chloride. This salt was treated with N-(4- 
methoxybenzoyl)glycineOPfp (Compound 28) in the presence of excess triethylamine base. 
This is in contrast to the previous experiments where the free amine was allowed to react 
with an activated ester. Both synthetic strategies have been shown to be successful. 
However, by shortening the synthetic route, the product yield was conserved.
Since N-(4-methoxybenzoyl)glycineOPfp has been shown to react well with a 
primary amine, the synthesis of the target tetrapeptide compound was investigated. The 
hydrochloride salt of PheLeuGly N-(2-(4-methoxyphenyl)ethyl)amide {Compound 46) was
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added dropwise to a dilute mixture of 4-methoxybenzoylGlyOPfp /  HOBt /  DMAP and an 
excess of base which exposed the free amine in situ, {Scheme 323). Removal of the 
organic solvent gave the crude product as a multi-component mixture, but direct 
application to a chromatography column and subsequent elution permitted the isolation of 
a single product in satisfactory yield. This material was identified by mass spectroscopy, 
with observation of the M + H ion at m!z 660 and the M - H ion at 658 for FAB [+] and 
FAB [-] respectively. This characterisation was confirmed by NMR, {Compound 15).












35.1.4. The Tri Peptide Compounds. (GlyPheGly).
In an attempt to synthesise a tripeptide model compound, BOCPheOPfp 
{Compound 47) was allowed to react with glycine N-(2-(4-methoxyphenyl)ethyl)amide, 
{Compound 37). The protected dipeptide was converted to the N-(phenylalanyl)glycine 
N-(2-(4-methoxyphenyl)ethyl)amide hydrochloride {Compound 49) and treated in a 
catalysed reaction with N-(4-methoxybenzoyl)glycineOPfp in an excess of base.
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Conventional work-up gave a crude product that was separated by column 
chromatography. Subsequent elution permitted the isolation of a product, the bis(4- 
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A considerable amount of time was spent in optimising the experimental conditions 
that led to the formation of the bis(methoxyaryl)tetrapeptide compound, (Compound 15). 
Unfortunately, the progress of this work was abruptly terminated when deprotection of
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Compound 15 proved problematic (Section 2.43.), An alternative, more successful, 
approach involved substituting benzyloxyphenyl side groups onto the tetrapeptide chain,
(Figure 3.17). As a close relationship exists between the previous target compounds and 
those discussed presently, many of the same synthetic approaches have been adopted.
Gly—Phe— Leu- Gly‘
Fig. 3.17.
3.5.2.I. The Di Peptides. (GlyGly).
Since the glycine esters have been shown to be more amenable than glycine for 
reaction with an acid chloride, synthesis of N-(4-(phenylmethoxy)benzoyl)glycine methyl 
ester was investigated. Glycine methyl ester hydrochloride was suspended in 
dichloromethane and converted to the free amine by the addition of excess triethylamine.
The aryl acid chloride was carefully added to this buffered solution and allowed to react, 
before a conventional work-up afforded a product which was recrystallised in good yield,
(Scheme 325). This material was identified by NMR spectroscopy. Study of the 
NMR spectral data showed a singlet at 5 3.78, assigned to the methyl ester and an 
aromatic cluster between 8 6.98 and 8 7.77 which corroborated the identity of Compound 
51.
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Compound 51. Compound 52.
Scheme 325.
Removal of the methyl ester group by base hydrolysis from Compound 51 formed 
an a-carboxylic acid component for activation with a suitable leaving group. Removal of 
the solvent afforded a material in good yield that was analysed by standard techniques. 
Mass spectroscopy confirmed the presence of an M + H ion at m/z 286 and an M - H ion 
at 284 for FAB [+] and FAB [-] respectively. This characterisation was corroborated by 
lH NMR which showed the replacement of the methyl singlet peak at 5 3.78 with a broad 
peak at 8 12.60, which was assigned to the COOH, {Compound 52).
The activated ester was prepared using pentafluorophenol in an analogous 
experiment to that for Compound 28. A product was separated by column 
chromatography in good yield and was identified as Compound 53, by elemental analysis, 
mass spectroscopy and proton NMR spectroscopy, {Scheme 326).
By slightly modifying a standard procedure, the active pentafluorophenyl ester of 
Compound 53 was successfully treated with glycine N-(2-(4-phenylmethoxy)phenyl)ethyl 
amide hydrochloride {Compound 55). The latter compound was prepared in good yield 
via the DCC coupling of BOCGly and N-(2-(4-phenylmethoxy)phenyl)ethylamine
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(iCompound 32). Subsequent a-amino deprotection of Compound 54 in dioxan with 
hydrogen chloride afforded the amine salt in good yield, a small portion of which was 
treated with aqueous base to give the free amine. The chloride salt of Compound 55 was 
dissolved in dry dichloromethane with an excess of N,N-diisopropylethylamine (a hindered 
base) to facilitate the formation of the free amine in situ, {Scheme 326.). N-(2-(4- 
phenylmethoxy)benzoyl)glycine pentafluorophenol ester was added dropwise and the 
mixture stirred for 6 hours. The organic solvent in the filtrate was evaporated to afford a 
multi-component white powder which was separated to give a single product in poor yield 
following column chromatography. This material was identified as the dipeptide 
{Compound 21) by !H NMR and COSY. This characterisation was confirmed by 
observation of the M + H ion at m/z 552 and the M - H ion at m/z 550 in the FAB [+] and 

































3S.2.2. The tripeptide PheLeuGly.
Phe— Leu—Gly
Fig. 3.18.
The strategic approach adopted for the preparation of the tripeptide analogue 
(Figure 3.18) was based on previous work (Section 3.5.1.)- Since BOCPheLeuOPfp 
(<Compound 44) had been successfully coupled to glycine N-(2-(4-methoxyphenyl)ethyl)- 
amine, the synthesis of N-(N-(N-(BOC)phenylalanyl)leucyl)glycine N-(2-(4- 






The hydrochloride salt of Compound 55 [glycine N-(2-(4-(phenylmethoxy)phenyl)- 
ethyl)amide] was converted to the free amine using N,N-diisopropylethylamine in an 
organic solvent, {Scheme 3.27). The pentafluorophenyl ester {Compound 44) was treated 
with the free amine in situ in a reaction catalysed by DMAP and HOBt Following a brief 
wash with aqueous acid, the organic solvent was evaporated to give a multi-component 
oil. Application of the crude material to a chromatography column and subsequent elution 
permitted the isolation of a single product, as a solid, in moderate yield, {Compound 56). 
Characterisation of this material with !H NMR identified the desired compound, together
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with an excessive number of signals. Further extrapolation of the proton spectrum 













Surprisingly, the synthesis of BOCPheLeuGlyN-(2-(4-(phenylmethoxy)phenyl)- 
ethyl)amide (Compound 56) resulted in a mixture of diastereoisomers, which was 
unexpected for a number of reasons. Firsdy, !H NMR data from the optically-active 
starting materials (BOCPheLeu (<Compound 43) and BOCPheLeuOPfp (iCompound 44)) 
showed no loss of chiral integrity (Figure 320 (a) and (b)). Secondly, the synthesis of an 
analogous compound, BOCPheLeuGly N-(2-(4-methoxyphenyl)ethyl)amide (Compound 
45) using a similar experimental protocol had shown no signs of racemisation (Figure 3.20 
(c)).
Proton spectroscopy was used to compare the diastereomeric mixtures using the 
shift values of four leucine y-methyl doublets, which could be resolved more easily from
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the "busy" spectra, {Figure 320 and 321). IsomericaUy pure precursors containing 
leucine enabled the two doublets at 5 0.87 and 5 0.89 to be identified as the L-isomer, 
whereas the more shielded doublets at 5 0.73 and 5 0.80 were assigned to the D-isomer 
{Figure 320 (d)). Comparison of the integrals for the leucine y-methyl L and D doublets 
showed a 2 :1 ratio of L-isomer to D-isomer. An attempt to separate this mixture by 
column chromatography was not successful and provided a product with the same ratio of 
diastereoisomers. Characterisation of Compound 56 was corroborated by observation of 
the M + H ion at mlz 645 for FAB [+] and the M - H ion at m!z 643 for FAB [-] in the 
mass spectra.
The formation of diastereoisomers, elucidated from the NMR data suggested that 
either the phenylalanine or leucine or both had undergone racemisation during the coupling 
reaction. If only the leucine chiral centre had been effected then the material would exist 
as a mixture of L, L or L and D diastereoisomers. If, on the other hand, both asymmetric 
centres had been involved then the compound would exist as a mixture of both 
diastereoisomers and their enantiomers, i.e., L L; L D; D D; D L. The enantiomers to the 
diastereoisomers are invisible to NMR spectroscopy since they are identical in most 
physical properties. However, they do differ in the way they interact with plane polarised 
light In order to determine if one or both of the chiral centres of Compound 56 had 
racemised the optical rotation of the material was measured. A specific rotation 
measurement of [a ] 23589 +24.6° suggested that the compound did not exist as a racemic 
mixture, as this has no optical activity. It was concluded therefore that only the leucine 
had racemised and the material contained both L-Phe L-Leu and L-Phe D-Leu.
The integrity of the chiral precursors to Compound 56 were also investigated and 
found to be [a ] 23589 + 10.4° and [a ] 23589 -14.4° and for BOCPhe and BOCPheLeu, 
respectively.
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The BOC group of Compound 56 was cleaved using hydrogen chloride in 
dichloromethane. Evaporation of the solvent provided a white solid in good yield. This 
material was identified as a mixture of diastereoisomers of the hydrochloride salt of the 
tripeptide, {Compound 57). As expected, the broad singlet associated with BOC circa 5 
1.3 was absent from the !H NMR spectrum of Compound 57, but a new broad singlet 
which integrated correctly for the phenyl +NH3 was observed at 8  5.58. Both 
diastereoisomers of Compound 57 were assigned within the spectrum, but a comparison of 
the integrals of the leucyl y-bis(methyl) groups showed an approximate 1:1 ratio of 
diastereoisomers.
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Figure 3.20. A Comparison of XH NMR Leucine-y-Methyl Signals for
Chirally Active Intermediate Compounds.
Fig. 3.20(a) BOC-Phe— Leu-OH
Compound 43.
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Fig. 3.20(b)
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The possibility of preparing further conjugates with a peptidic hydrochloride salt has been 
used successfully in previous experiments. An attempt was therefore made to treat 4- 
(phenylmethoxy)benzoyl chloride (iCompound 18) in dichloromethane with an excess of 









Evaporation of the solvent afforded a multi-component residue which was applied directly 
to a chromatography column. Spectroscopy of an isolated product provided further 
evidence of the diastereomeric nature of the product {Figure 3.21 (b)). Correlation 
spectroscopy (COSY) together with !H NMR enabled each signal in the spectrum to be 
assigned to the respective isomer {See spectrum 2, Appendix 2). The identity of the 
product {Compound 22) was corroborated by accurate mass spectroscopy with the 
observation of an ion at m!z 756.3892 (calculated 756.3887).
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3.S.2.3. The tetrapeptide - GlyPheLeuGly
In analogy to the known reaction of aryl carboxypeptideOPfp and peptidic 
hydrochloride salt, the arylGlyOPfp (iCompound 53) was allowed to react with the 
hydrochloride salt of the tripeptide {Compound 57), (Scheme 329).











The hydrochloride salt {Compound 57) was suspended in dichloromethane and converted 
to the free amine by the addition of excess NJ^-diisopropylethylamine (base). A catalytic 
amount of DMAP and HOBt was added to the solution before an equimolar amount of N- 
(2-(4-(phenylmethoxy)benzoyl)glycineOPfp was allowed to react in situ with the mixture. 
On evaporation of the solvent, the resulting gum was applied directly to a chromatography 
column and a single product was eluted in good yield. The ratio of diastereoisomers was 
not changed during chromatographic separation according to NMR {Figure 321 (c)),
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however, the spectra corroborated the proposed identity of the product as that of the 
target compound, Compound 23.
3.5 J .  Attachment of ligands.
According to Duncan et al (252) attachment of a drug to a macromolecular carrier 
can be used to manipulate biodistribution, permeability through biological barriers and 
pharmacokinetics. However, the proposed PEG-peptide polymers under investigation, 
have been designed in a linear fashion with amino acids selected for their lability to 
enzymatic degradation. The lack of peptide functional groups severely limits not only the 
drug" loading" of such conjugates, but also the design options for PEG-peptide based drug 
carrier systems. To circumvent this limitation, we attempted to prepare copolymers of 
PEG and peptide containing reactive pendant groups along the polymer backbone.
Controlled peptide bond formation with glutamic acid (Figure 322) involving the 
a-carboxy group absolutely requires obstruction of the y-carboxy group. In addition the 




An initial attempt to incorporate glutamic arid into the tetrapeptide chain involved 
the reaction of 4-(phenylmethoxy)benzoyl chloride and a a,y-carboxy protected glutamic
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acid. A method adapted from Schwarz et al (252a) involved the introduction of 
trimethylsiloxy onto the a-carboxy compartment of a y-methyl protected glutamic acid, 
{Scheme 330). However, treatment of the carboxy protected compound with the acid 
chloride gave no material which could be identified as the required product
Since FMOCglutamic acid-y-f-(butyl) ester provides a suitable orthogonal 
protecting group to the benzyloxy tetrapepdde chain, (Compound 23) the synthesis of an 
a-amino FMOC pentapeptide compound was investigated. The a-amino, y-carboxy 
protected glutamic acid was converted to an active ester using pentafluorophenol in a 
DCC coupling reaction, {Scheme 331). Conventional work-up afforded a single product 
in good yield which was characterised inter cUia by 19F NMR. Comparison of the shift 
values for the ortho, para and meta fluorine signals at -152.69, -157.63 and -162.21 
respectively showed a considerable de-shielding effect compared to the pentafluorophenol. 
A trace amount of pentafluorophenol was detected in the spectrum which was not 








Compound 58. Scheme 3 31.
To provide the appropriately derivatised tetrapeptide the activated ester of glycine 
(iCompound 59) was synthesised by treating BOCglycine (249) with pentafluorophenol in 
the presence of DCC. By slightly modifying a previously discussed procedure, the 
reaction between Compound 59 and the tripeptide (Compound 57) was investigated. A 
solution of the hydrochloride salt of Compound 57 was treated with an excess of base in 
dichloromethane. The tripeptide, as a free base, was allowed to react with BOCGlyOPfp 
in situ in the presence of HOBt and DMAP. A single product was eluted from a 
chromatography column after a conventional work-up, and identified as the desired 
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Since FMOCGlu(7 -rBu)OPfp (iCompound 58) is susceptible to nucleophilic attack, 
the hydrochloride salt of Compound 61 was converted to the free amine. Compound 58 
and Compound 61 were suspended in dry dichloromethane and care was taken to add an 
exact equimolar amount of N,N-(diisopropyl)ethylamine to the mixture. The FMOC 
protecting group is cleaved swiftly under alkaline conditions and the base was therefore 
added dropwise over one hour. Removal of the solvent by evaporation gave a crude 
product but direct application to a chromatography column and subsequent elution 










Compound 62. Scheme 333.
This material was characterised by accurate mass spectroscopy with the observation of an 
M + H ion at mlz 1008.5023 (requires 1008.4997). The identity of Compound 62 was 
further corroborated by ^  NMR and COSY analysis, (see Spectrum 3, Appendix 3).
In order to synthesise the target pentapeptide compound an attempt was made to 
couple 4-(phenylmethoxy)benzoyl chloride, (Compound 18) in situ with freshly 
deprotected Compound 62. The routine reagent for FMOC removal is 20% piperidine in 
DMF. Compound 62 was treated in dry dichloromethane with an excess (20 eq.) of 
piperidine (99%) and monitored by T.L.C. Following complete deprotection the solution 
was basified and the acid chloride immediately introduced. Unfortunately, following a 
conventional work-up gave no material that could be identified as the required 
pentapeptide derivative, (Scheme 3.34).
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Chapter 4. Poly(ethylene) Glycol
4.1. Strategy.
To provide the appropriately derivatised prepolymeric monomers various terminal 
groups were attached to PEG. The aim was to synthesise nucleophilic PEG endgroups 
which would be allowed to react with a,co-glycidylether(peptide) functionalities in a 
polymerisation step. In order to encourage linear polymerisation a PEG terminal secondary 
amine was more preferable than a primary amine as the reaction of a glycidylether with a 
secondary amine is limited to only once. To accomplish this the PEG's were converted to a, 
a>-bis(chlorofonnate) with phosgene. Treatment with a suitable nucleophile [N- 
(BOC)sancosine N-(2-aminoethyl)amide] gave the corresponding bis(carbamate) and 
deprotection of this compound with hydrogen chloride gave the required a,CD- 
bis(methylamino) derivatised PEG.
4J2. Introduction.
This chapter commences with a brief overview of the synthetic strategy that was 
adopted to activate the PEG in order to provide the appropriate functional groups for 
attachment to the peptide chain. The biological chemistry of a variety of PEG-enzyme and 
drug conjugates is discussed together with a review of the chemical literature concerning 
PEG. Finally there is a discussion on the work pertinent to the project.
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43. Biological Chemistry of PEG.
To date, over 40 different proteins and other compounds have been modified with 
PEG (253) (see Table 4.1). Their uses vary considerable, although the majority of 
conjugates find their application within the biomedical and biotechnological spheres. In 
general, all the PEG-protein conjugates share the advantageous properties that are discussed 
in the introduction for macromolecular compounds. This section will focus on a number of 
examples which illustrate how the choice of coupling agent, molecular weight of the PEG, 
the percentage of groups modified and the specific properties of the protein being modified 
can alter the characteristics of the final PEG-adduct
The effect of coupling PEG to enzymes has been well documented with extensive 
reviews being written (275). Studies on the modification of alkaline phosphatase with PEG
(276) indicate that, if different coupling methods are compared, then it is apparent that some 
methods are more suitable at retaining enzyme activity than others. The monomethyl ether 
of PEG (M-PEG) with an average molecular weight of 5000 was activated using four 
electrophilic groups to couple covalently via reaction with protein nucleophilic centres. The 
derivatives were:- the cyanuric chloride [1]; the tresylate (2 ,2 ,2 -trifluoroethanesulphonate)
[2]; carbonyldiimidazole [3]; and the succinimidyloxycarbonyl [4]. Free and modified 
phosphatase activities were measured by following the enzyme catalysed hydrolysis of 
disodium p-nitrophenylphosphate to p-nitrophenol. With no modification the free 
phosphatase activity was assumed to be 100%. The percentage activity of the four types of 
activated M-PEGs, with high and low percentage modifications were compared to this 
control. The most active M-PEG protein was obtained by the use of the succinate conjugate 
[4] which gave a protein conjugate of comparable activity to the enzyme, even at a high 
modification level of 79%. The tresylate [2] and imidazole [3] gave a slightly less active
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conjugate than the succinate whilst the cyanuric chloride method [1] gave extensive 
deactivation.
Table 4.1. PEG modified derivatives.





blood coagulation factors IX 256
elastase 257
a-galactosidase 2 1 1
p-galactosidase 214



























Previous observations (205,212) corroborate that the cyanuric chloride derivatives 
gives significantly more enzyme deactivation than do other activated PEGs. Boccu et al
(277) mooted that this deactivation results from the close proximity of the two chlorines 
which can cause intramolecular cross-linking and appreciable deformation of the protein 
chain during the coupling process. It has long been established that a conformational change 
in the enzyme tertiary structure will adversely affect the affinity of the active site to the 
substrate resulting in a loss of turnover ability. It is interesting that difunctional PEG shows 
no increase in enzyme deactivation, suggesting that if the active sites of the difunctional PEG 
are separated by the long polymer chain, cross-linking is reduced, or, if it occurs, it 
introduces little deformation or rigidity into the protein chain.
The advantages of macromolecular conjugates has been discussed at length in the 
introduction and more pertinently in the preceding section. Listed below are just three, 
more detailed, examples from Table 4.1 of how a drug carrier can be used to improve the 
clinical efficiency of drug delivery.
4.3.1. PEG Interleukin-2.
Human recombinant interleukin-2 (rIL-2) is currently being tested as an anti-cancer 
therapeutic agent. Unfortunately, the recombinant protein suffers from limited solubility at 
physiological pH and from immunogenic problems. The covalent attachment of PEG to rEL- 
2 produces a conjugate with bioactivity in vitro similar to that of unmodified rIL-2 (191) and 
gives a more hydrophilic molecule which is completely soluble at any pH. The enhanced 
solubility of PEG-rIL-2 eliminates the possibility of potential aggregates which may augment 
an immune response. This was corroborated when PEG-rIL-2 was tested in rabbits over an 
8  month period and did not elicit an immune response (278). However, rabbits that had 
already developed neutralising anti-bodies after injection of only rIL-2 neutralised the
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bioactivity of PEG-rIL-2 in vivo. This is suggestive that the conjugate does possess 
antigenicity but a reduced immunogenicity when compared to rIL-2. The conjugate can also 
display a marked increase in circulatory half life in mice when compared to free rIL-2. Two 
possible explanations for the decrease in plasma clearance could be due to the modification 
or shielding of the proteolytic sites of rIL-2 by PEG or the large increase in the size due to 
the hydration of the PEG within the conjugate, which reduces overall glomerular filtration.
Usually the covalent attachment of PEG to rIL-2 takes place by the random coupling 
of PEG to any or most of the lysines available, some of which may be in or near the active 
site. A recent report suggested that the covalent modification of four or more lysines 
resulted in a reduction in the bioactivity of the protein. This was probably caused by steric 
hindrance which prevented the binding of the conjugate to IL-2 receptors. Alternatively, 
there may have been some chemical modification at the active site. This prompted Goodson 
et al (276) to propose that PEGylation at a site distant from the active site would be 
preferable. Using mutagenesis techniques a 'handle' (a cysteine thiol) was engineered in a 
position distant from the receptor binding region of biological activity. Following reaction 
of a PEG-maleimide group with the thiol of cysteine, PEG-Cys3-rIL-2 was produced which 
had full biological activity.
The in vivo activity of a PEG-rEL-2 (Mw 95 000) species administered daily i.p has 
been investigated (191) in the murine tumour model, Meth A fibrosarcoma, and showed 
enhanced efficacy and reduced toxicity (8 ).
43 2 . PEGSuperoxide Dismutase.
Superoxide dismutase (SOD) has been used as a novel anti-inflammatory 
metalloprotein drug in rheumatoid arthritis and has been modified with PEG (279). Huber
145
and Saifer (280) reported that unmodified superoxide dismutase was removed efficiently by 
the kidney from the serum of rats with a half life of 6  minutes, making effective treatment 
difficult in the clinic. In contrast, PEG-SOD remained in the circulation for 8  days and 
exhibited 51% of the native enzymatic activity when M-PEG 5000 was attached to 19 of the 
20 lysine residues available on the enzyme (281). In addition, sensitisation work has 
demonstrated that the PEG-deiivatised superoxide dismutase is a poor immunogen (282). 
This is in agreement with the previous studies whereby the extent of protein modification 
affects the enzyme activity but also confers protection on the conjugate. More recent 
research (283) on the toxicity of PEG-SOD evaluated in mice showed that the conjugates 
could be tolerated in large doses with no signs of toxicity. This is encouraging, particularly 
if repeated dosage regimes are to be employed for future therapy.
433  PEG-Granulocyte Colony Stimulating Factor.
The action of Granulocyte Colony Stimulating Factor (G-CSF) is exclusive to 
neutrophil generation. The availability of large quantities of biologically active recombinant 
material (iG-CSF) has made it possible to study it's use therapeutically. Recently, G-CSF 
has been administered to patients in order to accelerate their haematological recovery 
following high dose irradiation or drug induced neutropenia (low levels of neutrophils). 
Although therapy is successful, the factor is rapidly cleared from the circulation making daily 
injections necessary.
A comparative study of iG-CSF and PEG-iG-CSF on haematopoiesis (284) revealed 
that the response to PEG-rG-CSF was reduced when compared to that of the native protein. 
This paper suggested that the PEG molecules may either sterically inhibit the G-CSF 
receptor binding or that some of the lysine residues that were bound to the PEG were 
important for biological activity. Despite this, PEG modification of iG-CSF exhibited an
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increased circulatory half life in vivo and consequently a sustained biological effect on the 
blood neutrophil level. This was beneficial as the effects of G-CSF are more positively 
influenced by the duration of G-CSF in the serum than by peak concentrations of G-CSF. 
Urinary excretion of rG-CSF is negligible and it was therefore assumed that the PEG was 
effectively shielding the potentially labile sites on the protein from circulatory proteases.
4.4. PEG Conjugates of Drugs.
The pharmacokinetic advantages displayed by PEG protein conjugates can be 
imparted to nonprotein moieties. The wide range of drugs which have been coupled to PEG 
is summarised in Table 4 2 .
Table 4.2. A summary of PEG-Drug Conjugates.
Drug. PEG. (Mw). Ref. Notes.





Penicillin remained active 
active.
Aspirin PEG-OH 285 Same activity,i toxicity
PEG-OH 285 1  toxicity
Amphetamine mPEG-SC 285 no reaction with DCC








285 hexamethylene spacer - 
Water soluble
mPEG-COOH, 1900 285 no reaction with DMAP
Cephradine polymeric 286 inactive
Procaine 289
4-isobutyl phenyl - 
2 -propionic acid
290 anti-inflammatory
Drugs can be attached to PEG via several functional groups which arc discussed in the next 
section. These include esters, amides, carbonates and urethanes. The polymer drug 
conjugates offers advantageous properties and a longer duration of activity due to their slow 
release.
4.5. Preparation of PEG Derivatives.
PEG has only two reactive groups (the hydroxyl groups at the ends of the chain) that 
are weak nucleophiles but they can be used directly, or after suitable funcdonalisation, for 
the covalent attachment of ligands. This process is often referred to as activation, and the 
product is sometimes called ’activated PEG’. With the development of new areas of 
application there is a growing demand for improved and versatile methods for the synthesis 
and characterisation of PEG derivatives. It is apparent that each of the activated forms of 
the polymer has features which can be considered an advantage or disadvantage, depending
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on the goal sought. As a chemical short-hand the symbol PEG-R will be used to represent a 
difunctional PEG derivative R-CH2CH2 0 (CH2CH20 )nCH2CH2-R.
There are three main approaches that can be used for the functionalisation of PEG:-
(1) activating the terminal hydroxyl group to a more active functional group, e.g.
NH2.
(2) reaction of the PEG with bi-functional components such that one of the 
functional groups reacts with PEG and the other remains active, e.g. bW-bisfphenylalanyl)- 
hexamethylene diamine.
(3) by preparing PEG ester derivatives through the generation of the fatty acid 
chlorides, followed by in situ condensation with PEG, e.g. RCOC1 + PEG.
PEG is a hygroscopic material and the manufacturing process can introduce water 
into the product Water can be a particular problem as this impurity and the PEG alcohols 
have similar nucleophilic reactivity. All commercial PEGs do contain some of this impurity 
with the lower molecular weight polymers have the highest amounts of water (approximately 
1.0% for PEG 750). It is, therefore, prudent to dry PEG before laboratory use. This is 
often done by azeotropic distillation with benzene or, more commonly and safely, toluene in 
the Dean-Stark apparatus. Other methods include stirring the polymer under vacuum at 110 
- 120°C. Any other purification is generally unnecessary as commercially obtained PEGs are 
often quite pure materials, having only trace (ppm) amounts of impurities such as dioxane, 
salts, and aldehydes. The concentrations of ethylene glycol and diethylene glycol, however, 
may vary considerably. Despite this, the molecular weight range is often reported as being 
narrow, for example PEG 8000 will vary by no more than 30 units in either direction (291). 
This is in contrast to other reports which suggest that the distribution of molecular weights 
of oligomers surrounding the mean value is often asymmetric. Approximately 95% of the 
mass of PEG 900 for instance is distributed between molecular weight 100 - 2000 with the 
distribution leaning towards the lower molecular weights (292). Experiments performed
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using these mixtures would make interpretation of the results unequivocal particularly if 
molecular weight and size were important factors, e.g. renal clearance studies, size standards 
for intestinal absorption. A prime practical consideration when using PEG - protein 
conjugates is to determine the optimum degree of substitution and PEG molecular weight 
needed to give the desired effect (on immunogenicity or partitioning, for example) without 
producing excessive protein deactivation. There appears to be no general rules in this 
regard, as effects vary greatly from system to system. Consequently, it is necessary to 
determine the effects of PEG molecular weight and degree of substitution in each case.
Proton NMR can be used for the qualitative identification of PEG functional groups 
although this technique has the disadvantage that the signals due to the repeating 
0(CH2CH20) units lie predominantly between 8  3.3 and 8  3.7 and obscure this area of the 
spectrum. Infrared spectroscopy (LR.) is of some use particularly when searching for 
functional groups such as PEG acid chlorides. However, as with !H NMR, the problem is 
that the absorbing functional groups at the polymer terminals are present in low 
concentrations and thus give weak signals. Mass spectroscopy techniques are generally of 
little value as the parent ion is not detected and small fragment ions of low mass are often 
produced. Qassical qualitative analysis can be useful in establishing end group functionality.
4J.1. Electrophilic Activation o f PEG.
There has been a great deal of interest in electrophilic PEGs for coupling to free 
amino groups of proteins and these same derivatives are potentially useful for reaction with 
other nucleophiles. The literature suggested that one route that had been successfully used 
to derivatise PEG was by nucleophilic substitution on electrophilic PEG derivatives. In this 
section these electrophilic derivatives are considered.
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(A ) In 1991 Zalipsky (293) described the preparation and use of a new protein modifying 
reagent methoxypoly(ethylene glycol)-N-succinimidyl carbonate (SC-PEG) and the 
bifimctional analogue poly(ethylene glycol)-bis-(N-succinimidyl carbonate) (BSC-PEG),
(Scheme 4.1).
1. Phosgpne
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The protocol Zalipsky employed was an overall improvement on the existing methods of 
protein conjugation as carbamate linkages between amino groups of a protein and PEG 
provide a stable attachment, more resistant to hydrolytic cleavage (294). N-Hydroxysuccin- 
amide (HOSu) released during polypeptide modification using BSC-PEG does not show 
affinity towards proteins and can be readily removed from the reaction solutions. An 
additional advantage of this activated PEG is that those reactive functional groups that do 
not react with amino groups of a protein or reagent undergo hydrolysis producing HOSu,
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C02 and hydroxy terminated polymer. This feature is of particular importance in the case of 
the bifunctional BSC-PEG.
Similarly, PEG chloroformate has been prepared and treated with an amine to make 
a carbamate by Takerkart (333), (,Scheme 42). The use of PEG-phenyl carbonate 
derivatives for the preparation of carbamate linked PEG-proteins was reported by Veronese 
(294). The main drawback of this approach lies in the toxicity of hydrophobic phenol 
residues (p-nitrophenol or 2,4,5-trichlorophenol) and their affinity for proteins.
PEG—OH + COCfe ^  p
X— (PEG)nO^ x n
O Scheme 42.
R-NH2 _ ^
------------ ► X— (PEG)nO N
H
Carbamate
Takerkart, by attaching p-aminobenzaldehyde (which is a trypsin inhibitor) used the 
chloroformate in the affinity phase partitioning of trypsin. It is also reactive toward other 
nucleophiles, e.g. reaction with alcohols gives carbonates (289). Nuzzo used this active 
derivative for preparing phosphine derivatives for binding transition metal catalysts (295), 
{Scheme 4.3).
O O
£  + HN(CH2CH2PPh2)2  ► C
X—(PEG)nO^ ''C l X—(PEG)nO^ ''N(CH2CH2PPb2)2
Scheme 43 .
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In one alternative route, Beauchamp treated PEG with carbonyldiimidazole to 
produce an activated electrophilic derivative, which is subject to nucleophilic attack by lysine 
amino groups (212), (.Scheme 4.4). The PEG is attached to a protein via a carbamate 
linkage and this intermediate is said to give little deactivation upon reaction with proteins. 
However, the polymer activated in this manner was not very reactive and therefore very long 
reaction times (48 - 72h at pH 8.5) were required to achieve sufficient modifications.
O O
PEG-OH + ^  ■» P E G O ^ / ^ l
N ^ /  V > N  \ ^ N
O
II
+ Protein—NH2 --------------------►L PEGO N—Protein
Scheme 4.4.
(B ) PEG Chloride and PEG bromide (334) have been prepared by reaction with thionyl 
chloride or bromide in toluene, (Scheme 45). The bromide derivative appears more stable 
than the chloride, with samples remaining unchanged for at least a year.
PEG—OH + SOCfe  ► PEG—Cl + HC1 + S 0 2 Scheme4 5
Bayer (296) noted that the preparation of the chloro derivative can be simplified by 
omitting solvent and simply running the reaction in an excess of thionyl chloride, which is 
subsequently removed by distillation.
Pillai et al (297) and Harris (298) have prepared the tosylate by a common route 











These authors have reported (298) that this procedure produces a reduction in PEG 
molecular weight of approximately 30% and that this compound decomposes slowly on 
storage. A preparation without chain cleavage is provided by eliminating the pyridine and 
preparing the PEG alkoxide by reaction with sodium hydride (Scheme 4.6(B)). This result 
indicates that pyridine hydrochloride may be the agent causing chain cleavage in the first 
tosylate preparation. Further evidence that this may be the case is indicated by preparing the 
tosylate (299) and mesylate (300) without cleavage by use of triethylamine as acid 
scavenger, (Scheme 4.7).
A further review or the literature reveals other candidate electrophiles which may 





Fig. 4.1. Nosylate Fig. 42. Brosylate
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(C ) The most frequently applied route to cyanuric chloride activation of PEG is that of 
Abuchowski and Davis in which the PEG-cyanuric chloride derivative is allowed to react 
with the protein (194,301,259), (Scheme 4.8). This approach suffers from disadvantages 
such as the toxicity of cyanuric chloride and limited applicability for modification of proteins 
having essential cysteine or tyrosine residues as manifested by their loss of activity (302,
199,212). Despite this there has been some success (197) for the covalent attachment of 
bovine serum albumin to PEG. The first of the two chlorines on this derivative is substituted 
by protein amino groups in about one day. The second site is much less reactive, although 
there does appear to be some reaction (277).
PEG—OH + C3N3CI3




PEG O N  Cl PEG—O. .N N—Protein




(D) Currently a common form of activated PEG is the succinate-N-hydroxysuccinimide 















It reacts with proteins in short periods of time under mild conditions producing extensively 
modified conjugates with well preserved biological activity. However, the ester linkage 
between the polymer and the succinic acid residue has limited stability in aqueous media. An 
early version of this approach is the synthesis by Royer (305) of the 1,2-bis(succinimidyl 
succinate) of ethylene glycoL
(E) Pitha has prepared PEG epoxides by reaction of PEG with epichlorohydrin in the 
prescence of the Lewis acid tin (TV) chloride followed by ring closure with sodium 
hydroxide (306) (,Scheme 4.10).




(F) The isocyanate is a reactive electrophilic derivative which can be reacted with amines 
or alcohols to yield ureas or carbamates (307), {Scheme 4.11).
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PEG-O H + OCN—(CH2)6—NCO
PEG—0 2CNH— (CHik—NCO ^  PEG—0 2CNH—(C H ^—NHC02— R
Scheme 4.11.
Zalipsky (285) found that dibutyldn dilaurate was an effective catalyst for the 
coupling reaction although it was noted that the PEG isocyanate decomposed upon standing 
and should therefore be freshly prepared before use. Interestingly, the carbamate linkage 
appears to be useful as a labile linkage for the controlled release of drugs (285).
452  Nucleophilic Activation of PEG.
PEG amines are important as intermediates in the synthesis of other derivatives, and 
several PEG amines are themselves useful in direct application.
(A) Buckmann and Johansson have described two direct syntheses for primary PEG 




PEG—Br + H2N(CH2)6NH2 B0H r  PEG-NHCCHjWttt
The first method is direct and produces 100% substitution by the use of gaseous ammonia. 
The second method is easily applied and although a primary and a secondary amine are 
produced, the primary is much more reactive. Since the hexane 1,6-diamine is difunctional,
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there is the possibility in this reaction of interconnecting PEG chains. Johansson has found 
this to occur if the molar ratio of bromide to amine is 0.19 but not if it is 0.05.
*
Zalipsky has described an effective three step synthesis of PEG amine, via the azide 
which gives an 80% yield of completely aminated product (285), {Scheme 4.13).
l.NaNa.DMF
MPEG—Cl -----------------------► MPEG-NH2 Scheme 4.13.
2.H2,Pd/C,EtOH
Another route is provided by the method of Kern (309), {Scheme 4.14), using the 
activated PEG-OTs derivative.
(CH^OOH
PEG-OTs + KOCH2 CH2 NH2  -------------- ► PEG-OCH2 CH2 NH2  Scheme 4.14.
QH*
Mutter (310), Geckeler (311) and Ciuffarin (312) have applied the Gabriel 
phthalimide-hydrazine sequence to the preparation of PEG amine, {Scheme 4.15). This has 
two steps and leads only to a primary amine, but it has been used with success in the many 
examples of peptide synthesis by Mutter and coworkers.
K+phthalimide








PEG amine can also be prepared by reductive animation of PEG aldehyde with 
ammonium acetate (313), (,Scheme 4.16), this method gives essentially complete substitution 





A preparation of PEG secondary amine has been published by Suzaki et al (314) 
who have carried out displacements on PEG tosylate and chloride with amines (Scheme
4.6. Investigations of Routes to ot,co-Bis (methylamino)PEG Derivatives.
Although the literature search reveals that a considerable amount of work has been 
done on PEG, the availability of a range of commercial products is still awaited. The 
reaction of a,co bis(amino) PEG with a,co-bis(glycidyl)peptides was chosen as the 
polymerisation strategy towards the alternating PEG-peptide linear polymer. To provide the 
appropriately derivatised monomer, a number of experimental strategies were investigated.
4.6.1. The alkyl halides. Tosylate esters.
Many a,co-bis(amino)PEGs have been prepared by substitution of a,o>-dichloro PEGs with 





was made to adapt Bayer’s synthesis (296) of a,o>-dichloro PEGs to hexa(ethylene glycol), a 
model oligomer of defined chain length. However, treatment of hexa(ethylene glycol) with 
refluxing thionyl chloride gave no material which could be identified as the required dichloro 
derivative, (Scheme 4.18).
PEG—OH + SOCk --------► PEG—Cl + HC1 + S02 Scheme 4.18.
A mechanistic scheme for this proposed transformation is shown in Scheme 4.19 whereby a 
tertiary amine R3N, e.g. triethylamine or pyridine is used to catalyse the reaction by forming 





P E G ^ ^ ^ ^  + + Cl
R3N + HC1 -  RjNH + Cl®
Scheme 4.19.
Since tosylate is a much better leaving group than chloride, synthesis of the a,co-bis(tosylate) 
of the model hexa(ethylene glycol) was investigated. These compounds react with primary 
and secondary alcohols, generally in the prescence of a tertiary amine, e.g. pyridine to
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produce sulphonate esters. The hexa(ethylene glycol) (Mw 282) was dried by azeotropic 
distillation of the water with toluene using a Dean and Stark trap. The diol was treated with 
tosyl chloride in the prescence of triethylamine (a tertiary amine base) and a catalytic amount 
of 4-(dimethylamino)pyridine (DMAP, a nucleophilic catalyst). Conventional work up gave 
only a multi-component intractable gum but direct application of the crude reaction mixture 
to a chromatography column and subsequent elution permitted the isolation of a single 
product in moderate yield.
This material was identified as the mono-tosylate by proton NMR spectroscopy, (»Compound 
63) (iScheme 420). Comparison of the integrals of the aromatic methyl singlet at 8  2.45; the 
aromatic signals at 8  7 - 8  8  and of the PEG CH2 cluster at 8  3.67 - 8  4.15 showed a 1: 1 
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Compound 63.
v  DMAP
0 1 3  BjN 0% />  Q% , 0
Scheme 420.
An alternative tosylation was attempted according to the method of Dellaria (321). 
This method was adapted to investigate the feasibility of activating penta (ethylene glycol) 
with a mono tosylate whilst protecting the alcohol with an olefin. The synthesis began with 
the mono alkyladon of the sodium anion of penta (ethylene glycol) with allyl bromide. After 
one hour the reaction was acidified and the crude product flash filtered through a silica plug
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to give a product in good yield, (Scheme 421). The identity of the product was confirmed 
by NMR which revealed characteristic allylic peaks at 4.02 - 5.90 which integrated 
correctly for Compound 64.
(l).NaH








Compound 65. Scheme 421.
Tosylation of Compound 64 was achieved by combining an excess of p-tosyl chloride 
with triethylamine and a catalytic amount of DMAP. A conventional work-up followed by 
column chromatography provided a product (Compound 65) in moderate yield which gave a 
parent ion at mlz 433 in the mass spectrum. Confirmation of the required product was 
corroborated by proton NMR which showed the methyl (tosyl) group at 6  2.45 and the 
aromatic signals at 8  7.34 - 5 7.79.
4.62. The Alcoholysis o f  Acyl Halides.
The reaction between the acyl halides and alcohols is the best general method for the 
preparation of esters (315), and it has been used successfully for the esterification of PEG.
A general formula is given, (,Scheme 422).
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o o
II + R'OH II
R—C—X R—C—OR'
Scheme 422.
The reaction is of wide scope as both R and Rf may be primary, secondary or tertiary, alkyl 
or aryl. An important example is the preparation of carbobenzyloxy chloride 
(PhCH2OCOCl) from phosgene and benzyl alcohol. This compound is widely used for the 
protection of amino groups during peptide synthesis.
Zalipsky (293) and Nathan et al (316) reported an efficient one-pot procedure for 
the preparation of succinimidyl carbonate (SC) activated PEG which was repeated 
successfully in our laboratory using hexa(ethylene glycol). Previously Zalipsky and Nathan 
had used this procedure to prepare an activated 'pre-polymer1 in essentially quantitative 
yields. They were able to treat bis succinimidyl carbonate (BSC)-PEG with L-lysine ethyl 
ester a poly (ether carbamate) consisting of strictly alternating units of PEG and L-lysine 
ethyl ester, was obtained, {Scheme 423).
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It was therefore hypothesised that these same activated groups should be capable of reaction 
with a secondary nucleophile.
PEG a,ci>-di(chlorofonnate) was generated from the diol by the treatment of hexa- 
(ethylene glycol) with excess phosgene (1 0  eq.) in a mixture of dry toluene and 
dichloromethane (Scheme 424). Due to the hazardous nature of the reagents involved and 
because the intermediate was known the bis(chloroformate) was not characterised but 
instead preliminary experiments were initiated on the derivatised hexa(ethylene glycol).
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HO(CHlCH20)sCH2CH20H „ £  £
Totlene c K  ''O(CH2CH20)5CH2CH20^ ^C1
°  o  o  0




The polymeric bis(chloroformate) was allowed to react with N-hydroxysuccinimide 
in situ to give a crude product which after column chromatography, afforded the 
corresponding bis (succinimidyl)carbonate (BSC-PEG) derivative (1Compound 66), in 
moderate yield
Following the successful synthesis of BSC-PEG the problem of treating the 
functionalised PEG to form a nucleophilic centre became more obvious. Further work 
(discussed in Chapter 5) had been completed on an analogue which was able to react with 
the bis(epoxide) in a similar fashion to PEG. In order to investigate the feasibility of a 
reaction between an amine on PEG and the oxiranyl group we considered 2-methoxyethyl- 
amine {Figure 43(A)) as a model. This compound behaved in a similar fashion to PEG but 
no polymerisation was possible because it was mono-functional. Further consideration of 
this reaction suggested that the amine group may, after the initial reaction be capable of a 
further reaction as a nucleophilic amine would be formed giving rise to cross-linking. It was 
therefore considered better to use 2-methoxy-N-methylethylamine (Figure 4.3(B)) which, as 
a secondary amine would be capable of a single reaction and therefore be a model for a 
linear polymer. Of course using 2-methoxy-N-methylethylamine further reaction remains
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impossible due to the methoxy group and to initiate a successful polymerisation, a 




4.63. The N-(BOC)sarcosine N-(ethane-12-diamine) formation.
It was anticipated that the electrophilic glycidyl ether (peptides) would be able to 
react with the PEG a,obis(amine) during the final polymerisation step. A strategy was 
devised using sarcosine which provided a preformed secondary amine on an amino acid,
CFigure 4.4).
H N ^^C j:—OH
. , Fig. 4.4. Sarcosine
Secondary
amine.
A conventional f-butyl (BOC) reaction provided the protected amine {Compound 67) 
in good yield which melted at the stated literature value, (317) {Scheme 425). 
Characterisation with NMR showed that following protection the methyl peak is 
transformed from a doublet to a singlet with the removal of the proton on the amine. An 
extra singlet was frequently seen with !H NMR in the spectrum of the product at 5 1.48 and 
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Scheme 4.25.
Conversion of the protected amino acid to an active ester was achieved with 2,4,5- 
trichlorophenol via dicyclohexylcarbodiimide (DCQ coupling. The two protons carried on 
the trichlorophenyl ester allow the progress of the coupling to be monitored by !H NMR and 



























C o m p o u n d  6 9 . Scheme 426.
The bifunctional, ethan-1  ^ -diamine was prevented from reacting with multiple active 
ester units by adding the activated ester dropwise into a large excess of the nucleophile. 
Statistically this reduces the chance of a nucleophile reacting with two electrophiles and the 
formation of the desired product is favoured. The excess amine was removed during the
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work up by washing the organic phase with a small amount of water in which the e than-1 ,2 - 
diamine was readily soluble. Evaporation of the organic phase gave a product {Compound 
69) in good yield which was analysed with proton NMR and mass spectroscopy. 
Comparison of the BOC singlet at 8  1.40, of the methyl singlet at 5 2.80, of the amide 
singlet at 8  7.90 and the broad peak of the amine at 8  4.00 suggested the product was 
BOCsarcosine N-(2-aminoethyl)amide. This was corroborated with the observation of the 
M + H ion peak at mlz 232 in the mass spectrum.
In order to attach Compound 69 to PEG and provide the a,co-bis(methylamino)PEG 
the weakly nucleophilic hydroxy groups were converted to the chloroformate. The PEG 
bis(chloroformate) was prepared using a method adapted from Zalipsky (213) and isolated 
free from any contamination with phosgene. A molar excess of triethylamine, a catalytic 
amount of DMAP and an excess of N-(BOC)sarcosine N-(2-aminoethyl)amide {Compound 
69) ensured that as the bis(chloroformate) was added in a dropwise fashion it would be 
allowed to react immediately, {Scheme 427). The acid labile BOC protecting groups were 
not compromised as the presence of triethylamine prevented the pH from becoming too low. 
The crude product was washed with water and weak acid before a moderate yield of 
product {Compound 70) was assigned with !H NMR. A large broad singlet which 
integrated to 18 reflected the prescence of the two r-butyl protecting groups at 8  1.38 and 
five sets of signals were assigned to the amides with the methyl protected amides positioned 
at the same shift value.
Deprotection of the sarcosyl protecting groups was effected with an excess of 
hydrogen chloride and the reaction was followed by thin layer chromatography (T.L.C.) 
using ninhydrin to visualise the newly exposed primary amines. Characterisation studies by 
NMR on the hydrochloride salt {Compound 71) of the product showed the characteristic 
broad singlet at 1.38 ppm for r-butyl protons was absent, but a multiplet had been formed
168
down field at 8  9.00 which was assigned to the a,co-bis(amines). Mass spectroscopy 
revealed a mother ion peak at miz 553 which corroborated that the product had been 
formed.
Mechanism of the acyl halide and N-(BOC)sarcosine N-(ethane- 1,2-diamine) reaction.
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Chapter 5. The Polymerisation Process.
5.1. Strategy
The appropriately derivatised PEG monomers and peptide chains for 
copolymerisation could be generated in a number of ways. One suitable strategy was to 
synthesise various di, tri, tetra and penta peptides with orthogonal side chain protecting 
groups bearing either a nucleophilic amine at each end or an electrophilic glycidyl ether at 
each end. These functional groups could be treated with PEG monomers bearing a,o>- 
bisoxiranes (,Scheme 5.1(A)) or a,oo-bisamines (Scheme 5.1(B)), respectively, to form the 
final polymers.
X (PEG)nO ^ < q  + h 2n —r - n h 2






R = peptide. Scheme 5.1.
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A series of peptides were prepared bearing a,o>-bis glycidyl ethers. Various PEG 
monomers were derivatised with a secondary amine and allowed to react with the glycidyl 
ethers in a polymerisation process.
Through the careful selection of the length of PEG monomers, the size and 
molecular weight of the copolymers could be adjusted to enhance the biodistribution of the 
conjugate through passive targeting. The polymerisation process should succeed in 
producing strictly alternating copolymers of PEG and an oligopeptide chain. The peptide 
sequences are labile to intracellular lysosomal enzymes, and provide an opportunity to make 
the polymer biodegradable. In addition, the copolymers should retain the desirable 
properties of PEG while providing an opportunity to attach reactive pendant groups (the 
carboxylic acid groups of glutamate) at predetermined intervals along the polymer backbone.
5.2. Introduction
The definition of a polymer (from the greek "polys", many, and "meros", parts) is a 
macromolecule made up of repeating structural units. The reaction that unites the small 
molecules (monomers) into a polymer is called polymerisation. Examples of naturally- 
occurring polymers include starch, cellulose, proteins and nucleic acids.
Synthetic polymers can be divided into two main classes, depending on their method 
of synthesis. Addition (chain growth) polymers are formed by a reaction in which the 
monomer units add to one another. The most common types are vinyl polymers, and 
examples include polyethylene, polypropylene and polystyrene.
Copolymers are prepared from the copolymerisation of two or more monomers. 
Since the ratio of the monomers can vary widely, copolymers for specific uses can be tailor
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made. Condensation (step growth) polymers are formed by reactions of difunctional or 
polyfunctional molecules, such as glycols, diamines and dicarboxylic acids, to form 
polyesters and polyamides, through the elimination of small molecules such as water, alcohol 
or ammonia. Nylon (polyamide), Dacron (a polyester) and polyurethanes are common 
examples of polymers formed by this type of reaction.
The polymerisation strategy used in this project is based upon similar reactions. For 
example reaction of a dicarboxylic acid or diacyl chloride (adipoyl chloride) with a diamine 
(hexamethylenediamine) leads to the formation of a linear polymer, namely nylon {Scheme 
52).
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Nylon 6 ,6  Scheme 52.
It should be noted that this type of polymer is not the product of a free radical chain 
reaction, but results from a simple repetition of a normal reaction of the polar type. The 
only requirement is polyfunctional compounds.
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53. PEG as a Monomer for Polymerisation:- A Review.
In the past, PEG chains have been copolymerised with a variety of difiinctional 
comonomers. Block copolymers of PEG and two isocyanates, 3 ,5-diisocyanato-benzyl 
chloride or 3-nitro-3-azapentan-1,5-diisocyanate have been prepared by Bayer for use as 
soluble protecting groups in peptide synthesis (318), (Scheme 53).
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Scheme 5.3.
These materials carry functional groups at defined distances all along the chain and thus a 
high degree of substitution is possible along the chain.
Water soluble poly(ether urethanes) have been prepared by Nathan et al (316) 
through the copolymerisation of bis(succinimidyl)carbonate derivatives of PEG with lysine 
(L-Lys) in a strictly alternating fashion. The resulting copolymers have physical properties 
similar to those of PEG while the carboxylic acid groups of L-lysine provide multiple 
pendant groups along the polymer backbone for further functionalisation.(see Scheme 5.4)
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Nathan et cd (316) also utilised the pendant lysyl carboxylic groups in cross linking reactions 
leading to amide cross links, new acyl semicarbazide cross links (Scheme 55) and 
hydroxyethyl acrylate and hydroxyethyl methacrylate-derived cross links. The resulting 
hydrogels had favourable physicomechanical properties and were non toxic, which may 
encourage their application as biomaterials.
A further pioneering paper by Nathan (286) in 1993 reported that activated pendant 
carbonyl groups of poly(PEG-Lys) had been used as anchors for the covalent attachment of 
penicillin V and cephradine (see Scheme 5.6), two clinically used antimicrobial agents. The 
versatility of this system was demonstrated by the preparation of conjugates having 
antibiotic ligands linked via a biostable or biodegradable linkages to the carrier. The dotted 
arrow indicates the most probable site of hydrolytic cleavage.
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The chemical versatility of this new class of polymers for the preparation of various drug 
conjugates represents a significant advantage over previously reported drug-carrier systems.
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A synthetic method has been developed (292) for the iterative preparation of PEG 
oligomers. Although this process does not constitute polymerisation, the strategy does 
provide discrete PEG oligomers all of homologous size. The scheme involves alkylating the 
sodium anion of mono-tritylated ethyleneglycol oligomers with O-tosyl-O’-allyl-triethylene 
glycol or Otosyl-O’-allyl-pentaethylene glycol {Scheme 5.7). Subsequent ozonolysis of the 
terminal olefin, followed by reduction with NaBU*, provided the next higher mono-tritylated 
ethylene glycol oligomer which could be deprotected to the final glycol oligomer, or carried 
on in the iterative process.
PEG derivatives containing transformed terminal hydroxyls (NH2, COOH, NCO 
groups) were treated with bifunctional reagents, [1] N, Nt-adipoyl bis (phenylalanine p- 
nitrophenyl ester) {Scheme 5.8) or [2] N,N'-bis (phenylalanyl) hexamethylenediamine 
{Scheme 5.9 and 5.10) to generate a number of polymeric substrates.
H(OCH20fe>ue-OH
PhaC (OCH^H^* OH
Ph,C (OCH2 CH2 )irO‘
Scheme 5.7.
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PEG Polymers Derived from Bifunctional Reagents, Scheme 5.8.
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PEG Polymers Derived from Bifunctional Reagents, Figure 5.9.




PEG Polymers Derived from Bifunctional Reagents, Scheme 5.10.
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Oligopeptides linked to poly(ethylene oxide), PEO, undergo an enzymatically 
catalysed polycondensation to form high molecular weight segmented block copolymers 
reported Leonhardt et al in 1982 (319). PEO-isocyanate (PEO-NCO) was allowed to react 
with oligopeptides (Leu-Phe) which had free amino and ethyl ester end groups (Scheme 
5.11). Triblock prepolymers with C-terminal peptide blocks were thus obtained. The PEO- 
NCO was treated with benzyl alcohol followed by cleavage of the Z-protecting group, which 
gave the required PEO with two amino acid end groups. The bis(amine) was used as the 
initiator for the polymerisation of phenylalanine N-carboxyanhydride. The enzymatic 
coupling of the two triblock copolymers formed a block copolymer under the action of 
chymotrypsin.
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Multiblock Copolymer Scheme 5.11
Pretula et al (320) have phosporylated PEG (200) with dimethyl phosphite leading to 
the polyphosphites and the PEG-polyphosphates on oxidation, (see Scheme 5.12).
Following condensation of the two end groups dimethyl phosphite was released together 
with the formation of the higher molecular weight polymer. The phosphonyl group contains 
a reactive P-H bond which can be used for the preparation of various derivatives, e.g. direct 
attachment of amino acids. Oxidation of PEG-200 polyphosphite led to the corresponding
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polyphosphate without decreasing the degree of polymerisation. Experiments at basic pH 













































Polyoxyethylene (PEO) diacid with carboxyl groups in both terminal positions is 
suitable for the preparation of various condensation polymers. Recently Imai et al (321) 
reported a direct polycondensation prompted by triphenyl phosphite and pyridine in which
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polyether-amides were readily obtained from aromatic diamines and PEO-diacids, (Scheme 
5.13). The polyether amides are very hygroscopic and readily soluble in water and a wide 
range of other solvents including benzene, acetone and methanol
HO
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Scheme 5.13.
Further polymerisation reactions based on PEO-diacids involve the copolymerisation of 
piperazine and 1,6-diaminohexane salts (322). These salts are analogous to the nylon 6 ,6  
salt formed between adipic acid and diamino hexane. They, like the "nylon salt" can be 
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A new type of polyether-polyester block copolymer consisting of two components of 
polyethers and one polyester has been synthesised by Wang (323). A mixture of 
polytetramethylene glycol (PTMG), PEG, dimethyl terephthalate (DMT), ethylene glycol 
(EG) and tetrabutyl titanate catalyst (TNBT) were made to undergo an ester exchange 
reaction. A mixed polyether-polyester block copolymer was obtained and tested for it’s 
biomedical properties. By altering the proportion of the mixed polyether content the 
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Scheme 5.15,
The copolymers showed an improved biocompatability and anti-thrombogenicity, through 
the introduction of hydrophilic PEG monomers into the polymer chain.
ABA-type block copolymers composed of poly(y-benzyl L-glutamate) (PBLG) and 
PEO were synthesised by polymerisation of 7-benzyl L-glutamate N-carboxyanhydride, 
initiated by primary amines at the terminal ends of the PEO chain (335), (Scheme 5.16). The 
ABA type block copolymer of incompatible A and B polymer chains is of interest with 
special reference to their biocompatability or antithrombogeneicity. The PBLG /  PEO / 
PBLG triblock copolymers are promising polymers for medical use.
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5.4. The PEG Hydrogels.
One approach to hydrogel formation involves the use of Pluronic F-127, a block 
copolymer of hydroxyl terminated propylene and ethylene oxides. At low temperatures a 
20% solution of Pluronic is clear, non-toxic and liquid. This solution can be poured easily 
onto a bum site and at body temperature will form a clear gel which fills the crevices in the 
wound (324).
One of the earliest and most widely studied hydrogel based wound dressing is the 
Hydron Bum Bandage. The dressing is formed directly on the bum from a two 
compartment system, poly (2-hydroxyethylmethacrylate) (/?(HEMA)] and polyethylene 
glycol as the solvent Alternate layers of PEG and p(HEMA) are applied to the wound until 
three or four layers have been built up. The PEG dissolves the p(HEMA) forming a
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saturated solution which solidifies after 30 mins. Further in vivo and in vitro studies in rats 
have confirmed the suitability of the dressing for the delivery of antimicrobial agents. 
Similarly clinical trials have shown that the dressing will release a variety of topical agents, 
e.g. gentamicin, silver nitrate and nitrofurazone.
5.5. Discussion.
5.5.1. Analogues to the polymerisation process.
The amination of the epoxides with, for instance a PEG-primary amine, e.g. PEG 
ethylene diamine or a PEG-secondary amine, e.g. PEG N-methyl-2-methoxyethylamine 
would afford the secondary and tertiary amines, respectively, {Scheme 5.17).
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Both strategies were used in the polymerisation studies involved in this project
The reaction between epoxides and ammonia is a general and useful method for the 
preparation of P-hydroxyamines. Ammonia gives largely the primary amine but also some 
secondary and tertiary amines, {Scheme 5.18).
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In order to test the feasibility of a reaction between a bis(glycidyl)ether and a primary 
amine a protocol was initiated using analogues.
Iterative addition was shown to occur when 4-(oxiranylmethoxy)-N-(2-(4-oxiranyl- 
methoxy)phenyl)ethyl)benzamide {Compound 80) was treated with decane-1,10-diamine 
{Scheme 5.19) in place of the activated PEG. The bis(glycidyl) ether was added slowly to 
the bis amine in equimolar concentrations and the reaction was boiled in ethanol for 36 
hours. A product {Compound 72) was isolated and the data from mass spectroscopy (FAB 
[+]) clearly showed a mother ion peak {m/z 542) followed by iterative peaks {mlz 1083) 
indicating that the reaction had been successful to some degree. Unfortunately the M.S. 
range was not sufficiently wide to be able to identify other fractions other than the monomer 
and dimer. It was unlikely that the secondary amine produced on the product was capable 
of playing any further significant role in the reaction. However, if the secondary amine was 
to take part in an additional reaction, with an electrophile group, then the linear nature of the 
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Compound 72.Scheme 5.19.
The problem of crosslinking at the primary amine site and characterising the resultant 
polymer was solved to a large degree by incorporating a monofunctional secondary amine 
into the polymerisation process as a model. N-Methyl-2-methoxyethylamine was allowed to 
react with the bis(glycidylethers) to determine the feasibility of the reaction at the methyl 
substituted secondary amine site. Iterative chain extension was made impossible due to the 
prescence of a terminal methoxy protecting group on the analogue compound. By 
incorporating this small, simple analogue into the reaction, the product, unlike the polymer 
could be characterised fully by standard laboratory techniques.
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N-Methyl-2-methoxyethylamine can be made in a number of ways. One straightforward 
strategy involves the use of iodomethane in an electrophilic substitution reaction with 2 - 
methoxyethylamine, (see Scheme 520). A disadvantage with this approach is that the 
iodomethane is an aggressive electrophile and is capable of substituting the newly formed 
secondary amine further to produce a tertiary amine with subsequent quatemisation. This 














An alternative route, which was adopted, was to convert 2-methoxyethylamine to the 
formamide using an excess ethyl formate. The conversion to N-2-(methoxyethyl)formamide 
was completed when the excess ethyl formate, which served to introduce the formyl group 
was removed by distillation and a product {Compound 73) was afforded in good yield. This 
material was treated with lithium aluminium hydride (LiAlH4) in THF, where the formamide 
was reduced to afford a product which was isolated from any impurities by distillation at 95° 
C. The known compound N-methyl-2 -methoxy ethylamine, (325) {Scheme 521) was 
isolated in poor yield and characterised as the methylamino compound, {Compound 74) by 
proton spectroscopy which corroborated the identity of this compound with observation of 
the newly formed methyl singlet at 8  2.45.
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Scheme 521.
As a model reaction, to test the feasibility of polymerisation with a secondary amine, 
a simple bis (oxiranyl) (Compound 80) [4-(oxiranylmethoxy) N-(2-(4-oxiranylmethoxy)- 
phenyl)ethyl)benzamide] was allowed to react with the methyl protected amine, (Scheme 
522).
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Compound 75. Scheme 522.
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A material was isolated from this reaction in good yield and characterised further with 
proton spectroscopy. Comparison of the integrals of the N-methyl singlets at 8  2.23 and 8  
2.24, of the methoxy signals at 8  3.19 and 8  3.20 and of the aromatic cluster between 8  6.85 
- 7.78 corroborated the identity of the material as Compound 75. This characterisation was 
confirmed by observation of the M + H ion at mlz 548 in the mass spectrum.
The preliminary polymerisation experiments using decane-1,10-diamine were re­
assessed in the light of the successful results obtained from the secondary amine analogues. 
The PEG analogue decane-1,10-diamine was converted to the formamide (Compound 76), 
again using an excess of ethyl formate and reduced to the methyl compound with LiAlH4 to 
give N,N-dimethyldecane-l,10-diamine, {Compound 77), {Scheme 523). This material was 
identified by !H NMR and mass spectroscopy with the observation of an ion peak at M + H 
mlz 201 and mlz 199 for FAB [+] and FAB [-] respectively.
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The formation of the secondary amine, N,N'-dimethyldecane-1,10-diamine which 
was capable of taking part in a polymerisation reaction was an important step. It was 
hypothesised that the reaction of the bis amine with the bis(glycidylether) would form a 
product with a tertiary amine, incapable of any further reaction with an electrophile and 
crosslinking would be avoided, (see earlier model reaction scheme, Scheme 5.17).
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In view of this a mixture of Compound 80 and N^-dimethyldecane-1,10-diamine was 
refluxed for 16 hours in ethanol and allowed to cool, (Scheme 524). The product 
(Compound 78) was separated into two populations each with different solubility's. It was 
envisaged that the high molecular weight polymeric products had a low solubility whereas 
the smaller oligomers remained in solution. The ethanol was removed by evaporation and 
these low molecular weight products were obtained as an oil in moderate yield. By 
incorporating a secondary amine onto the PEG the danger of cross linking through multiple 
reactions at the nucleophilic site was abolished and the linear nature of the polymer was 
conserved.















A study was undertaken to investigate a series of copolymers based on poly(ethylene 
glycol) [PEG] and a biodegradable oligopeptide spacer for use as polymeric prodrugs. The 
preparation of a number of oligopeptides bearing protected phenolic side groups, suitable for 
further derivatisation has been demonstrated by solution methods.
It was proposed that by generating a library of peptide sequences the enzymatic 
degradation of the spacer could be optimised. This would depend on the relative ease with 
which the polymeric substrates formed enzyme substrate complexes and therefore a series of 
up to five amino acids varying both in length and detailed structure were synthesised.
The polymerisation strategy adopted towards the alternating PEG-peptide linear 
polymer involved the reaction of a,co-bis(glycidylether) peptides with a,co-bis(methylamino) 
PEGs. To this end the oligopeptide chains were modified with a number of a,co-side groups 
including the alkenes, bis (4-methoxyphenyl) and bis 4(benzyloxy)phenyl. Each was capable 
of further derivatisation to form the glycidyl ether, but the two former reagents presented 
epoxidation and cleavage problems respectively. The bis 4 (benzyloxy)phenyl moiety 
provided a protecting group which could be cleaved readily in a hydrogenation step and was 
orthogonal to the requirements of peptide coupling.
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Following the conversion of the phenolic hydroxy groups to the bis(glycidylethers) 
by treatment with epichlorohydrin, these compounds were successfully allowed to react with 
primary and secondary amines in a model polymerisation reaction.
A Precursor to Polymerisation:- The Tripeptide PheLeuGly Modified 
With Glycidylether Groups.
‘Phe Leu Gly^
The feasibility of treating a,CD-bis(glycidylether)peptides with a PEG-amine 
derivative to form a copolymer was addressed using penta(ethyleneglycol). The
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appropriately derivatised PEG monomers were provided in a straightforward conversion of 
the PEG diol to the a,o>-bis(chloroformate) with phosgene. Further treatment with 
BOCsarcosine N-(2-aminoethy 1)amide gave the corresponding bis(urethane) and 
deprotection with hydrogen chloride gave the required a,o>-bis(methylamino) derivatised 
PEG. By introducing a secondary amine onto the PEG the risk of polymeric crosslinking 
was reduced.
Poly(ethyleneglycol) Derivatised With a Secondary Amine.
O O
f t  f t
hK  'XKPEG)50 ^  vN 
H H f t
The potential to functionalise the PEG-containing polymers further has been investigated 
successfully by the inclusion of glutamic acid within the oligopeptide sequence. Appropriate 
protection of the a-amino and y-carboxy groups of the glutamate led to the formation of the 
pentapeptide sequence which bears a side chain "handle”.
Glutamic Acid Provides a Suitable Side Chain for Further Activation.
H% - °
FMOCGluGly Phe Leu G1 f
6.2. Assessments and Future Prospects.
The feasibility of treating an a,co-bis(glycidyl)peptide with a methylamino group has 
been confirmed but tests using a,o>-bis(methylamino)PEGs are still pending. It is envisaged 
that an alteration in the molecular weight, ergo length of the PEG monomers used will 
generate a series of tailor made copolymers that will contain peptidic spacers at pre­
determined intervals along the polymer backbone. However, to achieve any uniformity at all 
would entail limiting the molecular weight distribution to a narrow range. This may be 
problematic with some of the large molecular weight PEG compounds.
Interest should be focused on the ability of various PEG monomers to influence the 
solubility of the oligopeptide conjugate. In addition the degree of polymerisation will dictate 
the molecular weight and consequently the hydrodynamic radius of the final copolymer.
Such issues have important ramifications if in vivo studies are to be considered. A target 
mass of between 80 -120 KDa should be considered if rapid renal clearance (>20 KDa) is to 
be avoided and extravascular migration made feasible.
A comprehensive series of enzymatic degradation studies on future PEG /  peptide 
copolymers are awaited with impatience. It is hypothesised that the linear PEG chains 
should not be the cause of any serious steric hindrance to the formation of the enzyme 
substrate complex. However, the presence of the aryl side groups adjacent to the 
oligopeptide may interfere with the S’ - P interactions to reduce the overall lability of the 
sequence. This problem could be addressed in the development of a second generation of 
protected peptide segments whereby the aryl groups are replaced with CBZsarcosine N-(2- 
(aminoethyl)amides. This approach is outlined below.
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A Precursor to the Second Generation of PEG / Peptide 
Copolymers.
H
,Gly Phe Leu G l y ^ / v ^ N ^ . ^ - s ^ C B Z  
Me O H O life
In contrast to those compounds discussed in the previous chapters, copolymerisation of 
these latter compounds is achieved via the reaction with a,co-(glycidyl)PEGs.
A variation on the above procedure could be found in a third generation of modified 
oligopeptides. In this strategy two BOCsarcosine protected amino acids are linked with a 
spacer via the peptide a-carboxy terminals. This approach is outlined below, using glycine 
as an example. These analogues are simple, accessible to enzymatic degradation and can be 
derivatised further through side chain activation. The symmetry of this peptide unit and the 
symmetry of the PEG unit obviate any potential problem of random orientations of 
'’directional" peptides in the polymers.
A Spacer Unit Separates Two Glycines in the Third Generation of Compounds
*  '  '  V ----
Glycine Glycine
More exploration in the area of soluble polymeric precursors is warranted as a viable 
alternative to the present day drug delivery regimes. Furthermore it is expected that the 
future development of copolymers based on PEG and biodegradable oligopeptide sequences 
will have a seismic effect on the whole of the drug targeting landscape.
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Appendix 1. COSY Spectrum for Compound 79.
Compound 79.
Appendix 2. COSY Spectrum for Compound 22,
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Appendix 3. COSY Spectrum for Compound 62.
n— i— i— |— i—i— r
7




























































Nuclear magnetic resonance. 





Infra-red (I.r.) spectra were recorded on a Peridn-Elmter 782 spectrometer, using KBr discs.
1H, 13C and 19F N.M.R. spectra were recorded usimg a Joel JNM-GX270 or with a Joel 
JNM-EX 400 spectrometer. Sandies were dissolved in CDC13 or (CD3)2SO and chemical 
shifts (8 ) were measured in ppm relative to tetramethylsilane (TMS) which was used as an 
internal standard. Values of the number of protons for each signal are given between the 
brackets. 19F-NMR was measured against CFQ3 internal standard. Multiplicities are 
indicated as follows; s (singlet); d (doublet); dd (double doublet); t (triplet); dt (double 
triplet); ddt (double double triplet); q (quartet) and m (multiplet).
Mass spectra were obtained using a VG 7070E analytical mass spectrometer, University of 
Bath, and reported in the form mJz (intensity relative to base = 100) for selected ions. 
Spectra were obtained from electron impact (E.I.), chemical impact (C.I.) or fast atom 
bombardment (FAB) ionisation techniques. Accurate mass spectra were obtained from the 
EPSRC Mass Spectrometry Service, University of Wales, Swansea having been run on a 
VG-Autospec Instrument using two known internal standard reference ions from 
polyethylene glycol to straddle the unknown mass.
Elemental analysis was carried out using a EMA System 1106, microanalysis unit, University 
of Bath.
Where appropriate, the stereochemistry of the compounds containing one or more chiral 
centres was investigated. Spectra generated by NMR revealed the presence of diastereo- 
isomers which are assigned in the data using isomer 1 or isomer 2. Measurements of optical 
activity were carried out using the Optical Activity Ltd. AA-10 polarimeter.
All reactions were monitored by thin layer chromatography (T.L.C.) which was performed 
on pre-coated silica sheets manufactured by Merck; (Merck tl.c  aluminium sheets silica 60 
F254, Art. no. 5635). Products were visualised in a variety of ways; ultraviolet (U.V.) light; 
spraying with phosphomolybdic acid in methanol followed by heating; iodine vapour, iron HI 
chloride in methanol; 4-methoxybenzaldehyde, ninhydrin in methanol. The following solvent 
systems were used: (A): chloroform; methanol (18: 1); (B): dichloromethane; (C): ethyl 
acetate, (D): 5% MeOH /  EtOAc. Chromatographic purification was carried out by forced 
air chromatography using Sorbsil C60 (0.040 - 0.063 mm) silica gel in the noted solvent
system. Suspensions where appropriate were filtered through a filter agent, Celite ® 521; 
(John Manville Corp.).
Melting points (corrected) were determined using a Thermo Galen Kofler block with 
samples between two glass plates.
Chemicals were purchased from Aldrich, Sigma, Novabiochem and Fluka as reagent grade 
and used without further purification. Licences for use of controlled substances were 
secured from the Home office where appropriate.
All solvents were evaporated under reduced pressure. When required tetrahydrofuran was 
passed down an alumina column and distilled from sodium wire and benzophenone. Ethanol 
was dried over magnesium turnings and iodine and distilled. Dimethylformamide, 
dichloromethane and triethylamine were dried over sodium hydride, distilled and stored over 
4 A molecular sieves. Light petroleum refers to the fraction with boiling point 60 - 80°C. 
Organic phases were dried over MgS04 unless otherwise stated.
Compound 1. N-(l,l-Dimethylethoxycarbonyl)phenylalanine. Phenylalanine (2.00 g,
12.10 mmol) was dissolved in water (23 mL) containing NaOH (0.48 g, 12.10 mmol) and 
stirred vigorously for 12h with a solution of di-t-butyl dicarbonate (3.96 g, 18.15 mmol) in
1,4-dioxan (10 mL). The reaction was quenched with diethyl ether and the aq. fraction was 
acidified with H2S04 (10%) and extracted with EtOAc. The solvent was dried and 
evaporated to afford N-(l,l-dimethylethoxycarbonyl)phenylalanine (3.14 g, 98%) as white 
crystals: mp 79 - 80°C (fit.*249): mp 79-80°C); NMR ((CD3)2SO) 270 MHz 8  1.32 (9H, s, 
(Ctf3)3); 2.84 and 3.02 (2H, dd, J = 13.0 Hz, J = 4.00Hz, P - H EM)\ 4.18 (1H, m, a  - H 
Phe): 7.09 (1H, d, J 8.4 Hz; N£); 7.26 (5H, s, 5H - Ar Phe): mass spectrum (CI.) mlz 266 
(1%) (M + H), 164 (100%), 192 (47%), 120 (45%), 91 (40%). T.L.C. (A), R* = 0.62. 
Anal. Found C, 63.20; H, 7.30; N, 5.25. C14H19N 04 requires C, 63.40; H, 7.15; N, 5.30; 
specific rotation, [a ] 23589 + 10.4°.
Compound 2. N-(l,l-dimethylethoxycarbonyl)phenylalanine N-allylamide. A 250 mL
flask was charged with N (l,l-dimethylethoxycarbonyl)phenylalanine (4.34 g, 16.35 mmol) 
in dry THF (50 mL) and maintained at 0°C as triethylamine (3.31 g, 32.75 mmol) and 3- 
methylpropyl chloroformate (2.25 g, 16.35 mmol) were added and the mixture stirred for 
lh. A precipitate was filtered off and the filtrate added dropwise to allylamine (9.32 g,
163.50 mmol) in THF (50 mL) and the reaction mixture maintained at 5°C for 16h. The 
solvent was evaporated and the residue, in CH2C12, washed with H2S04 (10%), NaHC03 
(1 0 %) and dried before the solvent was evaporated to yield the crude product as a white 
solid Recrystallisation from petroleum ether gave N- (1,1 -dimethylethoxycarbonyl)phenyl- 
alanine N-allylamide (4.35 g, 87%) as white crystals:: mp 96 - 98°C; *H NMR ((CD3)2SO) 
270 MHz 6  1.30 (9H, s, (Ctf3)30 ), 2.70 and 2.90 (2IH, dd, J = 10.3 Hz, J = 4.6 Hz, H - p, 
Phe). 3.69 (2H, brs, HNC#2CH), 4.14 (1H, dt, I  =  4.0 Hz, H - a , EM), 5.05 (2H, dd, 
CH2CHCtf2), 5.74 (1H, m, CH2CtfCH2), 6.94 (1H, d, J = 8 .8  Hz, NH, EM), 7.25 (5H, brs, 
5H - Ar, Phe). 8.07 (1H, brs, ZfNCH2CH); mass spectrum (C.I) mlz 305 (21%) (M + H), 
249 (100%), 205 (47%), 120 (30%). T.L.C. (A), R, = 0.75. Anal. Found: C, 66.90; H, 
7.95; N, 9.10. C17H24N20 3 requires C, 67.10; H, 7.95; N, 9.20.
Compound 3. Phenylalanine N-allylamide. Trifluoroacetic acid (6.90 g, 60.50 mmol) 
was added directly to N-(l,l-dimethylethoxycarbonyl)phenylalanine N-allylamide (3.68 g,
12.10 mmol) and the mixture stirred for 4h. CH2Q 2 (50 mL) was added followed by water 
(100 mL) containing KjCOj (16.80 g, 122 mmol). The organic phase was separated and 
dried and the solvent was evaporated to give phenylalanine N-allylamide (1.70 g, 69%) as a 
yellow oil: >H NMR ((CD3)2SO) 270 MHz 6  2.89 (2H, dd, J = 13.2 Hz, J = 4.6 Hz, H - p, 
Phe). 3.41 (1H, dd, J = 8.1 Hz, J = 5.2 Hz, H - a , EM), 3.68 (2H, brs, HNC#2CH), 5.02 
(2H, m, CH2CHC£2), 5.76 (1H, m, C H jC tfO y, 7.22 (5H, brs, 5H - Ar, EM), 7.99 (1H, 
brs, f£NCH2CH); mass spectrum (FAB) mlz 205 (100%) (M + H), 409 (60%), 120 (15%). 
TX.C. (A), Rf = 0.21. Anal. Found C, 70.20; H, 8.05; N, 13.50. C12H16N20  requires C, 
70.55; H, 7.90; N, 13.70.
Compound 4. N-(Allylaminocarbonyl)phenylalanine N-allylamide. Allyl isocyanate 
(1.30 g, 15.70 mmol) was added to a solution of phenylalanine N-allylamide (1.60 g, 7.85 
mmol) in CH2Q 2 (40 mL) and stirred for 2h. The solvent was evaporated and the residue 
was recrystallised from chloroform /  light petroleum to afford N-(aUylaminocarbonyl)phenyl- 
alanine N-allylamide as white crystals (1.84 g, 82%): mp 138 - 139°C; *H NMR ((CD3)2SO) 
270 MHz 5 2.78 (2H, dd, J = 13.2 Hz, J = 4.6 Hz, H - p, EM), 3.58 (2H, brs, CHC#2NH, 
3), 3.67 (2H, brs, HNCtf2CH) 4.38 (1H, q, J = 5.5 Hz, H - a , EM), 5.02 (4H, brs, 
C^CHCHj), 5.74 (2H, brs, CH2C#CH2), 6.16 (2H, brs, NH), 7.19 (5H, brs, 5H - Ar, 
EM), 8.14 (1H, brs, NH, EM); mass spectrum (C.I) mlz 288 (50%) (M + H), 205 (100%),
120 (49%), 231 (40%). T.L.C. (C), R, = 0.69. Anal. Found C, 67.01; H, 7.40; N, 14.75. 
C16H21N30 2 requires C, 66.90; H, 7.35; N, 14.60.
Compound 5. N-AIIylbenzamide. Benzoyl chloride (1.50 g, 10.65 mmol) was added 
carefully to allylamine (1.80 g,31.58 mmol) in CH2Q 2 (100 mL) and stirred for lh. The 
reaction mixture was washed with water, H2S04 (10%), water before evaporation of the 
dried extract afforded the product N-allylbenzamide (1.38 g, 81%). The product was a pale 
yellow liquid at 18°C but white crystals were formed at approximately 3°C: *H NMR 
(CDClj) 400 MHz 6  4.03 (2H, t, J = 5.8 Hz, CHj), 5.11 (1H, d, J = 10.1 Hz, CH), 5.22 
(1H, d, J = 17.1 Hz, CH), 5.89 (1H, ddt, J = 17.1 Hz, J = 10.0 Hz, J = 5.5 Hz, CH), 6.97 
(1H, brs, NH), 7.36 (2H, d, J = 7.9 Hz, 2H - Ar, meta). 7.45 (1H, t, J = 7.3 Hz, 1H - Ar, 
para). 7.79 (2H, d, J = 8.2 Hz, 2H - Ar, ortho): mass spectrum (E.I.) mlz 161 (100%) (M), 
105 (83%). TJL.C. (A), R* = 0.48. Anal Found C, 74.70; H, 6.85; N, 8.60. C10HnNO 
requires C, 74.50; H, 6.90; N, 8.70.
Compound 6 . 3-PhenyI-l-allylurea. Allyl isocyanate (1.34 g, 16.15 mmol) and aniline 
(1.5 g, 16.15 mmol) were dissolved in diethyl ether (50 mL) and stirred for 2h. The diethyl 
ether was evaporated and the residue, in CH2Q 2, was washed twice with aq. H2S04 (10%), 
and with water. After removing the dried solvent the impure product was triturated with 
heptane and a brown solid was collected to afford the product 3-phenyl-l-allylurea (0.62 g, 
22%): mp 102 - 104°C; NMR (CDC13) 400 MHz 5 3.77 (2H, d, J = 5.2 Hz, C #2), 5.07 
(1H, dd, J = 1.5 Hz, J = 10.2 Hz, Ctf), 5.17 (1H, dd, J = 1.5 Hz, J = 17.1 Hz, Ctf), 5.79 
(1H, m, Ctf), 6.99 (1H, t, J = 7.8 Hz, H - Ar, para). 7.24 (4H, m, H - Ar, ortho and meta). 
7.62 (2H, brs, N£0; mass spectrum (70 eV) mlz 176 (10%) (M), 93 (100%), 41 (22%), 56 
(18%), (E.I) mlz 176 (100%) (M + H), 93 (90%); T.L.C. (C),Rf = 0.78. Anal. Found C, 
67.60; H, 6.90; N, 16.10. C10H12N2O requires C, 68.15; H, 6.85; N, 15.90.
Compound 7. N-Phenylpent-4-enamide. Pent-4-enoic acid (3.90 g,39.00 mmol) was 
treated with SOCl2 (7.00 g, 59.00 mmol) and the mixture boiled under reflux for 5h. The 
fraction (114 - 118°C) was isolated by distillation to give pent-4 -enoyl chloride (1.76 g, 
14.90 mmol). This was stirred with an excess of aniline (3.80 g, 40.80 mmol) in CH2Q 2 
(lOOmL) at 0°C for lh. The mixture was washed with H2S04 (10%) (x 5) and water 
whereupon the CH2Q 2 was dried and evaporated to afford the product N-phenylpent-4- 
enamide as a white solid (2.13 g, 82%): mp 90 - 91°C (lit.*227) mp 90 - 91°C), !H NMR
(CDC13) 400 MHz 8  3.77 (2H, d, J = 5.2 Hz, CH^, 5.07 (1H, dd, J = 1.5 Hz, J s= 10.2 Hz, 
CH), 5.17 (1H, dd, J = 1.5 Hz, J = 17.1 Hz, CH), 5.79 (1H, m, CH), 6.99 (1H, t, J = 7.8 Hz, 
H - Ar, para\ 7.24 (4H, m, H - Ar, ortho and meta). 7.62 (2H, brs, NH); mass spectrum 
(E.I.) mlz 175 (100%), 93 (90%).
Compound 8 . N-(Oxiranylmethyl)benzamide. A mixture of N-(allyl)benzamide (1.07 g, 
6.65 mmol) and MCPBA (1.15 g, 6.65 mmol) were boiled under reflux in CH2Q 2 (30 mL) 
for lh. The reaction was cooled, filtered and the filtrate washed with aq. sodium 
metabisulphite (10%) twice, NaHC03 (10%) and water. The CH2Q 2 was dried and 
evaporated to furnish a pale orange oil which was purified by column chromatography 
(CH2Q 2; CH2Q 2 : EtOAc; EtOAc) to afford N-(oxiranylmethyl)benzamide (47 mg, 4%) as 
a pale orange oil. Further analysis revealed: JH NMR (CDQ3) 400 MHz 8  3.0 (1H, brs, 
NH), 3.69 (1H, dd, J = 5.8 Hz, J = 12.2 Hz, OH), 3.8 (1H, dd, J = 12.4 Hz, J = 3.2 Hz, 
OH), 3.83 (1H, dd, J = 14.5 Hz, J = 7.8 Hz, CH, 1), 4.07 (1H, dd, J = 14.6 Hz, J = 10.0 Hz, 
CH, 2), 4.80 (1H, m, CH, 3), 7.39 (2H, d, J = 7.6 Hz, 2H - Ar, meta). 7.47 (1H, t, J = 7.3 
Hz, 1H - Ar, para). 7.93 (2H, d, J = 8.2 Hz, 2H - Ar, ortho): mass spectrum (E.I) mlz 111 
(31%) (M), 146 (100%), 77 (70%), 118 (70%), 195 (25%). T.L.C. (C), R, = 0.31.
CioHnN0 2.
Compound 9. 4-Acetoxybenzoyl chloride. A mixture of 4-acetoxybenzoic acid (1.5 g,
8.33 mmol) and thionyl chloride (4.5 mL) was stirred at 50°C for 4h. Distillation at 78°C 
removed any excess thionyl chloride to leave a waxy solid. Further distillation under 
reduced pressure (140°C, 2 mmHg) afforded the 4-acetoxybenzoyl chloride (1.42 g, 8 6 %) 
as a white solid: !H NMR, ((CD3)2SO) 270 MHz 8  3.92 (3H, s, C#3CO), 7.00 (2H, d, J = 
8 .8  Hz, 2H-Ar 2', 6 '), 7.85 (2H, d, J = 8 .8  Hz, 2H-Ar 3', 5’), I.R. 1750, 1800 v cm 1; mass 
spectrum (C.I.) mlz 153 (100%) (M + H), 135 (20%). C&JOJCL
Compound 10. N-(4-(MethoxybenzoyI)gIydne methyl ester. Glycine methyl ester 
hydrochloride (2.65 g, 21.10 mmol) was dissolved in CH2Q 2 (100 mL) containing 
triethylamine (3.56 g, 35.16 mmol). Dropwise 4-methoxybenzoyl chloride (3.00 g, 17.58 
mmol) was added and the mixture stirred for 16h. Using aq. H2S04 (5%), Na2C03 (10%) 
and water the CH2Q 2 was washed, dried and evaporated to yield the product N-(4- 
(methoxybenzoyl)glycine methyl ester (3.39 g, 8 6 %) as a white solid: mp 110 - 113°C (lit 
t338) mp 110 - 115°C); !H NMR ((CD3)2SO) 270 MHz 8  3.65 (3H, s, OCtf3), 3.81 (3H, s,
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C££3OAr), 4.02 (2H, d, J = 5.9 Hz, QZj), 7.03 (2H, d, J = 8.9 Hz, 2H-Ar 2', 6 '), 7.88 (2H, 
d, J = 8.9 Hz, 2H-Ar 3', 5'), 8.84 (1H, t, J = 6.0 Hz, Nfl); mass spectrum (E.I.) mlz 223 
(100%) (M + H), 135(51%), 164(11%), 191(10%). T.L.C. (A),Rf = 0.55. Anal. Found 
C, 59.10; H, 5.90; N, 6.30. CnH13N 04 requires C, 59.20; H, 5.85; N, 6.25.
Compound 11. N-(2-(4-HydroxyphenyI)ethyl)-4-methoxybenzamide. Carefully, 4- 
methoxybenzoyl chloride (1.24 g, 7.30 mmol) was added to a solution of triethylamine (0.74 
g, 7.30 mmol) and 2-(4-hydroxyphenyl)ethylamine (1.00 g, 7.30 mmol) in DMF (12 mL) 
and the solution was stirred for lh. Water was added and the precipitate was collected and 
dried under vacuum to afford N-(2-(4-hydroxyphenylethyl)-4-methoxybenzamide (1.51 g, 
76%) as a white solid: mp 166 - 168°C; *H 270 NMR ((CD3)2SO) 6  2.73 (2H, t, J = 7.4 Hz, 
O^CEfe), 3.41 (2H, m, CHJCHJ, 3.78 (3H, s, (OC#3), 6.70 (2H, d, J = 8.3 Hz, 2H-Af 3', 
5’), 6.97 (2H, d, J = 8 .8  Hz, 2H-Ar 3’, 5’), 7.03 (2H, d, J = 8.4 Hz, 2H-Ari 2’, 6 ’), 7.83 (2H, 
d, J = 8 .6  Hz, 2H-Ar 2’, 6 ’), 8.42 (1H, m, NH), 9.25 (1H, s, OH); mass spectrum (CL) mlz 
271 (8 %) (M + H), 135 (100%), 152 (65%), 120 (52%). T.L.C. (A), R* = 0.40. Anal. 
Found C, 71.20; H, 6.70; N, 4.85. C16H17N 03 requires C, 70.80; H, 6.30; N, 5.15.
Compound 12. 4-Methoxy-N-(2-(4-methoxyphenyl)ethyl)benzamide. With care, 4- 
methoxybenzoyl chloride (3.50 g, 20.50 mmol) was added to 2-(4-methoxyphenyl)ethyl- 
amine (3.10 g, 20.50 mmol), triethylamine (2.07 g, 20.50 mmol) and DMAP (5 mg) in 
CH2Q 2 (50 mL) and stirred for 5h. The crude product, in CH2Q 2 (100 mL), was washed 
with water, H2S04 (10%) (twice), NaC03 (10%) and water after which the solvent was 
dried and evaporated to afford a solid. Recrystallisation from ethanol /  water furnished 4- 
methoxy-N-(2-(4-methoxyphenyl)ethyl)benzamide (5.35 g, 91%) as white crystals: mp 160 - 
162°C; !H 270 NMR (CDC13) 5 2.85 (2H, t, J = 7.0 Hz. CHjCtfJ, 3.65 (2H, q, J = 7.0 Hz, 
Q£2CH2), 3.79 (3H, s, ArOC££3), 3.82 (3H, s, ArOC£3), 6.15 (1H, m, NH), 6.85 (2H, d, J 
= 8.4 Hz, 2H - Ar' 2 \ 6 '), 6.90 (2H, d, J = 8.4 Hz, 2H - Ar 2', 6 ’), 7.15 (2H, d, J = 8 .6  Hz, 
2H - Ar' 3’, 5’), 7.65 (2H, d, J = 8 .8  Hz, 2H - Ar 3’, 5’); mass spectrum (CL) mlz 286 
(100%) (M + H), 134 (53%), 152 (16%), 69 (19%). T.L.C. (CHC13 : MeOH, 15 : 1), Rf = 
0.70. Anal. Found C, 71.20; H, 6.70; N, 4.85. C17H19N 03 requires C, 70.85; H, 6.30; N, 
5.15.
Compound 13. 4-Hydroxy-N-(2-(4-hydroxyphenyl)ethyl)benzamide. 4-Methoxy-N-(2- 
(4-methoxyphenyl)ethylbenzamide (2.00 g, 7.01 mmol) was boiled under reflux for 48h with
HBr /  acetic acid (30%) (20 mL, 74.15 mmol). After the solvent had been evapora ted to 
leave a volume of 10 mL, water was added. The crude product formed as a precipitate 
which was collected. The solid was further purified by column chromatography (CH2Q 2 : 
EtOAc; EtOAc) and the organic solvent was evaporated from an eluted fraction to give 4- 
hydroxy-N-(2-(4-hydroxyphenyl)ethyl)benzamide as a brown solid (0.34 g, 17%): mp 210 - 
212°C; NMR ((CD3)2SO) 270 MHz 5 2.70 (2H, t, J = 7.5 Hz, CH2Cife), 3.35 (2H, q, J 
= 7.5 Hz, C EjO L), 6.70 (2H, d, J = 8.5 Hz, 2H - Ar’ 2’ 60, 6.80 (2H, d, J = 8 .6  Hz, 2H - 
Ar 2’, 6 '), 7.00 (2H, d, J = 8.5 Hz, 2H - Ar' 3’, 5’), 7.70 (2H, d, J = 8 .8  Hz, 2H - Ar 3 \ 5’), 
8.25 (1H, t, J = 5.4 Hz, NH), 9.00 (1H, brs, OH), 10.00 (1H, brs, OH); mass spectrum 
(CL) mlz 258 (100%) (M + H), 69 (38%), 120 (35%), 138 (34%). T.L.C. (A), R* = 0.30. 
Anal. Found C, 70.35; H, 6.20; N, 5.15. C15H15N 03 requires C, 70.00; H, 5.90; N, 5.45.
Compound 14. (Identical to Compound 13). 4-Hydroxy-N-(2-(4-hydroxyphenyl)ethyl)- 
benzamide. 4-Methoxy-N-(2-(4-methoxyphenyl)ethyl)benzamide (2.00 g, 7.00 mmol) was 
boiled under reflux for 30 min with BBr3 /  CH2Q 2 (25 mL, 1.0M). The CH2Q 2 was 
evaporated and the residue washed with water before it was recrystallised from isopropanol / 
pe t ether to give the product 4-hydroxy-N-(2-(4-hydroxyphenyl)ethyl)benzamide (1.30 g, 
72%) as a white solid with properties as above.
Compound 15. N-(N-(N-(N-(4-Methoxybenzoyl)gIycyl)phenyIalanyl)leucyl)glycine N- 
(2-(4-methoxyphenyI)ethyI)amide. N-(4-Methoxybenzoyl)glycine pentafluorophenyl ester 
(5.22 g, 13.95 mmol), HOBt (200 mg) and diisopropylethylamine (2.13 g, 16.45 mmol) 
were dissolved in CH2Q 2 (150 mL). N-(N-(Phenylalanyl)leucyl)glycine N-(2-(4- 
methoxyphenyl)ethyl)amide (5.95 g, 12.65 mmol) in CH2Q 2 (50 mL) was added dropwise to 
the solution and stirred at 35°C for 24h with DMAP (30 mg). The CH2Q 2 was evaporated 
to give the crude product which was purified using chromatography (3:1 (EtOAc: CH2Q2); 
7:1 (CHC13: MeOH)). The solvent was evaporated and the product N-(N-(N-(N-(4- 
methoxybenzoyl)glycyl)phenylalanyl)leucyl)gycine N-(2-(4-methoxyphenyl)ethyl)amide 
obtained as white crystals: mp 82 - 84°C; !H NMR ((CD3)2SO) 270 MHz 8  0.86 (3H, d, J =
6.1 Hz, CH3, toO , 0.90 (3H, d, J = 6.4 Hz, CH3, toO , 1-54 (2H, brs, p - H, t o 0,1.56 (1H, 
m, 7  - H, t o 0,2.65 (2H, t, J = 7.5 Hz, HNCH2Q£2,), 2.85 (1H, dd, J = 9.5 Hz, p - H, Ehel
3.07 (1H, dd, J = 9.7 Hz, p - H, Phe). 3.25 (2H, q, J = 7.0 Hz, H N C^CH j), 3.63 (2H, d, J 
= 5.8 Hz, CH2 G M . 3.72 (3H, s, OCH3), 3.77 (1H, d, J = 5.8 Hz, CH, ££y), 3.83 (3H, s, 
CH3), 3.87 (1H, d, J = 5.8 Hz, CH2, £&), 4.27 (1H, m, a  - H, to O . 4.57 (1H, m, a  - H,
viii
Phe\ 6.84 (2H* d, J = 8.9 Hz, 2H - Ar* 2', 6 ’), 7.01 (2H, d, J = 8.9 Hz, 2H - Ar 2’, 6 ’), 7.12 
(2H, d, J = 8.9 Hz, 2H - Ar’ 3’, 5’), 7.24 (5H, brs, 5H - Ar, Phe). 7.81 (1H, brt, 
#NCH2CH2), 7.85 (2H, d, J = 8.9 Hz, 2H - Ar 3', 5’), 8.04 (1H, brt, NH G lv \  8.14 (1H, d, 
J = 8 .6  Hz, NH, Lm), 8.18 (1H, d, J = 7.7 Hz, NH. Phe). 8 .6 6  (1H, brt, NH - mass 
spectrum (FAB [+]) mlz 660 (10%) (M + H), 135 (100%), 120 (40%), 8 6  (35%). (FAB [-]) 
mlz 658 (100%) (M - H), 207 (9%), 154 (4%), 450 (5%). T.L.C. (A), R* = 0.20.
^36^45^507.
Compound 16. Phenylmethyl 4-(phenyImethoxy)benzoate. A mixture of 4-hydroxy- 
benzoic acid (27.60 g, 200 mmol), chloromethylbenzene (57.0 g, 450 mmol), K2CO3 (50 g) 
and Nal (25 g) was boiled under reflux in MeCN (500 mL) for 16h. The suspension was 
filtered and the solvent was evaporated to give a solid which was recrystallised from ethanol 
to give phenylmethyl 4-(phenylmethoxy)benzoate (48.8 g, 76%) as white crystals: mp 114 - 
116°C, (lit P39> mp 115.5 - 116.5°C); »H NMR (CDC13) 270 MHz 6  5.12 (2H, s, BnC#20),
5.34 (2H, s, OC££2Bn), 7.00 (2H, d, J = 8.9 Hz, 2H - Ar 2’, 6 ’), 7.35 - 7.46 (10H, m, 
£flCH20 , twice), 8.03 (2H, d, J = 8 .8  Hz, 2H - Ar 3', 5'); mass spectrum (CL) mlz 318 (M), 
227,211,107,91. Anal. Found C, 79.45; H, 5.65. C ^ H ^  requires C, 79.20; H, 5.70.
Compound 17. 4-(PhenyImethoxy)benzoic acid. Phenylmethyl 4-(phenylmethoxy)- 
benzoate (48.8 g, 150 mmol) was boiled under reflux with aq. NaOH (2M; 250 mL) and 
ethanol (250 mL) for 4h. The ethanol was evaporated and water (1000 mL) was added. 
The white solid was collected by filtration and stirred with aq. H2S 0 4 (2M; 300 mL) for lh 
at 65°C and then extracted with warm EtOAc. The solution was dried and the solvent 
evaporated to give 4-(phenylmethoxy)benzoic acid (27.15 g, 80%). The filtrate was washed 
twice with diethyl ether, acidified with H2S04 (2M) and extracted with diethyl ether. 
Evaporation of the diethyl ether gave the product 4-(phenylmethoxy)benzoic acid (6.0 g, 
18%). The total yield was 98% of white crystals: mp 186 - 187°C, (lit. P33* mp 186 - 187° 
C); m  NMR ((CD3)2SO) 270 MHz 6  5.18 (2H, s, BnC£20), 7.09 (2H, d, J = 8 .8  Hz, 2H - 
Ar 2’, 6 ’), 7.30 - 7.46 (5H, m, £aCH20), 7.89 (2H, d, J = 8 .8  Hz, 2H - Ar 3', 5’), 12.60 (1H, 
brs, OH); mass spectrum (C.I.) mlz 228 (M), 183, 159, 121, 91; IR v cm*1 1690, 1600 and 
1175; C14H120 3.
Compound 18. 4-(Phenylmethoxy)benzoyI chloride. To a stirred solution of 4- 
(phenylmethoxy)benzoic acid (500 mg, 2.2 mmol) and oxalyl chloride (280 mg, 2.2 mmol) in
ix
1,4-dioxan (25 mL), DMF (25 mg) was added. After the evolution of a gas had ceased, the 
solvent and catalyst were evaporated and the residue was recystallised from light petroleum 
to give 4-(phenylmethoxy)benzoyl chloride (460 mg, 85%) as a white solid: mp 104 - 106°C 
(lit mp 104 - 106°C); IR v cur11775,1600 and 1175 ; lR  NMR ((CD3)2SO) 270 MHz 
6  5.15 (2H, s, BnCtf20), 7.03 (2H, d, J = 8.9 Hz, 2H - Ar 2’, 6 ), 7.37 - 7.42 (5H, m, 
£ilCH20), 8.07 (2H, d, J = 8 .8  Hz, 2H - Ar 3', 5f); C14Hn 0 2Cl.
Compound 19. l-(2-Nitroethenyl)-4-(phenylmethoxy)benzene. Nitromethane (16.1 g, 
264 mmol) was added to 4-(phenylmethoxy)benzaldehyde (28 g, 132 mmol) in EtOH (900 
mL) at 5°C. NaOH (13.2 g, 330 mmol) in EtOH (200 mL) was added dropwise and the 
mixture was stirred for 30 min at 5°C. The reaction mixture was poured into a mixture of 
aq. HC1 (9M; 136 mL) and water (208 mL). The precipitate was collected and 
recrystallised from EtOH to give l-(2-nitroethenyl)-4-(phenylmethoxy)benzene (14.0 g, 
42%) as a yellow solid: mp 120 - 121°C (lit. 041> mp 120 - 121°C); lK NMR (CDC13) 8  5.02 
(2H, s, ArCtf20 ), 6.92 (2H, d, J = 8 .8  Hz, 2H - Ar 3', 5’), 7.29 (5H, m ,5H -A c O C H ^ , 
7.38 (2H, d, J = 8 .8  Hz, 2H - Ar 2', 6 ’), 7.43 (1H, d, J = 13.5 Hz, CtfCHN02), 7.85 (1H, d, 
J = 13.5 Hz, CHC£N02); T.L.C. (heptane : diethyl ether, 1: 1), Rf = 0.58. C15H13N03.
Compound 20. 2-(4-(Phenylmethoxy)phenyl)ethylamine. Lithium aluminium hydride 
(8.48 g, 223 mmol) was suspended in dry diethyl ether (600 mL). Using a Soxhlet 
apparatus, l-(2-nitroethenyl)-4-(phenylmethoxy)benzene (13.9 g, 55 mmol) was extracted 
into the mixture and boiled under reflux for 16 h. Water (7.38 mL) was added, followed by 
aq. NaOH (20%; 5.53 mL) and water (27.8 mL). The suspension was filtered and the 
solvent was evaporated to give 2-(4-(phenylmethoxy)phenyl)ethylamine (11.25 g, 91%) as a 
white solid: mp 44 - 46°C (lit P41* mp 196 - 206°C as the chloride salt); !H 400 NMR 
((CD3)2SO) 8  2.56 (2H, t, J = 7.1 Hz, CEfeCH^, 2.71 (2H, t, J = 7.3 Hz, CR2C d ^  5.05 
(2H, s, CH2, &l), 6.91 (2H, d, J = 8 .8  Hz, 2H - Ar 2* - 6 ’), 7.10 (2H, d, J = 8 .8  Hz, 2H - Ar 
3' - 5'), 7.31 - 7.44 (5H, m, Ar, £b); mass spectrum (70 E.I.) mlz 227 (4%) (M), 91 (100%), 
198 (40%), 30 (31%); (C.L) m/z 228 (M+) (8 6 %), 91 (100%), 198 (61%), 212 (56%)TX.C. 
(A), Rf = 0.23. C15H17NO.
Compound 21. N-(N-(4-(Phenylmethoxy)benzoyl)glycyl)glycine N-(2-(4-
(phenylmethoxy)phenyI)ethyI)amide. Dry CH2Q 2 (14 mL) containing N-(2-(4- 
(phenylmethoxy)phenyl)ethyl)amide hydrochloride (140 mg, 0.437 mmol) and N,N-
diisopropylethylamine (118.61 mg, 0.918 mmol) was stirred for 6 h as N-(4-(phenyl- 
methoxy)benzoyl)glycine pentafluorophenyl ester was added dropwise to the mixture (197.3 
mg, 0.437 mmol). A precipitate was removed by filtration before the CH2Q 2 was 
evaporated and the residue applied to a chromatography column, (EtOAc : CHCb [1 : 1]). 
A single product was eluted and the solvent evaporated to give N-(N-(4-(phenylmethoxy)- 
benzoyl)glycyl)glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide (19 mg, 8 %): JH NMR 
((CD3)2SO) 270 MHz 8  2.65 (2H, t, J = 7.5 Hz, HNCH2C£f2,), 3.23 (2H, q, J = 6 .8  Hz, 
HNC££2CH2), 3.67 (2H, d, J = 5.5 Hz, CH2 Gb>')., 3.87 (2H, d, J = 5.5 Hz, CH2 £& ), 5.03 
(2H, brs, CH2, OC#2Bn), 5.15 (2H, brs, CH2, OCtf2Bn), 6.83 (2H, d, J = 8.3 Hz, 2H - Ar1 
2', 6 ’), 7.01 (2H, d, J = 8 .8  Hz, 2H - Ar 2', 6 ’), 7.12 (2H, d, J = 8.5 Hz, 2H - Ar' 3 ',5 ’), 7.43 
(10H, m, O C H ^ , 7.85 (1H, m, N#CH2CH2), 7.88 (3H, d, J = 8.9, 2H - Ar 3’ - 5, 1H - 
#NCH2CH2), 8.18 (1H, brt, NH G lv \  8.73 (1H, brt, NH - £&); mass spectrum (F.A.B. 
[+]) mlz 552 (15%), 285 (100%), 391 (23%); (F.A.B. [-]) mlz 550 (40%), 97 (100%), 457 
(29%); T.L.C. (C), R, = 0.74; € 33^ 3^ 0 5 .
Compound 22. N-(N-(N-(4-(PhenyImethoxy)benzoyl)phenylaIanyI)Ieucyl)glycine N-(2- 
(4-(phenylmethoxy)phenyl)ethyI)amide. N,N-Diisopropylethylamine (200 mg, 1.575 
mmol) was added to N-(N-(N-phenylalanyl)leucyl)glycine N-(2-(4-(phenylmethoxy)phenyl)- 
ethyl)amide hydrochloride (403 mg, 0.693 mmol) and 4 -(phenylmethoxy)benzoyl chloride 
suspended in dry CH2Q 2 (50 mL) and was stirred for 3h. The CH2Q 2 was evaporated and 
the residue was further purified by column chromatography (E^O; EtOAc) to afford N-(N- 
(N-(4-(phenylmethoxy)benzoyl)phenylalanyl)leucyl)glycine N-(2-(4-(phenyl-
methoxy)phenyl)ethyl)amide (450 mg, 94%) as a white solid: mp 157 - 159°C; !H NMR 
((CD3)2SO) 400 MHz 5 0.76 (3H, d, J = 6.3 Hz, CH3 Mu, Isomer 1), 0.82 (3H, d, J = 6.4 
Hz, CH3 Lm, Isomer 1), 0.83 (3H, d, J = 6.3 Hz, CH3 Lm, Isomer 2), 0.88 (3H, d, J = 6 .8  
Hz, CH3 Lm, Isomer 2), 1.33 (1H, m, y - H Lm , Isomer 1), 1.45 (2H, t, J = 7.3 Hz, p - H 
Leu, Isomer 1), 1.56 (2H, t, J = 7.3 Hz, p - H Leu. Isomer 2), 1.61 (1H, m, y - H Leu, 
Isomer 2), 2.54 (2H, t, J = 7.6 Hz, HNCH2C&2, Isomer 1), 2.62 (2H, t, J = 7.6 Hz, 
HNCH2CU2, Isomer 2), 3.05 (2H, dd, J = 7.8 Hz, p - H Ehz, Isomer 1), 3.10 (2H, dd, J = 
7.8, J = buried, p - H EM, Isomer 2), 3.12 (2H, q, HNCtf2CH2, Isomer 1), 3.22 (2H, q, J =
6 .8  Hz, HNC£f2CH2, Isomer 2), 3.66 (2H, m, CH2 G&, Isomer 1), 3.70 (2H, d, J = 6.3 Hz, 
CH2 G /v . Isomer 2), 4.17 (1H, q, J = 7.5 Hz, a  - H Leu. Isomer 1), 4.28 (1H, q, J = 7.5 Hz, 
a  - H Mu, Isomer 2), 4.67 (1H, q, J = 6.7 Hz, a  - H Phe. Isomer 1), 4.69 (1H, m, a  - H 
EM, Isomer 2), 5.03 (4H, brs, CH2, OCtf2Ph', Isomer 1 and 2), 5.12 (4H, brs, CH2, 
OCtf2Ph, Isomer 1 and 2), 6.87 (4H, d, J = 8 .6  Hz, 2H - Ar’ 2’, 6 ’), 7.02 (4H, d, J = 8 .6  Hz,
2H - Ar 2', 6 '), 7.22 - 7.45 (30H, m, 5H - Ar EM, Isomer 1 and 2, 10H - A r.O C H ^ , 
Isomer 1 and 2), 7.30 (4H, approx'd, 2H - Ar' 3’, 5'), 7.59 (1H, t, J = 5.6 Hz, #NCH2OH2, 
Isomer 1), 7.80 (4H, d, J = 6.7 Hz, 2H - Ar 3', 50, 7.81 (1H, buried, #NCH2CH2, Isomer 
2), 8.12 (1H, t, J = 5.8 Hz, NH £& ), 8.19 (1H, d, J = 7.8 Hz, NR Leu. Isomer 2), 8.26 (1H, 
t, J = 5.9 Hz, NH G&), 8.42 (1H, d, J = 7.8 Hz, NH EM, Isomer 2), 8.43 (1H, d, J = 7.3 
Hz, NH Leu. Isomer 1), 8.57 (1H, d, J = 6 .8  Hz, NH Phe. Isomer 1); mass spectrum (FAB 
[+]) mlz 755 (8 %) (M + H), 111 (2%). (FAB [-]) mlz 753 (100%) (M - H), 663 (20%), 571 
(2%). Accurate mass. Found 756.3892, calculated C46H52N40 6 requires 756.3887. T.L..C. 
(CHClj: MeOH, 9 : l),R f = 0.50.
Compound 23. N-(N-(N-(N-(4-(Phenylmethoxy)benzoyl)gIycyl)phenyIalanyI)leucyI)- 
glycine N-(2-(4-(phenyImethoxy)phenyl)ethyl)amide. N-(N-(N-Phenylalanyl leucyl)- 
glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide hydrochloride (165 mg, 0.284 mmol) 
was treated with N,N-diisopropylethylamine (100 mg, 0.774 mmol), DMAP (10 mg) and 
HOBt (lOmg) in dry CH2Q 2 (15 mL) until dissolved. N-(4-(Phenylmethoxy)benzoyl)glycine 
pentafluorophenyl ester (117 mg, 0.258 mmol) in CH2Q 2 (lOmL) was added dropwise and 
the mixture stirred for 5h. The solvent was evaporated and the residue was purified by 
column chromatography (CHC13 : MeOH (50:1)) to afford N-(N-(N-(N-(4-(phenyl- 
methoxy)benzoyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(4-(phenylmethoxy)phenyl)- 
ethyl)amide (170 mg, 81%) as a glass: softening at 6 8  - 70°C; !H 400 MHz NMR 
((CD3)2SO) 5 0.75 (3H, d, J = 6.4 Hz, CH3 Lm, Isomer 1), 0.79 (3H, d, J = 6.4 Hz, CH3 
Leu. Isomer 1), 0.83 (3H, d, J = 6.4 Hz, CH3 Leu. Isomer 2), 0.87 (3H, d, J = 6.4 Hz, CH3 
Leu. Isomer 2), 1.45 (2H, t, J = 7.2 Hz, P - H Lm, Isomer 1), 1.51 (2H, t, J = 7.3 Hz, P - H 
Leu. Isomer 2), 1.62 (1H, m, y - H Leu. Isomer 1), 1.73 (1H, m, y - H Leu. Isomer 2), 2.62 
(2H, t, J = 7.0 Hz, HNCH2C£2, Isomer 1), 2.64 (2H, t, J = 7.0 Hz, HNCH2Q£2, Isomer 2),
2.78 - 2.88 (2H, m, p - H EM, Isomer 1), 2.97 - 3.07 (2H, m, p - H EM, Isomer 2), 3.22 
(4H, q, J = 7.0 Hz, HNCtf2CH2, Isomer 1 and 2), 3.62 (2H, d, J = 6.7 Hz, CH2 Isomer
1), 3.66 (2H, d, J = 6.7 Hz, CH2 QbL Isomer 1), 3.81 (2H, m, CH2 £&, Isomer 2), 3.85 
(2H, d, J = 6.7 Hz, CH2 GIV. Isomer 2), 4.22 (2H, m, a  - H Leu. Isomer 1 and 2), 4.54 (2H, 
m, a  - H Phe. Isomer 1 and 2), 5.04 (4H, brs, CH2, OC££2Ph', Isomer 1 and 2), 5.16 (4H, 
brs, CH2, OC#2Ph, Isomer 1 and 2), 6.90 (4H, d, J = 8 .6  Hz, 2H - Ar' 2', 6 '), 7.06 (4H, d, J 
= 8 .6  Hz, 2H - Ar 2', 6 '), 7.20 (4H, d, J = 8.7 Hz, 2H - Ar' 3’, 5'),7.29 - 7.46 (30H, m, 10H - 
Ar Phe. Isomer 1 and 2, 10H - Ar OCHJta. Isomer 1 and 2, 10H - Ar Q C H Jn1. Isomer 1 
and 2), 7.77 (1H, brs, £NCH2CH2, Isomer 1), 7.83 (4H, d, J = 8 .8  Hz, 2H - Ar 3', 5'); 8.00 
- 8.60 (1H, £NCH2CH2, Isomer 2), (1H, t, J = 5.8 Hz, NH GbO (1H, t, J = 5.8 Hz, NH
GM. (1H, t, J = 5.8 Hz, NH G/v7. (1H, d, J = 7.8 Hz, NH Leu. Isomer 2), (1H, t, J = 5.9 
Hz, NH £&), (1H, d, J = 7.8 Hz, NH EM, Isomer 2), (1H, d, J = 7.3 Hz, NH L m , Isomer
1), (1H, d, J = 6 .8  Hz, NH EM, Isomer 1); T.L.C. (EtOAc : MeOH [9 : 1), R, = 0.4.
Compound 24. N-(N-(N-(4-Hydroxybenzoyl)phenylalanyl)Ieucyl)glydne N-(2-(4- 
hydroxyphenyl)ethyl)amide. N-(N-(N-(4-(Phenylmethoxy)benzoyl)phenylalaniyl)-
leucyl)giycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide (122 mg, 0.161 mmol) was 
dissolved in absolute alcohol (10 mL) and stirred vigorously with palladium/charcoal (25 
mg, (Pd /  C, 10%)) under hydrogen for 16h. After filtering the suspension through Celite®, 
the EtOH was evaporated to furnish the product N-(N-(N-(4-(hydroxy)benzoyl)pheeyl- 
alanyl)leucyl)glycine N-(2-(4-hydroxyphenyl)ethyl)amide (85 mg, 91%) as a white solid: 115) 
104 - 106°C; lR  NMR ((CD3)2SO) 400 MHz 8  0.80 (3H, d, J = 6.4 Hz, CH3 La f, Isomer
1), 0.86 (3H, d, J = 6.7 Hz, CH3 Leu. Isomer 1), 0.88 (3H, d, J = 7.3 Hz, CH3 Leu. Isomer
2), 0.93 (3H, d, J = 6.4 Hz, CH3 Leu. Isomer 2), 1.36 (1H, m, y - H Lai, Isomer 1), 1.48 
(2H, t, J = 7.3 Hz, p - H Leu. Isomer 1), 1.56 (2H, t, J = 7.0 Hz, p - H Leu. Isomer 2), 1.65 
(1H, m, y - YLLeu, Isomer 2), 2.51 (2H, HNCH2C££2, Isomer 1), 2.62 (2H, t, J = 7.6 Hz, 
HNCH2Ctf2, Isomer 2), 3.08 (4H, m, p - H EM, Isomer 1 and 2), 3.14 (2H, m, 
HNCtf2CH2, Isomer 1), 3.25 (2H, m, HNC/£2CH2, Isomer 2), 3.66 (2H, m, CH2 G/v. 
Isomer 1), 3.70 (2H, d, J = 5.8 Hz, CH2 Gly, Isomer 2), 4.19 (1H, q, J = 7.3 Hz, a  - H Lm , 
Isomer 1), 4.31 (1H, q, J = 7.3 Hz, a  - H Leu. Isomer 2), 4.69 (1H, q, J = 7.6 Hz, a  - H 
EM, Isomer 1), 4.73 (1H, m, a  - H EM, Isomer 2), 6.70 (4H, approx't, 2H - A f 2', 6 '), 6.81 
(4H, approx'd, 2H - Ar 2’, 6 ’), 7.00 (4H, approx’ d, 2H - Ar' 3’, 5’), 7.30 - 7.38 (10H, brs, 
5H - Ar Phe. Isomer 1 and 2), 7.60 (1H, brs, ££NCH2CH2, Isomer 1), 7.70 (4H, approx* dd, 
2H - Ar 3', S'), 7.85 (1H, brt, flNCH2CH2, Isomer 2), 8.17 (1H, brt, NH £&), 8.21 (1H, d, J 
= 7.6 Hz, N IL to , Isomer 2), 8.31 (1H, brt, NH G/v. Isomer ?), 8.34 (1H, d, J = 8.2 Hz, 
NH EM, Isomer 2), 8.46 (1H, d, J = 6.4 Hz, NH Lm, Isomer 1), 8.50 (1H, d, J = 6.7 Hz, 
NH Phe. Isomer 1), 9.22 (1H, s, OH), 10.06 (1H, s, OH); mass spectrum (FAB [+]) mlz 575 
(20%) (M + H), 597 (10%), 121 (100%). (FAB [-]) mlz 573 (100%) (M - H), 453 (18%). 
TX.C. (C),Rf = 0.63. C ^ g ^ O fi.
Compound 25. N-(N-(N-(N-(4-Hydroxybenzoyl)glycyl)phenylalanyl)leucyl)glycine W- 
(2-(4-hydroxyphenyl)ethyI)amide. N-(N-(N-(N-(4-(Phenylmethoxy)benzoyl)glycyl)- 
phenylalanyl)leucyl)glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide (444 mg, 0.547
mmol) dissolved in EtOH (45 mL) was stirred vigorously over palladium/ charcoal catalyst 
(50 mg, (Pd/ C, 10%)) and hydrogen for 12 h. The suspension was filtered through Celite® 
and the solvent was evaporated from the filtrate to afford the product N-(N-(N-(N-(4- 
hydroxybenzoyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(4-hydroxyphenyl)ethyl)amide (304 
mg, 8 8 %) as an oil; mass spectrum (FAB [-]) mlz 630 (40%) (M - H), 188 (100%), 489 
(25%). T.L.C. (C), Rf = 0.46. C ^ H ^ O ? .
Compound 26. N-(4-(Methoxybenzoyl)glycine. N-(4-(Methoxybenzoyl)glycine methyl 
ester (2.00 g, 8.92 mmol) was boiled under reflux for 2h in MeOH (50 mL) containing 
NaOH (2.00 g, 50 mmol). Once the methanol had been evaporated the residue was 
dissolved in water, washed with CH2Q 2 and acidified (H2S 0 4 (10%)). The precipitate was 
extracted into CH2Q 2, the solution was dried and the solvent was evaporated to afford N- 
(4-(methoxybenzoyl)glycine (1.85 g, 98%). A small sample was recrystallised from water: 
mp 173-175°C softening at 168°C (lit t342) mp 168°C); *H NMR, ((CD3)2SO) 270 MHz 8
3.79 (3H, s, CH30), 3.92 (2H, d, J = 5.8 Hz, CH2), 7.00 (2H, d, J = 8 .8  Hz, 2H-Ar 2', 6 ’),
7.85 (2H, d, J = 8 .8  Hz, 2H-Ar 3’, 5’), 8.71 (1H, t, J = 5.9 Hz, HN); mass spectrum (CI.) 
mlz 153 (100%), 135 (20%). TJL.C. (A), R* = 0.20. Anal. Found C, 52.10; H, 5.65; N, 
5.90. C10HnNO4 requires C, 52.85; H, 5.75; N, 6.15.
Compound 27. N-(4-MethoxybenzoyI)gIycine N-(2-(4-methoxyphenyl)ethyl)amide. A
mixture of N-(4-methoxybenzyl)glycine (0.5 g, 2.40 mmol) and DCC (0.45 g, 2.20 mmol) 
was stirred at 0°C in THF (20 mL) for 30 mins. 2-(4-(methoxyphenyl)ethylamine (0.30 g,
2.00 mmol) was added to the suspension which was stirred for a further 16h at 5°C. A 
precipitate was removed and the organic solvent evaporated under reduced pressure. A 
residue was redissolved in EtOAc and washed with H2S04 (10%), NaHC03 and water 
before the dried solvent was removed to give N-(4-methoxybenzoyl)glycine N-(2-(4- 
methoxyphenyl)ethyl)amide (0.34 g, 50%) as a white solid: mp 172 - 174°C; NMR 
((CD3)2SO) 270 MHz 5 2.65 (2H, t, J = 7.5 Hz, HNCH2C #2,), 3.23 (2H, q, J = 6 .8  Hz, 
HNCtf2CH2), 3.70 (3H, s, OCH3'), 3.81 (3H, s, OCH3), 3.87 (2H, d, J = 5.5 Hz, CH2 £&), 
6.83 (2H, d, J = 8.3 Hz, 2H - Ar' 2\ 6 ’), 7.01 (2H, d, J = 8 .8  Hz, 2H - Ar 2’, 6 '), 7.12 (2H, d, 
J = 8.5 Hz, 2H - Ar1 3’, 5’), 7.85 (1H, m, NtfCH2CH2), 7.88 (3H, d, J = 8.9, 2H - Ar 3* - 5),
8.73 (1H, brt, NH Gly): mass spectrum (CL) mlz 343 (85%) (M + H), 134 (100%), 152 
(60%), 192 (30%). T.L.C. (A),Rf =0.23. C ^ N ^ .
Compound 28!. N-(4-MethoxybenzoyI)gIydne pentafluorophenyl ester. Dry THF (50
mL) containing N-(4-methoxybenzoyl)glycine (1.00 g, 4.75 mmol) and DCC (0.98 g, 4.75 
mmol) was stirred at 0°C for 30 min. Pentafluorophenol (0.87 g, 4.75 mmol) in dry THF 
(20 mL) was added dropwise and the mixture was stirred for 2h at 0°C. After maintaining 
the mixture at 5°C for 16h the suspension was filtered and the solvent was evaporated to 
give a residue which was dissolved in CH2Q 2 and washed with sat NaHC03. The CH2Q 2 
was dried and evaporated to give N-(4-methoxybenzoyl)glycine pentafluorophenyl ester 
(1.66 g, 93%) obtained as a yellow oil which soon crystallised to give a pale yellow solid: 
mp 130 - 132°C; !H, NMR (CD3COCD3) 270 MHz 8  3.86 (3H, brs, OMe), 4.57 (2H, d, J =
5.9 Hz, CHj), 7.02 (2H, d, J = 6 .8  Hz, 2H-Ar 2’, 6 '), 7.93 (2H, d, J = 6 .6  Hz, 2H-Ar 3’, 5'), 
8.36 (1H, brs, NH); ” F NMR 400 MHz ((CD3)2SO) 8  -162.66 (2F, dd, J = 23.0 Hz, J = 
19.5 Hz, F - metaY -157.98 (IF, tt, J = 23.0 Hz, F - /aza), -153.27 (2F, dd, J = 19.5 Hz, F - 
orthoY mass spectrum (CL) mlz 376 (17%) (M + H), 192 (100%), 135 (80%), 69 (52%). 
TX.C. (A), R,** 0.65. Anal. Found C, 51.10; H, 2.60; N, 3.70. C16H10NO4F5 requires C, 
51.20; H, 2.70; N, 3.75.
Compound 29. N-(N-(4-(Methoxybenzoyl)glycyl)gIydne methyl ester N-(N-(4- 
(Methoxybenzoyl)glycyl)glycine methyl ester (2.70 g, 72%) was prepared in a similar way as 
N-(4-(methoxybenzoyl)glycine methyl ester, Compound 10, using the N-(glycyl)glycine 
methyl ester hydrochloride: mp 157 - 159°C; !H 400 MHz NMR ((CD3)2SO) 8  3.65 (3H, s, 
OCH3, rZZ^ O. 3.83 (3H, s, OCH3, Ar), 3.88 (2H, d, J = 5.8 Hz, CH2, GbO, 3.91 (2H, d, J =
5.8 Hz, CH2, Gly), 7.03 (2H, d, J = 8.5 Hz, 2H - Ar 2’, 6 ’), 7.89 (2H, d, J = 8.5 Hz, 2H - Ar 
3’, 5*), 8.35 (1H, t, J = 5.8 Hz, NH, G lv \  8.69 (1H, t, J = 5.9 Hz, NH, £&); mass spectrum 
(E.I.) mlz 281 (28%) (M+), 165 (100%), 135 (51%). TX.C. (A),Rf = 0.35. Anal. Found 
C, 55.50; H, 5.70; N, 9.80. C13H16N20 5 requires C, 55.70; H, 5.75; N, 10.00.
Compound 30. N-(N-(4-(Methoxybenzoyl)glycyI)glydne ethyl ester N-(N-(4- 
(Methoxybenzoyl)glycyl)glycine ethyl ester (3.85 g, 30%) was prepared in a similar way as 
N-(4-(methoxybenzoyl)glycine methyl ester, Compound 10, using the N-(glycyl)glycine 
ethyl ester hydrochloride: mp 118 - 120°C; lU 270 MHz NMR ((CD3)2SO) 8  1.18 (3H, t, J 
= 7.9 Hz, CH2C£3), 3.80 (3H, s, OCH3, At), 3.83 (2H, d, J = 5.5 Hz, CH2, GbO, 3.89 (2H, 
d, J = 5.5 Hz, CH2, Git), 4.08 (2H, q, J = 7.1 Hz, CU2CR3)t 7.00 (2H, d, J = 7.7 Hz, 2H - 
Ar 2’, 6 ’), 7.86 (2H, d, J = 7.7 Hz, 2H - Ar 3’, 5'), 8.30 (1H, brs, NH, Gb0 , 8 .6 6  (1H, brs, 
NH, £&); mass spectrum (C l.) mlz 295 (11%) (M + H), 153 (100%), 135 (25%). T.L.C.
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(A), Rj = 0.34. Anal. Found C, 57.20; H, 6.10; N, 9.10. C14H18N20 5 requires C, 57.15; H, 
6.15; N, 9.50.
Compound 31. N-(N-(4-(Methoxybenzoyl)gIycyl)glycine. N-(N-(4-(Methoxybenzoyl)- 
glycyl)glycine was prepared in a similar way to Compound 26 to give the product (3.4 g, 
84%) as white crystals: mp 231 - 233°C; 270 MHz NMR ((CD3)2SO) 8  3.76 (2H, d, J  =
5.9 Hz, CHj, <260, 3.80 (3H, s, OMe), 3.90 (2H, d, J = 5.7 Hz, CH2, £60, 6.99 (2H, d, J =
8 .6  Hz, 2H - Ar 2’, 6 ’), 7.86 (2H, d, J = 8 .6  Hz, 2H - Ar 3’,5’), 8.20 (1H, t, J = 5.8 Hz, NH, 
£ 6 0 , 8.65 (1H, t, J = 5.9 Hz, NH, £60; T.L.C. (MeOH), R* = 0.30. Anal. Found C, 
53.90; H, 5.20; N, 10.40. C12H14N20 5 requires C, 54.15; H, 5.30; N, 10.50.
Compound 32. N-(N-(4-(Methoxybenzoyl)glycyI)glycine 2,5-dioxopyrroIidin-l-yIoxy 
ester. N-(N-(4-Methoxybenzoyl)glycyl)glycine (1.45 g, 5.45 mmol) was dissolved in DMF 
(30 mL) and stirred with DCC (1.12 g, 5.45 mmol) for 2h at 0°C. A solution of N-hydroxy- 
succinimide (0.63 g, 5.45 mmol) was added to this mixture and the whole maintained at 5°C 
for 16h. A precipitate was removed and the organic phase evaporated to give a residue. 
Recrystallisation from toluene and DMF gave N-(N-(4-(methoxybenzoyl)glycyl)glycine 2,5- 
dioxopyrrolidin-l-yloxy ester (1.21 g, 61%) as a white solid: !H 270 MHz NMR 
((CD3)2SO) 8  2.80 (4H, s, C H jC H j), 3.81 (3H, s, OCH3, Ar), 3.91 (2H, d, J =  6.0 Hz, CHj, 
£ 6 0 ,4 .2 6  (2H, d, J = 5.9 Hz, CH2, £ 6 :), 7.01 (2H, d, J = 8 .8  Hz, 2H - Ar 2’, 6 ’), 7.87 (2H, 
d, J = 8 .8  Hz, 2H - Ar 3', 5’), 8.60 (1H, t, J = 5.8 Hz, NH, £ 6 0 , 8.75 (1H, t, J = 5.8 Hz, 
NH, £60; Anal. Found C, 52.90; H, 4.50; N, 11.65. C16H17N307 requires C, 52.90; H, 
4.70; N, 11.55.
Compound 33. N-(N-(l,l-DimethyIethoxycarbonyl)glycyI glycine 2,5-dioxopyrrolidin- 
1-yloxy ester. N-(N-(l,l-Dimethylethoxycarbonyl)glycyl)glycine (5.95 g, 25.70 mmol) in
1,4-dioxan (190 mL) was treated with DCC (5.30 g, 25.70 mmol) at -10°C for 0.5h. After 
adding HONSu (2.96 g, 25.70 mmol) the reaction mixture was stored at 5°C for 16h before 
a precipitate was removed and the solvent evaporated to afford N-(N-( 1,1 -dimethylethoxy- 
carbonyl)glycyl glycine 2,5-dioxopyrrolidin-l-yloxy ester as a white solid (8.24 g, 97%): 
lU 400 MHz NMR ((CD3)2SO) 8  1.37 (9H, s, (CH3)30), 2.79 (4H, s, O ^C H j), 3.58 (2H, 
d, J = 5.8 Hz, CH2, £60, 4.24 (2H, d, J = 5.8 Hz, CH2, £60, 7.02 (1H, t, J = 6.0 Hz, NH), 
8.43 (1H, t, J = 5.8 Hz, NH); C13H19N30 7 .
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Compound 34. N-(N-(l,l-Dimethylethoxycarbonyl)gIycyI)gIycine N-(2-(4-methoxy- 
phenyl)ethylamine. A solution of DCC (4.59 g, 22.30 mmol) in DMF (15 mL) was briskly 
added to N-(N-(l,l-dimethylethoxycarbonyl)glycyl)glycine (5.17 g, 22.30 mmol) in DMF 
(30 mL) and stirred for 30 min at 0°C. Dropwise 2-(4-(methoxyphenyl)ethylamine (3.06 g,
20.25 mmol) was added to the above and the mixture maintained at 5°C for 16h. Following 
the removal of a precipitate the filtrate was evaporated under reduced pressure and a residue 
redissolved in EtOAc. The organic phase was washed with H2S04 (10%), N^COj and 
aqueous NaG (Sat.). The organic layer was separated, dried and the solvent evaporated to 
give N-(N-( 1,1 -dimethylethoxycarbonyl)glycyl glycine N-(2-(4-methoxyphenyl)ethylamine 
as a white solid (6.75 g, 91%): *H 270 MHz NMR (CDG3) 6  1.44 (9H, s, (CH3)30), 2.74 
(2H, t, J = 7.2 Hz, CHjCffj), 3.44 (2H, q, J = 6.7 Hz, C ^ C H J, 3.77 (3H, s, OMe), 3.80 
(2H, d, 5.7 Hz, CH2, G /v \ 3.88 (2H, d, J = 5.5 Hz, CH2, £ 6 0 , 5.49 (1H, brs, N£CH2CH2),
6.70 (1H, brs, NH, £ 6 0 , 6.82 (2H, d, J = 8 .6  Hz, 2H - Ar 2', 6 ’), 7.09 (2H, d, J = 8 .6  Hz, 
2H - Ar 3', 5'), 7.19 (1H, brs, NH, £60; T.L.C. (A),Rf = 0.64. Anal. Found C, 60.35; H, 
7.05; N, 11.15. C ^ H ^ N ^  requires C, 59.15; H, 7.45; N, 11.50.
Compound 35. N-(l,l-DimethyIethoxycarbonyI)gIycine. Glycine (11.81 g, 157 mmol) 
was dissolved in water (200 mL) containing NaOH (6.29 g, 157 mmol). Di-l-butyl 
dicarbonate (45 g, 204 mmol) in 1,4-dioxan (150 mL) was added to this and the mixture was 
stirred vigorously for 16h. The reaction mixture was washed with diethyl ether (2 x 100 
mL). The aqueous portion was acidified with H2S04 (10%) and extracted with EtOAc (200 
mL). The EtOAc was dried and evaporated to yield N-(l,l-dimethylethoxycarbonyl)glycine 
(25.5 g, 93%) as a white solid: mp 85 - 87°C (lit378 mp 8 8  - 89°C); JH NMR ((CD3)2SO) 
270 MHz 8  1.37 (9H, s, (C#3)30), 3.51 (2H, d, J = 5.9 Hz, CU2 £6 0 , 7.81 (1H, brs, NH); 
mass spectrum (C.I.) mlz 176 (8 %) (M + H), 120 (100%), 76 (31%), 102 (30%). T.L.C. 
(AXR^O.40. C7H13N04.
Compound 36. N-(1,1-Dimethylethoxycarbonyl)glycine N-(2-(4-methoxyphenyl)- 
ethyl)amide. A mixture of N-(l,l-dimethylethoxycarbonyl)glycine (2.90 g, 16.60 mmol) 
and DCC (3.13 g, 15.18 mmol) were stirred at 0°C in dry THF (50 mL) for 30 min. A 
solution of 2-(4-methoxyphenyl)ethylamine (2.09 g, 13.80 mmol) in dry THF was added and 
the suspension maintained at 5°C for 16h. A precipitate was filtered and the THF was 
evaporated from the filtrate to give a white solid which was recrystallised from ethanol and 
water to give N-(l,l-dimethylethoxycarbonyl)glycine N-(2-(4-methoxyphenyl)ethyl)amide
(3.3 g, 78%) as a white solid: mp 116-118°C; NMR ((CD3)2SO) 270 MHz 5 1.37 (9H, s, 
(C#3)30), 2.63 (2H, t, J = 7.2 Hz, H N O ^Q fc), 3.29 (2H, q, J = 6.4 Hz, HNC#2CH2), 
3.51 (2H, d, J = 5.9 Hz, Cd2 G&)> 3.72 (3H, s, OCH3), 6.82 (2H, d, J = 8.4 Hz, 2H - Ar 2’, 
6’), 6.91 (1H, brt, NH), 7.10 (2H, d, J = 8.2 Hz, 2H - Ar 3’, 5'), 7.81 (1H, brs, NH); mass 
spectrum (C.I.) mlz 309 (54%) (M + H), 235 (100%), 253 (65%), 134 (86%), 209 (51%). 
T.L.C. (A), Rf = 0.20. Anal. Found C, 62.50; H, 8.10; N, 9.30. C16H24N20 4 requires C, 
62.30; H, 7.85; N, 9.10.
Compound 37. Glycine N-(2-(4-methoxyphenyI)ethyI)amide. N-(l,l-Dimethylethoxy- 
carbonyl)glycine N-(2-(4-methoxyphenyl)ethyl)amide (3.5 g, 11.35 mmol) was dissolved in
1,4-dioxan (80 mL) and acidified with hydrogen chloride. A solid was isolated and partly 
characterised by JH NMR ((CD3)2SO) 270 MHz 5 2.67 (2H, t, J = 7.3 Hz, HNCHjCtfj), 
3.29 (2H, q, J = 6 .6  Hz, H N C^C H ^, 3.49 (2H, brs, CR2 G&), 3.72 (3H, brs, OCH3), 6.85 
(2H, d, J = 8.4 Hz, 2H - Ar 2’, 6 ’), 7.14 (2H, d, J = 8.1 Hz, 2H - Ar 3', 5'), 8.25 (3H, brs, 
NH3), 8.65 (1H, brs, NH). The suspension was filtered and the white solid in water (150 
mL), was basified with aq. NaOH (2M) and extracted with CHC13 (2 x lOOmL). 
Evaporation of the solvent from the dried extract followed by trituration with diethyl ether 
gave the product glycine N-(2-(4-methoxyphenyl)ethyl)amide (1.79 g, 76%) as a white 
solid: NMR ((CD3)2SO) 270 MHz 8  2.65 (2H, t, J = 7.3 Hz, HNCH2Ctf2), 3.27 (2H, q,
J = 6.4 Hz, HNCtfjCHj), 3.49 (2H, d, J = 5.5 Hz, CU2 G&), 3.68 (3H, brs, OCH3), 6.81 
(2H, d, J = 8.4 Hz, 2H - Ar 2', 6 ’), 7.11 (2H, d, J = 8.4 Hz, 2H - Ar 3', 5’), 8.30 (2H, s, 
NH2), 8.71 (1H, t, J = 5.3 Hz, NH); mass spectrum (C.I.) mlz 209 (78%) (M + H), 134 
(100%), 69 (58%), 183 (26%). T.L.C. (EtOH), R, = 0.31. Anal. Found C, 63.20; H, 7.35; 
N, 13.40. CnH16N20 2 requires C, 63.40; H, 7.75; N, 13.45.
Compound 38. N-(N-(4-Methoxybenzoyl)glycyl)glycine N-(2-(4-methoxyphenyl)- 
ethyl)amide. Glycine N-(2-(4-methoxyphenyl)ethyl)amide (3.55 g, 14.2 mmol) was added 
to a solution of N-(4-methoxybenzoyl)glycine pentafluorophenyl ester (5.35 g, 14.2 mmol), 
N,N-diisopropylethylamine (2.95 g, 22.8 mmol) and HOBt (30 mg) in EtOAc (200 mL). 
After stirring for 12h a light precipitate was removed by filtration and the solvent was 
evaporated from the mother liquor. A white solid was collected and recrystallised from 
MeOH to afford N-(N-(4-methoxybenzoyl)glycyl)glycine N-(2-(4-methoxyphenyl)- 
ethyl)amide (2.86 g, 50%) as white crystals: mp 199 - 201°C; mass spectrum (FAB [+]) mlz 
400 (80%) (M + H), 130 (100%), 209 (50%), 192 (39%). (FAB [-]) mlz 398 (100%) (M -
xviii
H), 552 (50%), 183 (35%), 311 (19%). T.L.C. (MeOH), R, = 0.21. Anal. Found C, 
63.10; H, 6.45; N, 10.70. requires C, 63.15; H, 6.30; N, 10.50.
Compound 39. N-(l,l-DimethyIethoxycarbonyI)Ieudne. Leucine (2.00 g, 15.25 mmol) 
was dissolved in water (25 mL) containing NaOH (0.61 g, 15.25 mmol) and stirred 
vigorously for 12h with a solution of di-t-butyl dicarbonate (4.98 g, 22.85 mmol) in 1,4- 
dioxan (15 mL). The reaction was quenched with diethyl ether and the aq. fraction was 
acidified with H2S04 (10%) and extracted with EtOAc. The solvent was dried and 
evaporated to afford N-(l,l-dimethylethoxycarbonyl)leucine (3.30 g, 94%) as white 
crystals: mp 64 - 6 6 °C, (lit C249) mp 67 - 72°C, softening at 61°C); NMR (CDC13) 270 
MHz 8  1.06 (6 H, d, J = 6.3 Hz, C H tC H ^, 1.55 (9H, s, (CH3)30), 1.78 (3H, m, 7  - H, p -
H, Leu), 4.44 (1H, m, <x - H, L ed , 5.10 (1H, d, J = 8.5 Hz, NH), 10.11 (1H, s, OH); mass 
spectrum (CL) mlz 232 (10%) (M + H), 176 (100%), 132 (42%), 8 6  (46%). T.L.C. (A), 
Rf = 0.40. CnH21N04.
Compound 40. N-(l,l-DimethyIethoxycarbonyl)Ieucine pentafluorophenyl ester. N- 
(1,1 -Dimethylethoxycarbonyl)leucine (3.45 g, 14.95 mmol) and DCC (3.08 g, 14.95 mmol) 
were stirred together at -10°C in THF (30 mL) for lh. Dropwise pentafluorophenol (2.75 g, 
14.95 mmol) in THF (40 mL) was added and the suspension was maintained at 5°C for 16h. 
After removing a precipitate, the solvent was evaporated to afford N-(l,l-dimethylethoxy- 
carbonyl)leucine pentafluorophenyl ester (5.07 g, 85%) as a white solid: mp 48 - 50°C (lit 
<332> Mpt 48 - 50°C); »H NMR (CDC13) 270 MHz 8  1.06 (6 H, d, J = 6.3 Hz, CH(CH3)2),
I.55 (9H, s, (CH3)30), 1.78 (3H, m, 7  - H, P - H, Led, 4.44 (1H, m, a  - H, Led, 5.10 (1H, 
d, J = 8.5 Hz, NH); mass spectrum (CL) mlz 398 (10%) (M + H), 342 (100%), 8 6  (60%), 
225(40%). T.L.C. (A),Rf =0.91.
Compound 41. N-(N-(l,l-Dimethylethoxycarbonyl)leucyI)glycine N-(2-(4-
methoxyphenyl)ethyl)amide. A solution of Compound 40 (1.80 g, 4.55 mmol) was 
dissolved in CH2Q 2 (30 mL) with N^N-diisopropylethylamine (0.59 g, 4.55 mmol) and 
HOBt (0.61 g, 4.55 mmol) and stirred as glycine N-(2-(4-(methoxyphenyl)ethyl)amide 
(Compound 37) (1.10 g, 4.55 mmol) was added. The mixture was stirred for 16h before the 
organic phase was washed with a minimum amount of water and Na2HC03. The dried 
extract was evaporated under reduced pressure and the residue separated by column 
chromatography (CH2G 2 : EtOAc) to give N-(N-(l,l-dimethylethoxycarbonyl)
leucyl)glycine N-(2-(4-methoxyphenyl)ethyl)amide (0.55 g, 29%) as a white solid: llH NMR 
(CDCI3) 400 MHz 8  0.94 (3H, d, J = 6.1 Hz, C&3, Lea), 0.95 (3H, d, J = 6.4 Hz, Ctf3,
1.45 (9H, s, (CH3)30), 1.45 - 1.55 (2H, m, p - H, L m ), 1.59 (1H, m, y - H, I^  2.75 
(1H, dt, J = 14 Hz, J = 7 Hz, CH2CUJ, 2.76 (1H, dt, J = 14 Hz, J = 7 Hz, CH2C 3.45 
(2H, q, J = 7 Hz, C #2CH2), 3.79 (3H, s, OCfl3), 3.82 (2H, dd, J = 14.5 Hz, J = 5.2Hz, Ctf2, 
GlvY 4.05 (1H, ddd, J = 9.5 Hz, J = 6.7 Hz, J = 5.2 Hz, a  - Ctf, La*), 5.01 (1H, d, J = 6.5 
Hz, NH, L a0, 6.70 (1H, brs, tfNCHjCHj), 6.84 (2H, d, J = 8.5 Hz, 2H-Ar 3', 5’), 8.14 (1H, 
m, NH, £{y), 7.11 (2H, d, J = 8.5 Hz, 2H-Ar2’, 6 ’); mass spectrum (CL) mlz 422 (5%) (M 
+ H), 89 (100%), 322 (10%), 207 (31%). T.L.C. (A),Rf = 0.39. Anal. Found C, 62.60; 
H, 8.35; N, 9.60. C ^ H ^ O j requires C, 62.70; H, 8.35; N, 10.00.
Compound 42. N-(1,1-Dimethylethoxycarbonyl)phenylalanine 2,5-dioxopyrroIidin-l- 
yloxy ester. N-(l,l-Dimethylethoxycarbonyl)phenylalanine (4.54 g, 17.12 mmol) in 1,4- 
dioxan (70 mL) was treated with DCC (3.53 g, 17.12 mmol) at -10°C for 0.5h. After 
adding HONSu (1.97 g, 17.12 mmol) the reaction mixture was stored at 5°C for 16h before 
a precipitate was removed and the solvent evaporated to afford a yellow oil. Trituration 
with diethyl ether gave the product N-(l,l-dimethylethoxycaibonyl)phenylalanine 2,5-dioxo- 
pymolidin-l-yloxy ester (4.20 g, 6 8 %) as a white solid; mp 152 - 153°C (lit s^o) 115) 152- 
153°C); JH NMR ((CD3)2SO) 270 MHz 8  1.32 (9H, s, (Cfi3)3); 2.84 (1H, dd, J = 13.0 Hz, J 
= 4.00Hz, p - H Ete)\ 2.79 (4H, s, Ctf2CtL& 3.02 (1H, dd, J = 13.0 Hz, J = 4.00Hz, p - H 
Phe): 4.18 (1H, m, a  - HEM); 7.09 (1H, d, J 8.4 Hz; NH); 7.26 (5H, s, 5H - ArPhe): mass 
spectrum (CL) mlz 263 (55%) (M + H), 100 (100%), 307 (10%), 69 (58%), 120 (38%). 
TJL.C. (EtOAc : light ether, 1 : 1), Rf = 0.82. Anal. Found C, 59.40; H, 6.20; N, 7.85. 
Ci8H22N20 6 requires C, 59.65; H, 6.10; N, 7.75.
Compound 43. N-(N-(l,l-Dimethylethoxycarbonyl)phenylalanyl)leucine. Aqueous 
NaOH (30 mL, 2.0 M) and NaHC03 (8 .6 8  g, 103.32 mmol) were added to a suspension of 
leucine (15.30 g, 116.70 mmol) in water (200 mL) and stirred for 30 rrrins before a solution 
of N-(l,l-dimethylethoxycarbonyl)phenylalanine 2 ,5 -dioxopyrrolidin-l-yloxy ester (42.25 g,
116.70 mmol) (Compound 42) in DMF (250 mL) was added. The mixture was stirred for 
lh  before water (100 mL) and DMF (100 mL) were added to the reaction mixture. After 
16h the semi-solid mass was distributed between EtOAc (200 mL) and H2S04 (100 mL, 
10%) and extracted (three times). The dried extracts were pooled and the organic solvent 
evaporated to give a pale yellow solid. Recrystallisation from EtOAc and pet. ether
xx
afforded N-(N-( 1,1 -dimethylethoxycarbonyl)phenylalanyl)leucine (22.95 g, 52%) as a white 
solid: mp 139 - 141°C (lit. <*«> mp 138 - 140°C); »H NMR ((CD3)2SO) 270 MHz 5 0.85 
(3H, d, J = 6.4 Hz, Ctf3, t o ) ,  0.90 (3H, d, J = 6.4 Hz, CU3, t o ) ,  1.29 (9H, s, (Ctf3)30),
1.55 (2H, q, J = 7.0 Hz, P H, t o ) ,  1.68 (1H, m, 7  H, t o ) ,  2.69 - 2.99 (2H, dd, J = 14 Hz, J 
= 3.7 Hz, p H, EM), 4.18 (1H, q, J = 6.3 Hz, a H, t o ) ,  4.27 (1H, q, J = 7.5 Hz, a H, EM),
6 .8 6  (1H, d, J = 8 .8  Hz, NH, EM), 7.27 (5 H, brs, 5H - Ar, EM), 8.10 (1H, d, J = 7.9 Hz, 
NH, t o ) ;  mass spectrum (CL) mlz 379 (2%) (M + H), 279 (35%), 91 (100%), 305 (20%), 
71(70%). T.L.C. (A), Rf = 0.40. Anal. Found C, 63.20; H, 8.10; N, 7.55. C ^ A ^ 20 5 
requires C, 63.50; H, 7.95; N, 7.40; [ a ]23589 = -14.4°.
Compound 44. N-(N-(1,1-Dimethylethoxycarbonyl)phenylalanyl)leucine
pentafluorophenyl ester. N-(N-(l,l-Dimethylethoxycarbonyl)phenylalanyl)leucine (23.0 g,
61.0 mmol) was stirred with pentafluorophenol (11.2 g, 61.0 mmol) and DCC (12.50 g, 61.0 
mmol) in THF (170 mL) for lh at 0°C before the solution was filtered and the solvent was 
evaporated from the filtrate. The residue, in CH2Q 2 (200 mL), was washed with sat. aq. 
NaHC03 (twice) and water. The organic phase was dried and the CH2Q 2 was evaporated 
to give N-(N-(l,l-dimethylethoxycaibonyl)phenylalanyl)leucine pentafluorophenyl ester 
(28.0 g, 85%) as a yellow solid: *H NMR (CDC13) 270 MHz 6  0.96 (6 H, d, J = 6  Hz, 
(C#3)2CH t o ) ,  1.41 (9H, s, (Ctf3)30), 1.71 (3H, m, p - 2H, t o ,  7  - H, t o ) ,  3.09 (2H, d, 
J = 6 .8  Hz, P - 2H, EM), 4.40 (1H, q, J = 7.5 Hz, a - H, to ), 4.85 (1H, m, a - H, EM),
5.06 (1H, brs, NH, t o ) ,  6.44 (1H, d, J = 7.7 Hz, NH, EM), 7.30 (5H, m, 5 H - Ar, 
Phenylalanine1: mass spectrum (C.I.) mlz 545 (3%) (M + H), 489 (7%), 184 (100%), 120 
(45%). TX.C. (A), Rf = 0.80. Anal. Found C, 57.50; H, 5.55; N, 5.40. C ^ H ^ O ^  
requires C, 57.35; H, 5.35; N, 5.15.
Compound 45. N-(N-(N-(l,l-DimethylethoxycarbonyI)phenylalanyl)leucyl)glycine N- 
(2-(4-methoxyphenyI)ethyI)amide. N-(N-( 1,1 -Dimethylethoxycaibonyl)phenylalanyl)-
leucine pentafluorophenyl ester (30.80 g, 56.60 mmol) was dissolved in dry THF (300 mL) 
with HOBt (100 mg), DMAP (100 mg) and N,N-diisopropylethylamine (8.05 g, 62.26 
mmol). Slowly glycine N-(2-(4-methoxyphenyl)ethyl)amide (11.83 g, 56.60 mmol) in THF 
(300 mL) was added and the mixture stirred for 16h. The THF was filtered and evaporated 
to give a residue which, in CH2Q 2 was washed with aq. H2S04 (200 mL, 10%) and sat. 
NaH2C 03 (200 mL). Evaporation of the solvent from the dried extract, followed by column 
chromatography (EtOAc) gave the product .N-(N-(N-(l,l-dimethylethoxycarbonyl)-
phenylalanyl)leucyl)glycine N-(2-(4-methoxyphenyl)ethyl)amide (22.18 g, 69%) as a pale 
yellow solid: mp 124-125°C; >H NMR (CDC13) 270 MHz 5 0.88 (3H, d, J = 6.0 Hz, CH3 
Leu), 0.89 (3H, d, J = 6.2 Hz, CH, Leu), 1.38 (9H, s, (Cff3)30), 1.45 (1H, m, y - H U u). 
1.49 (1H, m, H - p Leu), 1.62 (1H, m, H - P Leu), 2.75 (2H, t, J = 7.4 Hz, CHjCHj). 3.43 
(2H, qnt, J = 6.05 Hz, Cfi2 Gty), 3.03 (2H, q, J = 6.05 Hz, H - P EM), 3.76 (3H, s, OCtf3), 
3.92 (1H, dd, J = 6.1 Hz, J = 5.9 Hz, H - a  Leu), 4.39 (2H, d, J = 7.1 Hz, CH2 Gly), 5.22 
(1H, d, J = 6 .8  Hz, a  - H Phe), 6.83 (2H, d, J = 8 .6  Hz, 2H - Ar 3’ - 5’), 7.09 (1H, m, Ntf), 
7.14 (8H, m, 2H - Ar 2' - 6 ', 3H - Nffs), 7.24 (2H, d, J = 7.6 Hz, 2H - Ar 2' - 6 '): mass 
spectrum (CL) mlz 569 (0.75%) (M + H), 134 (100%), 69 (71%), 469 (2%). T.L.C. (A), 
Rf= 0.38. C j ^ N A .
Compound 46. N-(N-(PhenyIalanyl)leucyl)glycine N-(2-(4-methoxyphenyl)ethyl)anude 
hydrochloride. An excess of hydrogen chloride was bubbled through 1,4-dioxan (400 mL) 
containing N-(N-(N-(l,l-dimethylethoxyearbonyl)phenylalanyl)leucyl)gIycine N-(2-(4- 
methoxyphenyl)ethyl)amide (21.26 g, 37.50 mmol). The solvent was evaporated and the 
residue was triturated with diethyl ether to give N-(N-(phenylalanyl)leucyl)glycine N-(2-(4- 
methoxyphenyl)ethyl)amide hydrochloride (13.01 g, 69%) as white crystals: mp 224°C; ’H 
NMR ((CD3)jSO) 270 MHz 6  0.87 (3H, d, J = 7.3 Hz, CH3, Leu), 0.89 (3H, d, J = 7.3 Hz, 
C a3, Leu), 1.50 (2H, brt, J = 6 .8  Hz, CHCfl^CH), 1.60 (1H, m, CH2Ca(CH3)2, 1 mi). 2.65 
(2H, t, J = 7.4 Hz, Q L fU j) , 3.10 (1H, ddd, J = 7.2 Hz, CHCi/2-Ar, EM), 3.25 (2H, m, 
C a2CH2 and 1H of the ddd @ 3.06), 3.65 (2 H, dd, CH2, Gly), 3.70 (3H, s, OCH3), 4.10 
(1H, m, a  CU, Leu). 4.30 (1H, q, J = 7.4 Hz, a  CH., EM), 6.85 (2H, d, J = 8 .8  Hz, 2H-Ar 
2’, G), 7.15 (2H, d, J = 8 .6  Hz, 2H-Ar 3’, 5'), 7.30 (5H, s, 5H-Ar, EM), 7.95 (1H, t, J = 5.5 
Hz, HNCHjCHj), 8.20 (1H, t, J = 5.6 Hz, HN, Gly), 8.40 (3H, m, H3N, Phe). 8.95 (1H, d, J 
= 7.8 Hz, HN, Leu); mass spectrum (FAB [+]) mlz 469 (30%) (M + H), 225 (100%), 98 
(25%), 209 (11%). (FAB [-]) mlz 467 (25%) (M - H), 188 (100%), 151 (60%), 341 (55%), 
377 (40%). C26H37N40 4a
Compound 47. N-(l,l-DimethyIethoxycarbonyl)phenylalanine pentafluorophenyl 
ester. N-(l,l-Dimethylethoxycarbonyl)phenylalanine (2.90 g, 10.95 mmol) and DCC (2.26 
g, 10.95 mmol) were stirred together at -10°C in 1,4-dioxan (25 mL) for lh. Dropwise 
pentafluorophenol (2.01 g, 10.95 mmol) in 1,4-dioxan (40 mL) was added and the 
suspension was maintained at 5°C for 16h. After removing the precipitate, the solvent was 
evaporated to afford N-(l,l-dimethylethoxycarbonyl)phenylalanine pentafluorophenyl ester
(2.85 g, 73%) as a white solid: mp 113 - 115°C (lit. P32> mp 111 - 112°C); >H NMR 
((CD3)2SO) 270 MHz 5 1.29 (9H, s, (CH3)30), 2.81 (1H, in, P - H EM), 3.01 (1H, m, P - H 
EM), 4.31 (1H, s, a  - H EM), 7.18 (1H, brt, NH Phe). 7.25 (5H, m, 5H - Ar Phe): mass 
spectrum (C.I.) mil 376 (100%) (M + H), 164 (62%), 332 (45%), 192 (35%). T.L.C. 
(CH2Q 2 : pentane, [1 :5 ]), R( = 0.30. [a]23569 = -26.9°. C2oH18N0 4F5.
Compound 49. N-(PhenylaIanyl)glycine N-(2-(4-(methoxyphenyI)ethyi)amide 
hydrochloride. Compound 49 was prepared using a method that was used for the 
preparation of Compound 39 to give N-(phenylalanyl)glycine N-(2-(4- 
(methoxyphenyl)ethyl)amide hydrochloride (19.56 g, 89%) as a white solid:
>H NMR (CDC13) 400 MHz 8  2.75 (1H, dt, J = 14 Hz, J = 7 Hz, CH2Ctf2), 2.76 (1H, dt, J 
= 14 Hz, J = 7 Hz, CH2CH2), 3.03 (2H, q, J = 6.05 Hz, H - p Phe). 3.45 (2H, q, J = 7 Hz, 
CHjCHj), 3.79 (3H, s, OCR}), 3.82 (2H, dd, J = 14.5 Hz, J = 5.2Hz, CU2, GbD, 5.25 (1H, 
d, J = 6 .8  Hz, a  - H Phe). 6.70 (1H, brs, flNCHjCHj), 6.84 (2H, d, J = 8.5 Hz, 2H-Ar 3', 
5'), 7.11 (2H, d, J = 8.5 Hz, 2H-Ar 2', 6 '), 8.14 (1H, m, NH, <2&), 8.35 (3H, m, Nff3 Phe): 
T.L.C. (CHQ3: MeOH, [6 : l]),R f = 0.78; CjoH^NjOjO.
Compound 50. N-(N-(N-(4-Methoxybenzoyl)glycyl)phenyIalanyl)gIycine N-(2 -(4 - 
methoxyphenyl)cthyl)amidc. N-(4-Methoxybenzoyl)glycine pentafluorophenyl ester (7.67 
g, 20.45 mmol), HOBt ( 2 0 0  mg) and diisopropylethyldiamine (3 .1 2  g, 24.15 mmol) were 
dissolved in CHjQj (300 mL). N-(N-(Phenylalanyl)glycine N-(2-(4-methoxyphenyl)- 
ethyl)amide (6.60 g, 18.60 mmol) in CH2Q 2 (300 mL) was added dropwise to the solution 
stirred and stirred at 35°C for 24h with DMAP (200 mg). The CH2Q 2 was evaporated to 
give the crude product which was purified using chromatography (EtOAc: CH2Q 2 [3 : 1]); 
CHQ3: MeOH [7 : 1 ]). The solvent was evaporated and the product N-N-(N-(N-(4- 
methoxybenzoyl)glycyl)phenylalanyl)leucyl)gycine N-(2-(4-methoxyphenyl)ethyl)amide 
(4.47 g, 44%) obtained as a white solid: mp 181 - 183°C; *NMR ((CD3)2SO) 270 MHz 5 
2.58 (2H, t, J = 7.3 Hz, HNCH2Cfl2,), 2.83 (1H, dd, J = 13.6 Hz, P - H, Phe). 3.03 (1H, dd, 
J = 13.6 Hz, p - H, Phe). 3.17 (2H, m, HNCifeCHj), 3.63 (2H, dd, J = 5.9 Hz, CH2, GIV). 
3.69 (3H, s, OCH3), 3.79 (3H, s, OCf£3), 3.9 (2H, dd, J = 5.9 Hz, CH2, Gh), 4.46 (1H, m, 
a  - H, Phe). 6.80 (2H, d, J = 8.4 Hz, 2H - Ar' 2’, 6 '), 6.97 (2H, d, J = 9.1 Hz, 2H - Ar 2’, 60,
7.04 (2H, d, J = 8.5 Hz, 2H - Ar' 3', 5'), 7.22 (5H, brs, 5H - Ar, Phe). 7.71 (1H, brt, 
flNCHjCHj), 7.82 (2H, d, J = 8.5, 2H - Ar 3', 5'), 8.23 (1H, d, J = 7.3 Hz, NH. Phe). 8.35
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(1H, brt, NH, G Ivl. 8.61 (1H, brt, NH, Gly): mass spectrum (FAB [+]) mlz 547 (100%) (M 
+ H), 192 (82%), 149 (55%), 495 (31%). (FAB [-]) mlz 545 (100%) (M - H), 493 (42%), 
531(10%). T.L.C. (C),Rf=0.25. C30H34N4O6.
Compound 51. N-(4-(Phenylmethoxy)benzoyl)glycine methyl ester. 4-(Phenyl- 
methoxy)benzoyl chloride (13.64 g, 55.5 mmol) in CH2Q 2 (90 mL) was added dropwise to 
glycine methyl ester hydrochloride (7.66 g, 61 mmol) and triethylamine (11.78 g, 116.5 
mmol) in CH2Q 2 (250 mL). The mixture was stirred for 16 h and the suspension filtered. 
The solvent was evaporated to afford, after recrystallisation from CH2Q 2 /  hexane, N-(4- 
(phenylmethoxy)benzoyl)glycine methyl ester (14.75 g, 89%) as a white solid: mp 105 - 107 
°C; !H NMR (CDC13) 270 MHz 8  3.78 (3H, s, OC#3), 4.22 (2H, d, J = 5.15 Hz, CH2, Gly),
5.10 (2H, s, BnC££20), 6.69 (1H, brs, NH), 6.98 (2H, d, J = 8.9 Hz, 2H - Ar 2', 6 ’), 7.37 - 
7.42 (5H, m, &lCH20), 7.77 (2H, d, J = 8.9 Hz, 2H - Ar 3’, 5'); TJL.C. (heptane : diethyl 
ether, 1 : 3), R* = 0.27. C17H17N 04.
Compound 52. N-(4-(PhenyImethoxy)benzoyl)gIycine. N-(4-(Phenylmethoxy)benzoyl)- 
glycine methyl ester (14.75 g, 49.2 mmol) was boiled under reflux with methanolic NaOH 
(1.0 M) (80 mL) for 2 h. The solvent was evaporated. The residue, in water, was acidified 
(aq. HC1, 5%) and extracted with EtOAc. The extract was washed with brine and the 
solvent was evaporated from the dried extract to give N-(4-(phenylmethoxy)benzoyl)glycine 
(6.59 g, 47%) as a white solid: mp 164 - 166°C; »H NMR ((CD3)2SO) 270 MHz 8  3.91 
(2H, d, J = 5.9 Hz, CH2, GH), 5.17 (2H, s, BnC#20), 7.09 (2H, d, J = 9.1 Hz, 2H - Ar 2', 
6 '), 7.31 - 7.48 (5H, m, &tCH20 ), 7.85 (2H, d, J = 8.9 Hz, 2H - Ar 3', 5’), 8.71 (1H, t, J =
5.8 Hz, NH), 12.60 (1H, br, OH); mass spectrum (FAB [+]) mlz 286 (58%) (M + H), 91 
(100%), 211 (58%), 149 (25%). (FAB [-]) mlz 284 (100%) (M - H), 97 (80%), 250 (42%). 
T.L.C. (C),Rf =0.30. C16H15N04.
Compound 53. N-(4-(PhenyImethoxy)benzoyl)glycine pentafluorophenyl ester. DCC
(720 mg, 3.5 mmol) was added to N-(4-(phenylmethoxy)benzoyl)glycine (1.00 g, 3.5 mmol) 
in dry THF (100 mL) at 0°C. Pentafluorophenol (640 mg, 3.5 mmol) was added dropwise 
and the mixture was maintained at 0°C for 17h. The suspension was filtered and the solvent 
was evaporated. The residue, in CH2Q 2, was washed with aq. Na2C 03 (10%) (75 mL, 
twice), and with aq. H2S04 (10%). The organic phase was dried and the solvent was 
evaporated to give a yellow solid, which was recrystallised from CH2Q 2 and hexanes to
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afford N-(4-(phenylmethoxy)benzoyl)glycine pentafluorophenyl ester (1.5 g, 95%) as white 
crystals: mp 141 - 143°C, softening at 125°C; *H NfMR (CDQ3) 270 MHz 5 4.59 (2H, d, J 
= 5.50 Hz, CH2, Gly), 5.10 (2H, s, BnCtf20), 6.81 (1H, t, NH), 6.99 (2H, d, J = 8 .8  Hz, 2H 
- Ar 2', 6 ’), 7.31 - 7.42 (5H, m, £flCH20), 7.77 (2H, d, J = 8 .8  Hz, 2H - Ar 3', 5’); mass 
spectrum (FAB [+]) mlz 452 (40%) (M + H), 91 (100%), 211 (45%), 225 (20%). (FAB [-]) 
mlz 183 (100%) (M - H). T.L.C. (B), R, = 0.52. Anal. Found C, 58.70; H, 3.30; N, 3.50. 
C ^H ^N O ^ requires C, 58.55; H, 3.15; N, 3.10.
Compound 54. N-(l,l-Dimethylethoxycarbonyl)glycine N-(2-(4-(phenyImethoxy)- 
phenyl)ethyl)amide. N-(l,l-Dimethylethoxycarbonyl)glycine (850 mg, 4.85 mmol) was 
stirred with DCC (1.00 g, 4.85 mmol) and 2-(4-(phenylmethoxy)phenyl)ethylamine (1.00 g,
4.4 mmol) in dry THF (30 mL) for 16 h. The suspension was filtered and the solvent was 
evaporated to give a residue which, in EtOAc, was washed with aq. H2S04 (10%) and with 
brine. The solvent was separated from the dried extract give N-(l,l-dimethylethoxy- 
carbonyl)glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide (1.65 g, 98%) as a white 
solid: mp 107 - 109°C; JH NMR ((CD3)2SO) 270 MHz 5 1.38 (9H, s, (Ctf3)30), 2.62 (2H, 
t, J = 7.3 Hz, CH2CHJ, 3.22 (2 H, q, QfcCHj), 3.48 (2 H, d, J = 6.0 Hz, CH2 Qjy), 5.06 
(2H, s, OCtf2Bn), 6.91 (3H, d, J = 8.4 Hz, 2H - Ar 2', 6 ’, Ntf), 7.11 (2H, d, J = 8.4 Hz, 2H - 
Ar 3’, 5'), 7.31 - 7.42 (5H, m, 5H - OCHj&O, 7.80 (1H, brs, NH); mass spectrum (FAB [+]) 
mlz 385 (10%) (M + H), 91 (100%), 210 (45%), 285 (30%). (FAB [-]) mlz 383 (20%) (M -
H), 309 (100%), 181 (50%), 430 (30%), 537 (40%). T.L.C. (A), Rf = 0.76. Anal. Found 
C, 69.15; H, 7.10; N, 6.95. C22H2SN20 4  requires C, 68.70; H, 7.35; N, 7.30.
Compound 55. Glycine N-(2-(4-(phenyImethoxy)phenyl)ethyl)amide. N -(l,l- 
Dimethylethoxycarbonyl)glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide (2.01 g, 5.23 
mmol) was treated with excess HQ in 1,4-dioxan (45 mL) for 2 h. The white solid was 
collected by filtration and identified as the N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide 
hydrochloride: mp 196 - 198°C; JH NMR ((CD3)2SO) 400 MHz 6  2.68 (2H, t, J = 7.3 Hz, 
CH2C££2), 3.30 (2H, q, J = 6.7 Hz, C #2CH2), 3.50 (2H, s, C #2), 5.07 (2H, s, OCtf2Bn), 
6.94 (2H, d, J = 8.3 Hz, 2H - Ar 2’, 6 ’), 7.11 (2H, d, J = 8.3 Hz, 2H - Ar 3', 5'), 7.30 - 7.45 
(5H, m, 5H - Ar O C H ^ , 8.31 (3H, s, N #3), 8.71 (1H, t, J = 5.4 Hz, NH); mass spectrum 
(FAB [+]) mlz 285 (100%) (M + H), 91 (50%), 211 (10. (FAB [-]) 188 (100%), 341 
(35%), 151 (20%). C17H21N20 2Q . The N-(2 -(4 -(phenylmethoxy)phenyl)ethyl)amide
hydrochloride was dissolved in water and EtOAc and the pH was adjusted with aq. NaOH
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(2.0 M) to pH 9. The organic phase was dried and the solvent was evaporated to give 
glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide (1.15 g, 77%) as a colourless oil: JH 
NMR (CDC13) 270 MHz 8  2.77 (2H, t, J = 7.0 Hz, O^CEfe), 3.30 (2H, s, Cd2 GM), 3.50 
(2H, q, J = 6 .8  Hz, C ^C H J, 5.04 (2H, s, OCtf2Rn), 6.91 (2H, d, J = 8 .6  Hz, 2H - Ar 2', 
6 '), 7.11 (2H, d, J = 8 .6  Hz, 2H - Ar 3', 5*), 7.31 - 7.44 (6 H, m, 5H - Ar O C H ^ , NH); 
T.L.C. (C H a3 : MeOH, [9 : l]),R f =0.40. C ^ H ^ O ^
Compound 56. N-(N-(N-(l,l-Dimethy!ethoxycarbonyl)phenyIaIanyl)Ieucyl)g!ycine N- 
(2-(4-(phenylmethoxy)phenyI)ethyI)amide. N,N-Diisopropylethylamine (7.41 g, 57.30 
mmol), DMAP (100 mg) and HOBt (100 mg) were stirred for 0.5h with a suspension of 
glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide hydrochloride (6.73 g, 21.0 mmol) in 
dry CH2Q 2 (350 mL) at 35°C. A solution of N-(N-(l,l-dimethylethoxycarbonyl)- 
phenylalanyl)leucine pentafluorophenyl ester (10.39 g, 19.10 mmol) in dry CH2Q 2 (150 mL) 
was filtered and added dropwise to the reaction mixture. After 16h the mixture was washed 
with H2S04 (10%). Evaporation of the solvent from the dried extract followed by column 
chromatography (EtjO; EtOAc) afforded N-(N-(N-(l,l-dimethylethoxycarbonyl)- 
phenylalanyl)leucyl)glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide as a yellow oil, 
which soon crystallised to give a pale yellow solid (8.97 g, 73%): mp 67 - 69°C; NMR 
((CD3)2SO) 400 MHz 5 0.73 (3H, d, J = 6.4 Hz, CH3 Lm, Isomer 1), 0.80 (3H, d, J = 6.4 
Hz, CH3 Lm, Isomer 1), 0.84 (3H, d, J = 6.4 Hz, CU3 Lm, Isomer 2), 0.89 (3H, d, J = 6.7 
Hz, CH3 Lm, Isomer 2), 1.29 (18H, s, 9H (Ctf3)30 , Isomer 1 and 2), 1.42 (2H, m, p - H 
Lm, Isomer 1), 1.49 (2H, m, p - H Leu. Isomer 2), 1.60 (1H, m, y - H Leu. Isomer 1), 1.71 
(1H, m, y - H Lm, Isomer 2), 2.64 (4H, t, J = 7.5 Hz, HNCH2Cf£2, Isomer 1 and 2), 2.81 
(1H, m, p - H Phe, Isomer 1), 3.01 (1H, m, P - H Phe. Isomer 2), 3.23 (4H, br q, 
HNC#2CH2, Isomer 1 and 2), 3.61 (4H, m, CH2 Glv. Isomer 1 and 2), 4.19 (2H, brs, a  - H 
Leu. Isomer 1 and 2), 4.31 (2H, s, a  - H Phe. Isomer 1 and 2), 5.05 (2H, s, CH2, OC#2Bn, 
Isomer 1), 5.06 (2H, s, CH2, OC£f2Bn, Isomer 2), 6.91 (4H, dd, J = 8 .6  Hz, 2H - Ar 2' - 6 ', 
Isomer 1 and 2), 6.99 (1H, d, J = 8.3 Hz, NH Lm), 7.12 (4H, dd, J = 8 .6  Hz, Hz, 2H - Ar 
3', 5', Isomer 1 and 2), 7.18 (1H, brt, NH EM, Isomer 1 and 2), 7.25 (1 0H, m, 5H - Ar EM, 
Isomer 1 and 2), 7.39 (10H, m, 5H - A r.O C H ^, Isomer 1 and 2), 7.81 (1H, t, J = 5.5 Hz, 
NH Gly), 8.06 (1H, t, J = 7.0 Hz, #NCH2CH2); mass spectrum (FAB [+]) mlz 645 (10%) 
(M + H), 8 6  (100%), 545 (20%), 285 (35%), 210 (56%). (FAB [-]) mlz 643 (8 %) (M - H), 
569 (100%), 797 (15%), 810 (16%). T.L.C. (C),Rf = 0.62. [ a p 589. +24.6°. C37H48N40 6.
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Compound 57. N-(N-(N-Phenylalanyl)Ieucyl)glydnd N-(2-(4-(phenyImethoxy)- 
phenyl)ethyl)amide hydrochloride. N-(N-(N-( 1,1 -Dimethylethoxycarbonyl)phenylalanyl)- 
leucyl)glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide (3.89 g, 6.05 mmol) was treated 
with excess hydrogen chloride in CH2Q 2 (200 mL) for 3h. The solvent was evaporated to 
give an oil which was triturated with diethyl ethex to give N-(N-(N-phenylalanyl)leucyl)- 
glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide hydrochloride (3.26 g, 93%) as a white 
solid mp 108 - 110°C; !H 400 MHz NMR ((CD3)2SO) 6  0.69 (3H, d. J = 6.1 Hz. CH3 Leu. 
Isomer 1), 0.76 (3H, d, J = 6.1 Hz, CU3 Lm, Isomer 1), 0.90 (3H, d, J = 6.4 Hz, C&3 Lm, 
Isomer 2), 0.93 (3H, d, J = 6.4 Hz, CH3 Lm, Isomer 2), 1.55 (2H, t, J = 7.3 Hz, p - H Lm, 
Isomer 1), 1.65 (2H, t, J = 7.3 Hz, p - H Leu. Isomer 2), 1.67 (1H, m, y - HJLm, Isomer 1),
1.74 (1H, m, y - H Lm, Isomer 2), 2.68 (4H, brs, HNCH2C #2, Isomer 1 and 2), 3.05 (2H, 
m, p - H Phe. Isomer 1), 3.21 (2H, m, P - H Phe. Isomer 2), 3.27 (4H, brs, HNC#2CH2, 
Isomer 1 and 2), 3.61 (2H, s, CH2 Gly. Isomer 1), 3.70 (2H, s, CH2 Gly. Isomer 2), 4.15 
(2H, brs, a - H Leu. Isomer 1 and 2), 4.36 (2H, s, a - H Phe. Isomer 1 and 2), 5.10 (4H, 
brs, CH2, OCZZ2Ph, Isomer 1 and 2), 5.58 (6 H, brs, NH3, Isomer 1 and 2), 6.96 (4H, d, J =
8.2 Hz, 2H - Ar 2’, 6 ’), 7.17 (4H, d, J = 8.2 Hz, 2H - Ar 3', 5'), 7.30 - 7.38 (10H, m, 5H - Ar 
Phe. Isomer 1 and 2), 7.41 - 7.49 (10H, m, 5H - Ar O C H ^ , Isomer 1 and 2), 7.88 (1H, 
approx. t, NH Gly. Isomer 1), 8.00 (1H, brt, NH Gly. Isomer 2), 8.40 (1H, brt, Z£NCH2CH2, 
Isomer 1), 8 .6 6  (1H, brt, Z£NCH2CH2, Isomer 1). C32H50N4O4Q .
Compound 58. N-(9-FIuorenyImethoxycarbonyl)gIutamic acid-y-(l,l-
dimethyIethyI)ester-a-pentafluorophenyl ester. In THF (35 mL) a mixture of N-(9- 
fluorenylmethoxycarbonyl)glutamic acid-y-(l,l-dimethylethyl)ester (0.92 g, 2.07 mmol) and 
DCC (0.43 g, 2.07 mmol) was stirred at -10°C for lh. Pentafluorophenol (0.38 g, 2.07 
mmol) in THF (15 mL) was added dropwise and the reaction mixture maintained at 5°C for 
2h. The precipitate was removed and the filtrate evaporated to furnish the crude product N- 
(9-fluorenylmethoxycarbonyl)glutamic acid-y-( 1,1 -dimethylethyl)ester-a-pentafluoropheny 1 
ester (1.11 g, 91%) as a white solid; mp 119 - 121°C; lH 400 MHz NMR ((CD3)2SO) 8
1.38 (9H, brs, (CH3)30), 1.76 (2 H, m, P - H Ghk,), 2.24 (2 H, t, J = 6.4 Hz, y - H C M , 4.02 
(1H, m, a  - H C M , 4.22 (3H, m, CtfCtf2, FMOCY 7.61 (2H, brt, NH. Glu). 7.70 (4H, m, 
2H - Ar FMOCY 7.89 (4H, d, J = 7.8 Hz, 2H - Ar FMOO: 400 MHz NMR ((CD3)2SO)
8  -162.21 (2F, dd, J = 20.8 Hz, J = 17.4 Hz, 2F - meta), -157.63 (IF, t, J = 22.0 Hz, IF - 
para), -152.69 (2F, d J = 18.5 Hz, 2F - ortho); T.L.C. (CHC13), Rf = 0.87. C ^H ^N O ^.
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Compound 59. N-(l,l-DimethyIethoxycarbonyI)glycine pentafluorophenyl ester. N-
(l,l-Dimethylethoxycaibonyl)gIycine (2.00 g, 11.45 mmol) and DCC (2.36 g, 11.45 mmol) 
were stirred together at -10°C in THF (50 mL) for lh. Dropwise pentafluorophenol (2.10 g,
11.45 mmol) in THF (40 mL) was added and the suspension was maintained at 5°C for 16h. 
After removing the precipitate, the solvent was evaporated to afford N-(l,l-dimethylethoxy- 
caibonyl)glycine pentafluorophenyl ester (2.85 g, 73%) as a yellow solid: mp 79 - 80°C (lit 
032) mp 79-80°C); lU NMR ((CD3)2SO) 270 MHz 5 1.40 (9H, s, (CH3)30 ), 4.16 (2H, d, J =
5.8 Hz, Gly), 7.55 (1H, t, J = 5.8 Hz, NH); 19F NMR ((CD3)2SO) 400 MHz 8  -163.95 (2F, 
dd, J = 23.1 Hz, 19.7 Hz, F - meta), -159.34 (IF, tt, J = 23.2 Hz, F - para), -154.61 (2F, dd, 
J = 18.5 Hz, F - ortho). C13H12N 04F5.
Compound 60. N-(N-(N-(N-(l,l-DimethylethoxycarbonyI)gIycyl)phenylalanyl)leucyl)- 
glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide. N,N-Diisopropylethylamine (0.40 
g, 3.10 mmol) was added to a suspension of N-(N-(N-phenylalanyl)leucyl)glycine N-(2-(4- 
(phenylmethoxy)phenyl)ethyl)amide hydrochloride (0.60 g, 1.05 mmol) in dry CH2Q 2 (45 
mL). The reaction mixture was stirred for 16h with N-(l,l-dimethylethoxycarbonyl)glycine 
pentafluorophenyl ester (0.35 g, 1.05 mmol), HOBt (30 mg) and DMAP (30 mg). A residue 
produced when the solvent was evaporated was separated by column chromatography 
(DCM; EtOAc) and triturated with pentane to give the product N-(N-(N-(N-(1,1- 
dimethylethoxycarbonyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(4-(phenylmethoxy)- 
phenyl)ethyl)amide (0.71 g, 96%) as brown crystals: mp 55 - 56°C, softening at 48°C; *H 
NMR ((CD3)2SO) 400 MHz 8  0.67 (3H, d, J = 6.4 Hz, C #3, Lm, Isomer 1), 0.73 (3H, d, J 
= 6.1 Hz, Ctf3, Leu. Isomer 1), 0.77 (3H, d, J = 6.4 Hz, CHy  Leu. Isomer 2), (0.81, d, J =
6.4 Hz, CK3, Leu. Isomer 2), 1.29 (11H, brs, (CZf3)30 , Isomer 1 and 2, CHCH2Cli, Leu. 
Isomer 1), 1.42 (2H, t, J = 7.0 Hz, CHC#2CH Lm, Isomer 2), 1.54 (1H, m, y H Lm, 
Isomer 2), 2.58 (2H, q, J = 6.3 Hz, CH2Ctf2, Isomer 1 and 2), 2.95 (2H, dd, J = 13.5 Hz, J 
= 6.4 Hz, p H EM Isomer 1), 3.04 (2H, dd, J = 13.90 Hz, J = 4.60 Hz, p H EM, Isomer 2), 
3.16 (2H, q, J = 6.4 Hz, HNC#2CH2, Isomer 1 and 2), 3.35 and 3.65 (2H, m, Ctf2, G t  
twice, Isomer 1 and 2), 4.09 and 4.21 (1H, m, H - a ,  Leu. Isomer 1 and 2), 4.47 (1H, d, J =
7.3 Hz, H - a, Phe. Isomer 1 and 2), 5.03 (2H, s,OCZ£2Bn, Isomer 1 and 2), 6.85 (2H, d, J =
8 .6  Hz, 2H - Ar 3’ 5’, Isomer 1 and 2), 7.05 (2H, d, J = 8.25 Hz, 2H - Ar 2’, 6 \  Isomer 1 and 
2), 7.15 (5H, brs, 5H - Ar, Phe. Isomer 1 and 2), 7.25 (5H, m, 5 H - Ar, OCH2£a, Isomer 1 
and 2), 7.60 - 8.25(5H, Ni£, Isomer 1 and 2). T.L.C. (C),Rf =0.72. G ^ N ^ .
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Compound 61. N-(N-(N-(N-gIycyIphenyIal:anyI)IeucyI)glycine N-(2-(4-(phenyI- 
methoxy)phenyl)ethyl)amide hydrochloride. An excess of hydrogen chloride was 
bubbled through a solution of N-(N-(N-([N-(l,l-dimethylethoxycarbonyl)glycyl)- 
phenylalanyl)leucyl)glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide (0.61 g, 0.87 
mmol) dissolved in CH2Q 2 (50 mL) for lh. The solvent was evaporated under high vacuum 
to afford the product N-(N-(N-glycylphenylalanyl)Ieucyl)glycine N-(2-(4-(phenylmethoxy)- 
phenyl)ethyl)amide hydrochloride. (0.54 g, 98%) as a buff crystalline solid: mp 166 - 168° 
C; 400 MHz NMR ((CD3)2SO) 8  0.75 (3H, d, J = 6.4 Hz, CHCtf3, Lm, Isomer 1), 0.80 
(3H, d, J = 6.4 Hz, CHC£f3, Leu. Isomer 1), 0.84 (3H, d, J = 6.4 Hz, CH.CH.zJLm, Isomer 
2), 0.89 (3H, d, J = 6.4 Hz, CHCtf3, Lm , Isomer 2), 1.41 (1H, m, P - H, Lo^Isom er 1), 
1.53 (2H, m, p - H, Leu. Isomer 2, y - H Leu, Isomer 1), 1.59 (1H, m, y - H Lm, Isomer 2), 
2.64 (4H, brq, J = ?, HNCH2Cff2, Isomer 1 and 2), 2.82 (2H, m, p - H, Ehs. Isomer 1 and 
2), 3.24 (4H, brq, J = ?, HNCtf2CH2, Isomer 1 and 2), 3.58 (4H, m, CU2, Gly, Isomer 1 and 
2), 3.65 (4H, dd, J = 14.4 Hz, J = 5.8 Hz, CR2, Gly, Isomer 1 and 2), 4.30 (2H, m, a  H, 
Leu. Isomer 1 and 2), 4.65 (2H, m, a  - H, Phe. Isomer 1 and 2), 5.06 (4H, s, OCZf2Ar, 
Isomer 1 and 2), 6.92 (4H, d, J = 6.4 Hz, 2H - Ar 2\ 6 ’, Isomer 1 and 2), 7.12 (4H, d, J =
7.0 Hz, 2H - Ar 3', 5’, Isomer 1 and 2), 7.20 (1H, buried, Nfl), 7.25 (10H, brs, 5H - Ar Phe, 
Isomer 1 and 2), 7.39 (5H, m, 5H - Ar, QCRJPh. Isomer 1 and 2), 7.93 (1H, brd, NH), 8.11 
(3H, brs, Ntf3), 8.51 (1H, brd, Nfl, twice), 8.82 (1H, brd, NW \ mass spectrum (FAB [+]) 
mlz 602 (49%) (M + H), 149 (100%), 85 (100%), 447 (23%), 285 (20%). (FAB [-]) mlz 
600 (50%) (M - H), 636 (100%), 188 (95%), 341 (26%). C34H44N50 5CL
Compound 62. N-(N-(N-(N-(N-(9-Fluorenylmethoxycarbonyl)-y-(l,l-dimethyl- 
ethyloxy)g!utamyl)gIycyl)phenylalanyl)leucyI)glycine N-(2-(4-(methoxyphenyl)phenyl)- 
ethyl)amide. N,N-Diisopropylethylamine (34.38 g, 0.266 mmol) in dry CH2Q 2 (3.0 mL) 
was added dropwise, over lh, to a suspension of N-(9-fluorenylmethoxycarbonyl)glutamic 
acid-y-(l,l-dimethylethyl)ester-a-pentafluorophenyl ester (78.60 mg, 0.133 mmol) and N- 
(N-(N-glycylphenylalanyl)leucyl)glycine N-(2-(4-(phenylmethoxy)phenyl)ethyl)amide 
hydrochloride (84.80 mg, 0.133 mmol) in dry CH2Q 2 (15 mL). The solution was stirred for 
5h and the residue, following evaporation of the solvent was separated by column 
chromatography (CH2Q 2: EtOAc [4 : 1]); EtOAc) to furnish N-(N-(N-(N-(N-(9-fluorenyl- 
methoxycarbonyl)-y-( 1,1 -dimethylethyl)glutamyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(4- 
(methoxyphenyl)phenyl)ethyl)amide (114 mg, 85%) as pale brown crystals: mp 85 - 87°C; 
m  400 MHz NMR ((CD3)2SO) 5 0.72 (3H, d, J = 6.3 Hz, CHC/f3, Lm, Isomer 1), 0.78 
(3H, d, J = 6.3 Hz, CHCZZ3, Lm , Isomer 1), 0.82 (3H, d, J = 6.3 Hz, CHQlL^Jjm, Isomer
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2), 0.87 (3H, d, J = 6 .8  Hz, CHCZ£3, Leu, Isomer 2), 1.24 (2H, t, J = 6.1 Hz, (J - H Leu. 
Isomer 1), 1.38 (20H, brs, (CH3)30 , Isomer 1 and 2 , 7  - H Leu. Isomer 1), 1.49 (2H, t, J =
7.0 Hz, p - H Leu. Isomer 2), 1.59 (1H, m, 7  - H Leu. Isomer 2), 1.76 (2H, m, p - H Glu. 
Isomer 1), 1.91 (2H, m, p - H Gill, Isomer 2), 2.24 (4H, t, J = 6.4 Hz, 7  - H Glu. Isomer 1 
and 2), 2.64 (4H, t, J = 6 .8  Hz, HNCH2C££2, Isomer 1 and 2), 2.82 (2H, m, P - H Phe 
Isomer 1), 2.96 (2H, m, p - H Phe. Isomer 2), 3.24 (4H, q, J = 6 .6  Hz, HNQ£2CH2, Isomer 
1 and 2), 3.65 (8H, m, CZ£2» G/v. twice, Isomer 1 and 2), 4.02 (2H, m, a  - H Glu. Isomer 1 
and 2), 4.22 (6 H, m, FMOC CHCH2, Isomer 1 and 2), 4.26 (2H, m, a  H Leu, Isomer 1 and 
2), 4.55 (2H, m, a  - H Ehe, Isomer 1 and 2), 5.04 (4H, s,OC#2Ar, Isomer 1 and 2), 6.92 
(4H, d, J = 6 .8  Hz, 2H - Ar 2’, 6 ’, Isomer 1 and 2), 7.12 (4H, d, J = 6 .8  Hz, 2H - Ar 3’, 5’, 
Isomer 1 and 2), 7.15 - 7.43 (28H, m, 5H - Ar Phe. Isomer 1 and 2, 5H - Ar Bn, Isomer 1 
and 2 ,4H - FMOC. Isomer 1 and 2), 7.61(2H, brt, NH. Glu. Isomer 1 and 2), 7.70 (4H, m, 
2H - Ar FMOC). 7.74 (1H, brt, ££NCH2CH2, Isomer 1), 7.81 (1H, brt, flNCH2CH2, Isomer
2), 7.89 (4H, d, J = 7.8 Hz, 2H - Ar FMOC. Isomer 1 and 2), 7.99 (1H, brt, GluG&Phe, 
Isomer 1), 8.05 (1H, d, J = 7.8 Hz, NH Leu. Isomer 1), 8.12 (5H, brs, NH Phe. Isomer 1 
and 2, NH PheLeuG/v. Isomer 1 and 2, NH GluG/vPhe. Isomer 2), 8.26 (1H, d, J = 7.8 Hz, 
NH Leu. Isomer 2); mass spectrum (FAB [+]) mlz 1009 (7.5%) (M + H), 1031 (1%), 409 
(8 %). (FAB [-]) mlz 1007 (2%) (M - H), 830 (23%), 812 (100%), 785 (70%). Accurate 
mass. Found 1008.5023, QgHggNgOjo requires 1008.4997. Accurate mass. Found 
1009.5100, CjgH^NgOjo requires 1009.5075. T.L.C. (C),Rf =0.34.
Compound 63. 2-(2-(2-(2-(2-Hydroxyethoxy)ethoxy)ethoxy)ethoxy)ethyl toIuene-4- 
sulphonate. A solution of hexa(ethyleneglycol) (6  g, 21.5 mmol) in toluene (120 mL) was 
dried by the azeotropic removal of water before triethylamine (9.69 g, 96.0 mmol), DMAP 
(250 mg) and tosyl chloride (18.25 g, 9.60 mmol) were added. The mixture was stirred for 
36h at 60°C and then allowed to cool. A suspension was removed by filtration and the 
organic solvent in the filtrate removed by evaporation. A residue was produced which was 
separated by column chromatography (CH2Q 2; CH2Q 2 : MeOH [9 : 1]) to afford 2-(2-(2- 
(2-(2-Hydroxyethoxy)ethoxy)ethoxy)ethoxy)ethyl toluene-4-sulphonate (11%) as an oil: !H 
270 MHz NMR (CDC13) 5 2.45 (3H, s, C#3Ar), 3.67 (20£f, m, 0CH2CH20 ), 3.75 (4H, m, 
TsOCH2C£2, CH2 - hydroxv). 4.15 (2H, t, J = 4.9 Hz, TsOCtfj), 7.34 (2H, d, J = 7.9 Hz, 
2H - Ar 3’, 5’), 7.79 (2H, d, J = 8.3 Hz, 2H - Ar 2’, 6 ’); T.L.C. (B), Rf = 0.40. C19H320 9.
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Compound 64. 2-(2-(2-(2-(2-Allyloxyethoxy)ethoxy)ethoxy)ethoxy)ethanoI. From 
Dellaria (7). From a flame dried, two necked flask pentaethylene glycol (3.02 g, 12.70 
mmol) in dry THF (10 mL) was slowly introduced into a dry mixture of NaH (0.12 g, 5.0 
mmol) and dry THF (15 mL) and stirred under nitrogen until all gas evolution had ceased. 
Fresh allyl bromide (0.61 g, 5.0 mmol) in dry THF (2 mL) was added to the reaction mixture 
and stirred for 1 h at 75°C. When the reaction had cooled to 40°C the pH was adjusted to 
pH 2 (glacial acetic acid) and the mother liquor collected after the suspension was filtered 
through Celite ®. The solvent was evaporated to afford a thick oil which was eluted 
through a funnel containing silica gel (15 g) using EtOAc, 5% MeOH /  EtOAc. The 
fractions containing the product were combined and the solvent evaporated to afford 2 -(2 - 
(2-(2-(2-allyloxyethoxy)ethoxy)ethoxy)ethoxy)ethanol (2.90 g, 82%) as a colourless oil: !H 
270 MHz NMR (CDClj) 8  3.66 (20H, m, ethoxx groups). 4.02 (2H, d, J = 5.7 Hz, 
Ctf2CHCH2), 5.19 (1H, d, J = 10.4 Hz, CH2CHCfl2), 5.24 (1H, d, J = 17.4 Hz, 
CH2CHC#2), 5.90 (1H, ddt, J = 17.4 Hz, J = 10.4 Hz, J = 5.8 Hz, CHjCftCHj); T.L.C. 
(C), Rf = 0.43. C^H^O,.
Compound 65. 2-(2-(2-(2-(2-AIIyIoxyethoxy)ethoxy)ethoxy)ethoxy)ethyI toIuene-4- 
sulphonate. In a method adapted bom Dellaria (7) tosyl chloride (0.44 g, 2.35 mmol) was 
added to a stirred solution of 2 -(2 -(2 -(2 -(2 -allyloxyethoxy)ethoxy)ethoxy)ethoxy)ethanol 
(0.54 g, 1.94 mmol), triethylamine (0.31 g, 3.10 mmol) and DMAP (20 mg) in CH2Q 2 (15 
mL). After 12h the reagents were washed with diethyl ether, aq. HQ (10%), sat NaHC03 
and brine. The dried extract was evaporated to a thick oil (0.84 g, 74%) which was 
seperated by column chromatography (EtOAc /  pentane [1 :1 ]) to give 2-(2-(2-(2-(2-allyl- 
oxyethoxy)ethoxy)ethoxy)ethoxy)ethyl toluene-4-sulphonate (0.30 g, 36%) as a thick, 
faintly yellow oil: *H 270 MHz NMR (CDQ3) 5 2.45(3H, s, Q£3), 3.58 (18H, m, ethoxy 
groups). 4.01 (2H, d, J = 5.7 Hz, C ^ C H O y , 4.15 (2H, t, J = 4.8 Hz, TsOC#2), 5.16 (1H, 
d, J = 10.3 Hz, CHjCHCtfy, 5.24 (1H, d, J = 17.2 Hz, CHjCHCflj), 5.92 (1H, ddt, J = 5.8 
Hz, J = 10.3 Hz, J = 17.1 Hz, CH2C&CH2), 7.34 (2H, d, J = 8.1 Hz, 2H - Ar 3', 5’), 7.79 
(2H, d, J = 8.4 Hz, 2H - Ar 2', 6 '); mass spectrum (C.I.) mlz 433 (30%) (M + H), 89 
(100%), 261 (76%), 279 (20%). T.L.C. (A),Rf = 0.20. C^H^OgS.
Compound 66. Bis(2-(2,5-dioxopyrroIidin-l-yIoxycarboxy)ethoxy)ethoxy)ethane.
Bis(2-hydroxyethoxy)ethoxy)ethoxy)ethane (5 g, 17.73 mmol), dried by azeotropic removal 
of toluene was dissolved in toluene /  CH2Q 2 (3 /  1, 80 mL) and treated with a toluene
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solution (20%) of phosgene (91.87 mL, 1.93 M) over 36h. The solution was evaporated to 
dryness and the remainder of the phosgene removed under vacuum. The residue was 
redissolved in toluene /  CH2C1 (2 / 1 , 1 0 0  mL) and treated with N-hydroxysuednimide (6 .1 2  
g, 53.19 mmol) followed by triethylamine (3.77 g, 37.23 mmol). After 3h the solution was 
filtered and evaporated to dryness. The residue was applied to a chromatography column 
and a single product was isolated bis(2-(2,5-dioxopyiTolidin-1 -yloxycarboxy)ethoxy)- 
ethoxy)ethane as a yellow oil (2.24 g, 22%): !H NMR ((CD3)2SO) 400 MHz 5 2.81 (8 H, s, 
C#2CH2, OSu), 3.35 (4H, s, Ctf2CH2OCO), 3.52 (16H, brs, OCtf2Ctf2), 3.70 (4H, 
CH2Cfi[2OCO); T.L.C. (CHC13: MeOH [6 : l]),R f =0.64. C ^ U ^ O ^ .
Compound 67. N-(l,l-Dimethylethoxycarbonyl)sarcosine. Sarcosine (2.00 g, 15.90 
mmol) was dissolved in water (25 mL) containing NaOH (1.27 g, 31.85 mmol) and stirred 
vigorously for 12h with a solution of di-X-butyl dicarbonate (5.20 g, 23.90 mmol) in 1,4- 
dioxan (10 mL). The reaction was quenched with diethyl ether and the aq. fraction was 
acidified with H2S04 (10%) and extracted with EtOAc. The solvent was dried and 
evaporated to afford N-(l,l-dimethylethoxycarbonyl)sarcosine (3.00 g, 99%) as buff white 
crystals: mp 89 - 90°C (lit P17> mp 89 - 90°C); *H NMR (CDC13) 270 MHz 5 1.45 (9H, s, 
(CH3)3), 2.94 (3H, s, CH3), 3.94 (1H, s, CH), 4.03 (1H, s, CH), 9.50 (1H, s, OH), (there is 
some restriction of rotation about the N methyl /  carbonyl group producing a duplicate 
singlet peak at 1.48 corresponding to the BOC, and at 2.95 corresponding to the methyl); 
mass spectrum (CL) m/z 190 (31%) (M + H), 134 (100%), 90 (72%). T.L.C. (A), R, = 
0.45. C8H15N 04.
Compound 6 8 . N-(l,l-DimethyIethoxycarbonyl)sarcosine 2,4,5-trichlorophenyl ester.
N-(l,l-Dimethylethoxycarbonyl)sarcosine (10.0 g, 53 mmol) was stirred with 2,4,5- 
trichlorophenol (10.6 g, 53 mmol) and DCC (10.9 g, 53 mmol) in EtOAc (lOOmL) at -10°C 
for 2.5h. The suspension was filtered and the solvent was evaporated. The residue was 
dissolved in EtOAc and filtered and the solvent was evaporated to give N-(l,l-dimethyl- 
ethoxycarbonyl)sarcosine 2,4,5-trichlorophenyl ester (19.3 g, 98%) as a white solid: 
NMR ((CD3)2SO) 270 MHz 5 1.40 (9H, s, (CH3)3), 2.90 (3H, s, CH3), 3.99 (1H, s, CH),
4.03 (1H, s, CH), 7.32 (1H, s, Ar - 6 H), 7.59 (1H, s, Ar - 3H); T.L.C. (A), R, = 0.88.
Compound 69. N-(1,1-Dimethylethoxycarbonyl)sarcosine N-(2-aminoethyl)amide. N-
(l,l-Dimethylethoxycarbonyl)sarcosine 2,4,5-trichlorophenyl ester (12.7 g, 34.5 mmol) in 
CH2Q 2 (50 mL) was added during 30 min to ethane-1,2 -diamine (20.7 g, 345 mmol) in 
CH2Q 2 (150 mL) and the solution was stirred for 2 h. The solution was washed with water 
(2 x 75 mL) and with aq. NaCOs (10%; 50 mL) and dried. The solvent was evaporated to 
give N-(l,l-dimethylethoxycarbonyl)sarcosine N-(2-aminoethyl)amide (6.9 g, 8 6 %) as a 
yellow foam: NMR ((CD3)2SO) 270 MHz 8  1.40 (9H, s, (Ctf3)30 ), 2.65 (2H, t, J  = 6.4
Hz, CH2C££2), 2.80 (3H, s, NCtf3), 3.10 (2H, q, J = 6.1 Hz, CffcCH^, 3.70 (1H, s, CH, 
Sar), 3.75 (1H, s, CtL Sar), 4.00 (2H, brs, N 7.90 (1H, s, Nfl); (FAB [+]) mJz 232 
(100%) (M + H), 172 (70%), 438 (40%), 215 (33%). T.L.C. (MeOH), R, = 0.20.
^ 10^ 21^ 3^ 3*
Compound 70. Bis(2-(2-(N-(2-(N-(l,l-DimethyIethoxycarbonyl)sarcosyl)aminoethyl)- 
aminocarboxy)ethoxy)ethoxy)ethane. Bis(2-hydroxyethoxy)ethoxy)ethane (5.0 g, 21 
mmol), dried by azeotropic removal of water with toluene (120 mL), was dissolved in 
toluene (120 mL) /  CH2Q 2 (40 mL) and treated with a solution of phosgene in toluene (1.93 
M) (109 mL, 210 mmol) for 4h. An aliquot (30 mL) of this solution was evaporated to yield 
the known compound (279, 283) bis(2-(2-(chlorocarboxy)ethoxy)ethoxy)ethane (900 mg,
2.5 mmol), which was re-dissolved in DCM (50mL) and added to N -(l,l- 
dimethylethoxycarbonyl)sarcosine N-(2-aminoethyl)amide (1.73 g, 7.5 mmol) in DCM (100 
mL). Triethylamine (1.26 g, 12.5 mmol) and DMAP (20 mg) were added to the solution 
and the mixture stirred for 6 h, washed with H20 , aq. HjSC^ (10%) and H20 . Evaporation 
of the dried extract afforded the product bis(2-(2-(N-(2-(N-(l,l-dimethylethoxycarbonyl)- 
sarcosyl)aminoethyl)aminocarboxy)ethoxy)ethoxy)ethane(l.l g, 59%) as a yellow oil: *H 
NMR (CDC13) 270 MHz 5 1.38 (9H, s, (CH3)30), 2.86 (6 H, s, NCHV SarcY 3.23 (4H, brs, 
CH2Cff2 , CZZ2CH2), 3.31 (4H, brs, Ctf2CH2, CH2Ctf2), 3.58 (16H, brs, CH2 - 2, 3 ,4 , 5, 6 , 
7, 8 , 9), 3.78 (4H, s, CHj - 1, 10), 4.13 (4H, s, CH2, 1SflCC), 5.53 (1H, brs, HN’), 5.83 (1H, 
brs, HN"H), 6.78 (1H, brs, HN"), 6.93 (1H, brs, HN’"); C ^ H ^ C ^ .
Compound 71. Bis(2-(2-(N-(2-sarcosyl)aminoethyl)aminocarboxy)ethoxy)ethoxy)- 
ethane hydrochloride. An excess of hydrogen chloride was bubbled through Q ^C ^  (30 
mL) containing bis(2-(2-(N-(2-(N-(l,l-dimethylethoxycarbonyl)sarcosyl)aminoethyl)- 
aminocarboxy)ethoxy)ethoxy)ethane (300 mg, 0.40 mmol) (Compound 70). The solvent 
was evaporated to afford Bis(2-(2-(N-(2-sarcosyl)aminoethyl)aminocarboxy)ethoxy)-
ethoxy)ethane hydrochloride (136 mg, 55%) as a yellow oil: *H NMR ((CD3)2SO) 400 MHz 
8  2.53 (6 H, t, J = 5.3 Hz, NCH3), 3.07 (4H, q, J = 5.8 Hz, CH2CH2 - 4,17), 3.14 (4H, q, J 
= 5.8 Hz, CHj - 3, 18), 3.55 (16H, m, CH2 - 7 - 14), 3.63 (4H, t, J = 5.7 Hz, CH2 - 1, 20),
4.04 (4H, t, J = 4.6 Hz, CH2 - 6 , 15), 7.28 (2H, m, NH, coupled to 3.07), 8.62 (2H, m, NH, 
coupled to 3.14), 9.00 (4H, m, NHj); mass spectrum (FAB [+]) mlz 553 (40%) (M + H), 
495 (100%), 414 (83%), 144 (70%), 396 (60%). (FAB [-]) mlz 188 (100%), 341 (29%), 
448 (12%), 529 (10%). C ^ N A o ^ -
Compound 72. A POLYMER. 4-(Oxiranylmethoxy)-N-(2-(4-oxiranylmethoxy)phenyl)- 
ethyl)benzamide (140 mg, 0.81 mmol) and decane-1,10-diamine (300 mg, 0.81 mmol) were 
suspended in EtOH (20 mL) and boiled under reflux for 36h. The solution was allowed to 
cool and the filtrate was evaporated to give an oil (430 mg, 77%): mass spectrum (FAB [+]) 
mlz 542 (100%) (M + H), 1083 (8 %), 912 (10%), 173 (92%), 89 (95%). C ^H ^N A .
Compound 73. N-(2-Methoxyethyl)formamide. Ethyl formate (29.63 g, (32.31 mL), 
400 mmol) was added to 2-methoxyethylamine (15 g, 200 mmol) in dry absolute ethanol 
(450 mL) and stirred under nitrogen for 6 h. Distillation (140°C, 20 torr) of the reaction 
mixture afforded N-(2-methoxyethyl)formamide (16.20 g, 79%) as a colourless liquid: *H 
NMR (CDC13) 270 MHz 5 3.25 (3H, brs, OC#3), 3.37 (4H, brs, CR2C R ^  6.67 (1H, m, 
NH), 8.06 (1H, s, HNCOZf); T.L.C. (A), Rf = 0.58. CAl^ N 0 2.
Compound 74. N-MethyI-2-methoxyethyIamine. A solution of N-(2-methoxy- 
ethyl)formamide (7.00 g, 6 8  mmol) in dry THF (30 mL) was carefully added to a suspension 
of LiAR^ (6.46 g, 170 mmol) boiling under reflux in dry THF (50 mL). After 8 h the 
reaction was quenched with water (30 mL) and extracted with diethyl ether (100 mL, x 3). 
The extract, after drying with KjCO^ was distilled (95 - 97°C) to afford N-methyl-2- 
methoxyethylamine (1.00 g, 15%) as a colourless liquid: (lit Bpt 98-99°C); !H NMR 
(CDC13) 270 MHz 8  1.60 (1H, brs, NH), 2.45 (3H, s, CH3), 2.74 (2H, t, J = 5.1 Hz, 
CH2C£f2), 3.36 (3H, brs, C&30), 3.49 (2H, t, J = 5.1 Hz, CffcCHj); T.L.C. (A), R, = 0.45. 
C4Hn NO.
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Compound 75. 4-(2-Hydroxy-3-(N-(2-methoxyethyl)methyIamino)propoxy) N-(2-(4- 
(2-hydroxy-3-(N-(2-methoxyethyl)methyIamino)propoxy)phenyI)ethyl)benzamlde. 4-
(Oxiranylmethoxy) N-(2-(4-oxiranylmethoxy)phenyl)ethyl)benzamide (100 mg, 0.27 mmol) 
was dissolved in absolute ethanol (15 mL) and N-methyl-2-methoxyethylamine (300 mg, 
2.96 mmol) added and the mixture was boiled under reflux for 2h. Evaporation of the 
solvent gave the product 4-(2-hydroxy-3-(N-(2-methoxyethyl)methylamino)propoxy) N-(2- 
(4-(2-hydroxy-3-(N-(2-methoxyethyl)methylamino)propoxy)phenyl)ethyl)benzamide (75 
mg, 51%) as a gum: NMR ((CD3)2SO) 500 MHz 8  2.23 (3H, s, N(C££3)), 2.24 (3H, s,
N(Ca3)), 2.34 - 2.58 (8H, m, CH2), 2.75 (2H, t, J = 7.5 Hz, NHCH2Cff2), 3.19 (3H, s, 
0(C tf3)), 3.20 (3H, s, 0(C&3)), 3.35 - 3.39 (10H, m, CH^, 3.78 - 3.94 (2H, m, O H tf),4.77 
(1H, brs, OH), 4.84 (1H, brs, OH), 6.85 (2H, d, J = 8.5 Hz, 2H - Ar’ 2’, 6 '), 6.97 (2H, d, J =
8.5 Hz, 2H - Ar 2', 6 '), 7.13 (2H, d, J = 8.5 Hz, 2H - Ar' 2‘, 6 '), 7.78 (2H, d, J = 8.5 Hz, 2H
- Ar 31, 5’), 8.38 (1H, m; NH); mass spectrum (CL) mlz 548 (62%) (M + H), 102 (100%), 
445 (25%), 146 (30%), 590 (6 %). TX.C. (CHC13 : MeOH [5 : 1]), R* = 0.45.
^ 9^ 45^ 0 7 .
Compound 76. l,10-Bis(formamido)decane. Ethyl formate (4.30 g, 58.00 mmol) and 
anhydrous potassium carbonate (0.81 g, 5.80 mmol) were added to decane-1,10-diamine 
(0.50 g, 2.90 mmol) in dry absolute ethanol (100 mL) and stirred for 8 h. A precipitate was 
removed and the solvent was evaporated from the filtrate to give a residue. The residue was 
taken up in CH2Q 2 (60 mL) and filtered, the solvent was evaporated to afford 1,10-bis- 
(formamido)decane (0.42 g, 64%) as a an oil; *H 400 MHz NMR (CDC13) 8  1.20 (12H, s, H
- 1, 3, 4, 5, 6 , 7, 8 ), 1.52 (4H, m, H - 2, 9), 3.30 (4H, q, J = 6.7 Hz, H - 1, 10), 5.80 (2H, 
brs, HCON# 1,10), 8.16 (2H, s, tfCONH, 1,10); mass spectrum (C.I.) mlz 229 (100%) (M 
+ H), 69 (19%), 201 (15%). Anal. Found C, 63.20; H, 10.80; N, 12.20. C12H24N20 2 
requires C, 63.10; H, 10.60; N, 12.25.
Compound 77. N,Nf-Diniethyldecane-l, 10-diamine. A mixture of 1,10-
bis(formamide)decane (0.5 g, 2.21 mmol) in dry THF (30 mL) was carefully added to a 
suspension of LiAlH4 (0.48 g, 12.75 mmol) boiling under reflux in dry THF (50 mL). After 
8 h the reaction was quenched with water (5 mL) and a solid removed by filtration. The 
filtrate was evaporated to afford N,N’-dimethyldecane-1,10-diamine (0.37 g, 8 6 %) as a 
colourless oil: 2.50 (2H, m, HCON# 1, 10), *H 400 MHz NMR (CDC13) 8  1.20 (12H, s, H
- 1,3, 4, 5, 6 ,7 , 8 ), 1.52 (4H, m, H - 2, 9), 2.53 (6H, s, NCH3), 2.70 (4H, q, J = 6.7 Hz, H -
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1, 10), 5.80 (2H, brs, NK  1, 10); mass spectrum (FAB [+]) mlz 201 (100%), 243 (10%), 
157 (9%). (FAB [-]) m/z 199 (20%) (M + H), 201 (100%), 213 (40%). C^H^Nj.
Compound 78. A POLYMER. 4-(Oxiranylmethoxy)-N-(2-(4-oxiranylmethoxy)phenyl)- 
ethyl)benzamide (0.46 g, 1.25 mmol) and N,N’-dimethyldecane-1,10-diamine (0.25 g, 1.25 
mmol) were suspended in EtOH (20 mL) and boiled under reflux for 16h. The solution was 
allowed to cool and a solid was collected by Alteration (0.24 g, 34%). The organic solvent 
in the filtrate was evaporated to afford an oil (0.37 g, 52%): C ^ H ^ N ^ . The products 
were not characterised any further.
Compound 79. N-(N-(N-(4-(OxiranyImethoxy)benzoyI)phenyIaIanyI)Ieucyl)gIycine N- 
(2-(4-(oxiranylmethoxy)phenyl)ethyl)amide.
N-(N-(N-(4-Hydroxybenzoyl)phenylalanyl)leucyl)glycine N-(2-(4-hydroxyphenyl)ethyl)- 
amide (1.05 g, 1.82 mmol) was suspended in water (10 mL) containing NaOH (0.73 g,
18.25 mmol). Epichlorohydrin (8.44 g, 91.23 mmol) in MeOH (35 mL) was added, 
followed by benzylammonium hydroxide (21 drops, 40% solution in water) and the solution 
was stirred at 40°C for 48h. The solvent and epichlorohydrin were evaporated under high 
vacuum and the residue was partitioned between water and EtOAc. The EtOAc was dried 
and evaporated. Column chromatography (CHC13; CHC13 : MeOH [100 : 1]; CHC13 : 
MeOH [100 : 5]) afforded N-(N-(N-(4-(oxiranylmethoxy)benzoyl)phenylalanyl)-
leucyl)glycine N-(2-(4-(oxiranylmethoxy)phenyl)ethyl)amide as a white solid (1.11 g, 89%): 
mp 73 - 75°C; lH NMR ((CD3)2SO) 400 MHz 5 0.76 (3H, d, J = 6.4 Hz, CH3 Leu, Isomer
1), 0.82 (3H, d, J = 6.7 Hz, CH3 Leu. Isomer 1), 0.84 (3H, d, J = 6.4 Hz, CH3 Leu. Isomer
2), 0.88 (3H, d, J = 6.7 Hz, CH3 Leu. Isomer 2), 1.32 (1H, m, y - H Leu. Isomer 1), 1.44 
(2H, t, J = 7.2 Hz, p - H Leu. Isomer 1), 1.52 (2H, t, J = 7.2 Hz, p - H Leu. Isomer 2), 1.60 
(1H, m, y - H_Lm, Isomer 2), 2.52 (2H, buried, HNCH2Ctf2, Isomer 1), 2.63 (2H, t, J = 7.5 
Hz, HNCH2C£f2, Isomer 2), 2.69 (2H, m, CH - 3, Oxiranyl. Isomer 1 and 2), 2.84 (2H, m, 
CH - 3, Oxiranyl. Isomer 1 and 2), 2.99 (4H, m, P - H Phe. Isomer 1 and 2), 3.12 (2H, m, 
HNCtf2CH2, Isomer 1), 3.25 (2H, m, HNC#2CH2, Isomer 2), 3.30 (2H, m, CH - 2, 
Oxiranyl. Isomer 1 and 2), 3.61 (2H, m, CH2 Glv. Isomer 1 and 2), 3.75 (2H, m, CH, CH2 
Oxiranyl. Isomer 1 and 2), 3.84 (2H, m, CH, CHZ Oxiranyl. Isomer 1 and 2), 4.19 (1H, q, J 
= 7.3 Hz, a - H Leil-, Isomer 1), 4.25 (1H, q, J = 7.3 Hz, a - H Leu. Isomer 2), 4.28 (2H, m, 
CH, CH2 Oxiranyl. Isomer 1 and 2), 3.30 (2H, m, CH, CH2 Oxiranvl. Isomer 1 and 2), 4.66 
(1H, q, J = 7.6 Hz, a - H Phe. Isomer 1), 4.73 (1H, m, a - H Phe. Isomer 2), 6.81 (4H, dd,
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J = 8.5 Hz, J = 8.5 Hz, 2H - Ar’ 2', 6', Isomer 1 and 2), 7.00 (4H, dd, J = 8.9 Hz, J = 8.9 Hz, 
2H - Ar 2’, 6’), 7.09 (4H, dd, J = 8.5 Hz, J = 8.5 Hz, 2H - Ar’ 3 \ 5’), 7.34 (10H, brs, 5H - Ar 
Phe. Isomer 1 and 2), 7.60 (2H, brs, Z£NCH2CH2, Isomer 1 and 2), 7.79 (4H, dd nature, J =
8.9 Hz, J = 8.9 Hz, 2H - Ar 3', 5'), 8.13 (1H, t, J = 5.6 Hz, NH Gly, Isomer 1), 8.19 (1H, d, 
J = 7.3 Hz, NR  Leu. Isomer 2), 8.27 (1H, t, J = 5.6 Hz, NH Gly» Isomer 2), 8.44 (1H, d, J =
7.6 Hz, NH Leu. Isomer 1), 8.60 (2H, d, J = 7.3 Hz, NH Phe. Isomer 1 and 2); mass 
spectrum (FAB [+]) mlz 687 (16%) (M + H), 177 (100%), 709 (2%), 723 (11%). (FAB [-]) 
mlz 684 (100%) (M - 2H), 721 (52%), 756 (15%), 628 (30%). Accurate mass. Found 
687.3383, C ^ K A  requires 687.3394. TX.C. (GHC13 : MeOH [1 : 1])), Rf = 0.60.
^38^46^08.
Compound 80. 4-(Oxiranylmethoxy)-N-(2-(4-oxiranylinethoxy)phenyl)ethyl)-
benzamide. 4-Hydroxy-N-(2-(4-hydroxyphenyl)ethyl benzamide (300 mg, 1.17 mmol) was 
dissolved in water (0.30 mL) containing NaOH (100 mg, 2.34 mmol) and added to an excess 
of epichlorohydrin (10.82 g, 117 mmol). The reaction mixture was wanned to 60°C and 
benzyltrimethylammonium hydroxide (200 mg, 1.17 mmol) was added to the solution. The 
mixture was for 16h and then, in CH2Q 2, was washed with water and the solvent was 
evaporated from the dried extract to give a residue. The product, 4- (oxiranylmethoxy)-N- 
(2-(4-oxiranylmethoxy)phenyl)ethyl)benzamide (290 mg, 67%) was afforded after column 
chromatography (EtOAc /  CH2Cl2 (10:1)) as a buff solid: mp 153 - 154°C; !H NMR 
((CD3)2SO) 270 MHz 5 2.69 (1H, dd, J = 5.2 Hz, J = 2.7 Hz, H - 3 Oxiranyl). 2.11 (1H, dd, 
J = 5.2 Hz, J = 2.7 Hz, H - 3 Oxiranvt). 2.76 (2H, t, J = 7.5 Hz, CH2Ctf2), 2.83 (1H, t, J =
4.7 Hz, H - 3 Oxiranyl). 2.85 (1H, t, J = 4.7 Hz, H - 3 Oxiranyl). 3.31 (1H, m, H - 2 
Oxiranyl). 3.34 (1H, m, H - 2 Oxiranyl). 3.42 (2H, q, J = 6 .8  Hz, Cfl^CHj), 3.78 (1H, dd, J 
= 11.3 Hz, J = 6.7 Hz, H - CH2OAr Oxiranyl). 3.88 (1H, dd, J = 11.3 Hz, J = 6.7 Hz, H - 
CH2OAr Oxiranyl). 4.27 (1H, dd, J = 11.3 Hz, J = 2.4 Hz, H - CH2OAr Oxiranyl). 4.39 
(1H, dd, J = 11.3 Hz, J = 2.4 Hz, H - CH2OAr OxiranyD.6 .8 8  (2H, d, J = 8.5 Hz, 2H-Arf 2’ 
6 ’), 7.01 (2H, d, J = 8.9 Hz, 2H-Ar 2’, 6 ’), 7.15 (2H, d, J = 8.5 Hz, 2H-Ar' 3', 5’), 7.80 (2H, 
d, J = 8.9 Hz, 2H-Ar 3’, 5'), 8.41 (1H, t, J = 5.5 Hz, NH); mass spectrum (E.I.) mlz 370 
(30%) (M+), 89 (100%), 176 (60%), 57 (48%). TX.C. (A), Rf = 0.55. Anal. Found C, 
68.50; H, 6.30; N, 3.85. C21H23N 05 requires C, 68.30; H, 6.30; N, 3.80.
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